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Kidney transplantation is the treatment of choice for patients with end stage renal disease. 
However adaptive immune responses to donor HLA antigens are a potent barrier to suc-
cessful transplantation and/or tolerance. Allograft rejection is initiated, and in many cases, 
executed by T-cells recruited into the graft (1). With current immunosuppressive regimens 
T-cell mediated rejection is less common than with previous regimens, but remains the domi-
nant early rejection phenotype and is also associated with chronic allograft nephropathy. B-
cells can make donor specific HLA antibodies which are associated with antibody mediated 
rejection.
The possible induction of specific tolerance towards the graft is the ultimate goal in clini-
cal transplantation. The successful blockade of co-stimulatory pathways to induce prolonged 
graft survival in mice raised hopes for the successful transfer of tolerance inducing regimens 
into the clinic. However all these protocols rapidly failed in pathogen exposed mice (2-6).
Accumulating evidence suggests that graft rejection is a result of allo-HLA crossreactivity by 
self-HLA restricted T-cells. Furthermore memory T-cells that are generated as a result of pre-
vious infections may cross-react against allogeneic HLA molecules (2,7). These pre-existing 
memory T-cells may provide a potent barrier to transplantation tolerance because of their 
higher activation state, cytokine production, cytotoxicity and lower requirements for T-cell 
help and/or co-stimulation.
The aim of this thesis was therefore to determine if the high frequency of pre-existing al-
loreactive memory T-cells in non-sensitized individuals could be accounted for by allo-HLA 
crossreactivity by viral specific memory T-cells. Prior to discussing the current knowledge of 
mechanisms underlying T-cell alloreactivity, a review of the normal immune response against 
antigens is warranted.
1. GENERAL IMMUNOLOGY: THE HUMAN IMMUNE SYSTEM
Pathogens, such as viruses, represent a major threat to the human body and the immune sys-
tem is the body’s natural defence against these infections. The immune system can be divided 
into innate and acquired immunity. The innate immune system consists of physical barriers 
and a number of non-specific molecules, receptors and cells which provide immediate protec-
tion against invading organisms and initiate an adaptive acquired immune response. 
The adaptive immune system comprises a repertoire of T-cells and B-cells that is generated 
upon antigenic challenge and thus depends on the individual’s exposure to pathogens. These 
cells bear receptors on their surface that provide specificity. T-cells that have not yet encoun-
tered their cognate antigen are naïve T-cells. Upon encounter with their specific antigen these 
cells will expand and mature into effector and memory T-cells. The acquired immune system 
is specific and retains memory for pathogens that have been previously encountered.
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Antigen presentation by the Major Histocompatibility Complex (MHC) initiates an antigen 
specific immune response by T-lymphocytes. In humans the MHC molecules are known as 
the human leukocyte antigens (HLA).
1.1 HUMAN LEUKOCYTE ANTIGENS
T-cells constantly survey tissue cells for the presence of pathogens. The T-cell receptor (TCR) 
recognizes foreign antigens in the form of peptides only when they are presented by specific 
molecules of the HLA complex. HLA molecules are expressed on all nucleated human cells 
and the phenomenon whereby T-cells recognize an antigenic peptide presented only by one 
self-HLA molecule is termed HLA restriction. There are two classes of HLA molecules, both 
with similar, yet distinct functions (Figure 1).
HLA Class I
The classical HLA class I molecules, HLA-A, HLA-B and HLA-C are constitutively expressed 
on all nucleated cells. HLA class I molecules consist of a transmembrane α-chain, a non-
covalently associated light chain β2-Microglobulin and the peptide presented in the peptide 
binding groove of the α-chain. The α-chain is encoded on chromosome 6 and contains three 
extracellular domains (α1, α2, and α3). The α1 and α2 domains form the peptide binding 
groove, are the sites of most polymorphisms within the HLA class I molecule and are also 
the sites of TCR contact with the HLA molecule. The α3 domain contains a CD8 binding site 
which is necessary for presentation of intracellular peptides to CD8 T-cells. Peptides pre-
sented by HLA class I molecules are generally 8-13 amino acids in length.
In case of intracellular infection, e.g. virus infection, HLA class I molecules present pathogen 
derived peptides to CD8 cytotoxic T-lymphocytes (CTLs) which can then immediately and 
specifically eliminate the infected cell.
HLA Class II
HLA class II molecules are constitutively expressed on professional antigen presenting cells 
(APCs) such as dendritic cells (DCs), macrophages, B-cells and activated T-cells. However 
inflammatory cytokines, such as IFNγ, can induce HLA class II expression on most cell types. 
HLA class II molecules are encoded by the HLA-DR, HLA-DQ and HLA-DP genes on chro-
mosome 6. HLA class II molecules consist of two transmembrane chains (α and β) that both 
contribute to the peptide binding site, and also contain a CD4 binding site. The β chain of the 
HLA-DR molecule is the most polymorphic of the class II molecules. Peptides presented in 
HLA class II molecules are typically 12-25 amino acids long.
The function of the HLA class II molecules is to present extra-cellular peptides to CD4 T-cells 




Figure 1. The structure of HLA class I and II molecules. 
HLA class I consists of a heavy chain (α chain) and a non-covalently associated invariant light chain 
(β2-Microglobulin). HLA class II is a heterodimer consisting of α and β chains. The peptide binding 
groove is formed solely by the α chain in HLA class I molecules and by both the α and β chains in HLA 
class II molecules. HLA class II molecules bind and present longer peptides than HLA class I molecules. 
TM=Transmembrane region. CT=Cytoplasmic tail. B2M=β2-Microglobulin.
Antigen Processing and Peptide/HLA Restriction
In all cells proteosomes degrade cellular proteins that are poorly folded, damaged or unwant-
ed. When a cell becomes infected, pathogen derived proteins in the cytosol are also degraded 
by the proteosome. Peptides are transported from the cytosol into the endoplasmic reticulum 
by a protein called transporter associated with antigen processing (TAP). Newly synthesized 
HLA class I molecules are also transported into the endoplasmic reticulum where they can 
now bind these peptides, before being transported to the cell surface in order to present these 
peptides to T-cells.
HLA class II molecules are prevented from binding peptides in the endoplasmic reticulum by 
the presence of the invariant chain bound in the groove. The invariant chain also targets class 
II molecules to endocytic vesicles where they bind proteins derived only from the extracellu-
lar space. When the HLA class II molecule has lost its invariant chain and has a tightly bound 
peptide it is carried to the cell surface.
It is known that HLA molecules can present both self and non-self peptides on the cell surface. 
The T-cell receptor specifically recognizes both the presented peptide and the HLA molecule.
Chapter 1
14
1.2 THE T-CELL RECEPTOR AND THYMIC EDITING
Antigen recognition by T-cells is central to the generation and regulation of an effective im-
mune response. The TCR recognizes antigen fragments (peptides) which are bound and pre-
sented by HLA molecules. T-cells do not recognize free antigen.
The T-cell Receptor (TCR)
The TCR is the highly variable recognition molecule used by T-cells. A typical TCR consists 
of an α and β chain, both embedded in the membrane. The diversity of the TCR is generated 
by gene rearrangement (Figure 2). The variable parts of the TCR are encoded by separate gene 
segments called V, D and J segments, each of which is present in the genome as a tandem array 
of polymorphic forms. For a functional TCR to be made one each of the different gene seg-
ments must be brought together by gene rearrangement with elimination of the intervening 
regions. The numerous combinations of V, D and J segments that can be brought together 
are the principal source of variable region diversity of the TCR. Each lymphocyte is clonal; a 
single TCR is expressed in each lymphocyte. An adaptive immune response is initiated when 
a naïve T-cell recognizes a pathogen specific peptide presented by an APC on a self-HLA 
molecule.
Antibodies are the receptors for antigen specific B-cells and are formed by very similar gene 
rearrangements to that used in formation of the TCR. Adaptive B-cell responses are not dis-
cussed in this thesis.
Figure 2. Synthesis of T-cell receptor β-chain. 
Rearrangements of different V, D and J segments result in the formation of a unique β-chain. Productive 
β-chain gene rearrangement commits the T-cell to the α:β lineage. The T-cell receptor α-chain genes 
then commence comparable gene rearrangements except that they do not have D segments. Following 
successful α:β TCR generation the double-positive cell is signaled to survive and can proceed to positive 
and negative selection. V=Variable gene segment. D=Diversity gene segment. J=Joining gene segment. 





The first phase of T-cell development is the production of a functional TCR, irrespective of 
antigen specificity. The TCR repertoire that actually exits the thymus is then the product of 
“positive” and “negative” selection based on self-peptide/HLA recognition in the thymus. 
Only a small percentage of the T-cells with successful TCR gene rearrangements have a TCR 
that can interact with one of the HLA class I or II isoforms expressed by the individual, these 
T-cells are positively selected for further development. T-cells that are positively selected by 
HLA class I molecules become CD8 T-cells and T-cells that are positively selected by HLA 
class II molecules become CD4 T-cells. Thus both CD4 and CD8 T-cells develop from a com-
mon precursor in the thymus.
Tissue-specific proteins are expressed in the thymus and T-cells that bind self-peptides pre-
sented on self-HLA molecules are removed in the thymus by negative selection. For example 
the TCR that uses the VB6 gene segment is specific for the EBV FLRGRAYGL peptide pre-
sented by HLA-B*08:01 (7,8). This TCR also binds the EEYLQAFTY self-peptide from the 
ABCD3 gene presented on HLA-B*44:02 (9). In HLA-B8 B44 heterozygous individuals this 
TCR is negatively selected in the thymus to avoid auto-immunity (10).
Thus during T-cell development any T-cells having receptors that respond to complexes of 
self-peptide and MHC class I and II molecules of healthy cells are eliminated. However this 
quality control mechanism encompasses only HLA isoforms expressed by that individual (au-
tologous HLA), and not other HLA isoforms (allogeneic HLA). Accordingly T-cells that can 
respond to complexes of self-peptide and allogeneic HLA class I and II molecules are theo-
retically able to exit the thymus as they are not negatively selected. T-cells that have survived 
positive and negative selection leave the thymus and enter the circulation as mature naïve T-
cells. Mature naïve T-cells exhibit a high frequency (10%) of crossreactivity against allogeneic 
HLA to which they have not been previously exposed (11,12). 
1.3 T-CELL EFFECTOR MECHANISMS
T-cell mediated immunity is critical to the control and eradication of infectious agents. The 
first part of an adaptive immune response occurs when a naïve T-cell encounters its specific 
antigen and undergoes T-cell activation in a germinal centre reaction, and is stimulated to 
differentiate into an effector T-cell. Effector CD8 T-cells are long lived and travel to the sites 
of infection where they can kill any type of cell whose HLA class I molecule are presenting 
antigens to which the T cells are specific. Effector CD4 T-cells recognize their specific antigen 
presented via HLA class II molecules and via cell-cell contact and cytokine production can 




Naïve T-cells and T-cell activation
Naïve T-cells have not yet encountered their specific antigen and are characterized by surface 
expression of CD45Ra, the lymph node homing receptor CCR7 and the presence of costimu-
latory molecule CD28 (Table 1).
Dendritic cells are adept at capturing and processing antigens from pathogens. Dendritic cells 
travel to the afferent lymph node that drains from the site of infection, where naïve T-cells 
first encounter their specific antigen presented by the dendritic cells. The intracellular signal 
generated by ligation of the T-cell receptor with a specific peptide/HLA complex is necessary 
to activate a naïve T-cell, but is not sufficient. Participation of the CD4 or CD8 co-receptor 
is essential for effective naïve T-cell activation. Activation of naïve T-cells also requires a co-
stimulatory signal delivered by an APC. The co-stimulatory signal is delivered by the CD80/
CD86/CD28 and CD40/CD40L co-stimulatory molecules delivered only by the professional 
APCs – dendritic cells, macrophages and B-cells.
In the absence of infection the APCs do not express co-stimulatory signals and thus the ca-
pacity of APCs to activate naïve T-cells is acquired only during infection.
Memory T-cells
Immunological memory is the result of clonal selection of antigen specific T-cells. When na-
ïve T-cells are activated by antigen and co-stimulatory signals they are driven to proliferate 
and differentiate into memory T-cells, a process driven by the cytokine interleukin-2. The ac-
tivation of naïve CD8 T-cells generally requires stronger co-stimulatory signals than is needed 
to activate naïve CD4 T-cells. Memory T-cells express the marker CD45Ro and thereby the 
cells gain an increased survival potential. 
Naïve CD8 T-cells are activated to become cytotoxic effector memory CD8 T-cells. Effector 
memory CD8 T-cells lose expression of the CCR7 receptor and therefore leave the lymph 
node and enter the circulation where they can home to sites of inflammation. Effector func-
tion is turned on when the TCR bind to specific peptide/HLA complexes on a target cell, 
however effector T-cells have major functional differences versus their naïve counterparts 
as their responses to infection do not depend on co-stimulatory signals. Once generated, 
CD8 memory T-cells persist in high frequency and have lower activation requirements with 
novel co-stimulatory pathways that may be constitutively expressed (5,13). Upon activation, 
memory T-cells produce a wide variety of cytokines including IL-2, IL-4, IFNγ, TNFα and are 
capable of rapid up-regulation of cytolytic effector function without the need for CD4 T-cell 
help (14) (Table 1).
Effector memory CD8 T-cells are selective and specific serial killers of target cells at sites of 
infection. Therefore if viral specific memory T-cells do indeed crossreact against allogeneic 





On activation CD4 T-cells acquire distinctive helper functions. Activated CD4 T-cells syn-
thesize cell-surface molecules and cytokines that activate and help other types of cells, par-
ticularly macrophages and B-cells, to participate in the immune response. Antigen specific 
regulatory CD4 T-cells can limit the activities of effector CD4 and CD8 T-cells via production 
of inhibitory cytokines such as IL-4, IL-10 and TGF-β.




Alloreactive T-cells are recruited to the transplanted graft and initiate and execute organ re-
jection. A series of recent studies have characterized the frequency and cytokine profiles of T-
cells responding to allogeneic grafts (12). Naïve and memory T-cells are capable of responding 
with similar frequency against allogeneic cells, even in non-sensitized transplantation recipi-
ents. Furthermore CD4 and CD8 memory populations mount similar proliferative responses 
and contain comparable frequencies of alloreactive precursors, even though effector molecule 
expression is significantly higher among CD8 T-cells. These alloreactive memory T-cells are 
a major barrier to successful transplantation because of their lower activation thresholds, ab-
sent requirements for T-cell help and immediate cytotoxic function.
2.1 DIRECT ALLORECOGNITION
Direct allorecognition occurs when recipient T-cells directly recognize donor cells expressing 
intact mismatched HLA molecules, and is usually associated with acute T-cell mediated rejec-
tion. It is generally accepted now that direct allorecognition is dependent on donor derived 
self-peptide presentation by the allogeneic HLA molecule (1). Direct allorecognition from 
pre-existing viral specific CD8 T-cells is the topic of this thesis.
2.2 INDIRECT ALLORECOGNITION
Indirect allorecognition involves donor antigen uptake by recipient APCs. Allopeptides can 
be derived from allogeneic HLA molecules or minor histocompatibility antigens that differ 
between donor and recipient. After processing and peptide presentation in the context of 
autologous HLA class II molecules, antigen specific CD4 T-cells are activated and can initiate 
an alloimmune response. The frequency of T-cell clones involved in indirect allorecognition 
is about 100 fold lower than in the direct pathway. Indirect allorecognition is not investigated 
as part of this thesis.
2.3 NON-SENSITIZED TRANSPLANTATION RECIPIENTS HAVE STRONG “MEMORY” 
RESPONSES FOR ALLO-HLA
Transplantation recipients can be sensitized against alloantigen by pregnancy, blood trans-
fusion or previous transplantation. B-cell sensitization is revealed by the presence of HLA 
specific antibodies, which are not detectable in non-sensitized individuals. However, even 
in non-sensitized individuals a substantial portion of the pre-existing memory T-cell rep-
ertoire is already alloreactive (12,15-17), which is far greater than the proportion of T-cells 
that respond to any individual pathogen. The origin of these high-frequency pre-existing al-
loreactive memory T-cells in non-sensitized individuals was previously unclear, but has been 





3. ALLOREACTIVITY BY VIRAL SPECIFIC MEMORY T-CELLS
In humans, acute rejection has been associated with varying viral infections, and CMV 
prophylaxis with oral ganciclovir is associated with improved long-term renal graft survival 
(20). Mismatched donor HLA antigens have differential impact on graft survival depending 
on the HLA phenotype of the recipient (21), and one possible explanation for the occurrence 
of these harmful HLA combinations may be that patients have had previous immunological 
contact with pathogens that elicit T-cell responses which crossreact against the HLA mis-
matches (7,19,21). The fact that cord blood T-cells are less able to mediate graft vs. host dis-
ease (GvHD) than marrow derived T-cells because of their naïve status supports this theory 
(22-23).
In-vivo, the presence of virally induced alloreactive T-cell memory is a potent barrier to trans-
plantation tolerance in mice (2-3,5,24-26). Many strategies have been used to successfully in-
duce tolerance to transplanted tissue in mice, most of which primarily block the CD80/CD86/
CD28 and/or CD40/CD154 co-stimulatory pathways. For example, donor specific transfu-
sion and anti-CD154 antibody readily induce tolerance to solid organ grafts in pathogen free 
mice; however, all these protocols fail in pathogen exposed mice as viral infections induce 
alloreactivity associated with the development of memory cells, which abrogate the induction 
of transplant tolerance (1,6,27-29). Furthermore, Adams clearly demonstrated a viral dose ef-
fect whereby mice previously exposed to multiple viral infections were refractory to tolerance 
induction and rejected their allografts, whereas naïve mice or single pathogen exposed mice 
were susceptible to tolerance induction (2). Evidence for virally induced alloreactive T-cell 
memory in mice is already extensively documented in the literature (2-3,5,24).
Taken together this evidence provides strong support for the ability of viral specific memory 
T-cells to directly elicit acute rejection, and for viral memory having a negative influence on 
graft survival and/or tolerance induction.
3.1 HUMAN EBV SPECIFIC CLONES ARE CROSSREACTIVE AGAINST ALLO-HLA-
B*44:02 VIA MOLECULAR MIMICRY
Burrows and colleagues demonstrated the dual specificity of EBV EBNA3A specific T-cell 
clones for the immunodominant peptide FLRGRAYGL presented on HLA-B*08:01 and the 
alloantigen HLA-B*44:02, to which the individual had never been exposed (7). In fact the 
HLA-B8/FLR restricted response in a HLA-B8+ B44- individual gives rise to a public BV6S2 
TCR which always cross-reacts against allogeneic HLA-B*44:02 (8). This finding has been 
reproducibly found in different individuals from different genetic backgrounds using differ-
ent techniques (7-8,12,18). HLA-B44 mismatching has been identified as higher risk among 
HLA-B8+ renal transplant recipients (30).
The EBV EBNA3A T-cell allo-HLA-B*44:02 crossreactivity is dependent on presentation of 
the EEYLQAFTY self-peptide derived from the ABCD3 gene (9). Molecular mimicry, as re-
vealed by crystallography studies, is the mechanism for this human T-cell alloreactivity from 
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a viral specific memory T-cell (figure 3). Despite extensive amino acid differences between 
HLA-B*08:01 and HLA-B*44:02, and the disparate sequences of their bound viral and self 
peptides respectively, the HLA-B8/FLR restricted TCR engages these peptide-HLA com-
plexes identically. The viral and allopeptides adopted similar conformations after TCR liga-
tion, revealing that molecular mimicry is associated with TCR specificity. Structural studies 
confirm the exquisite specificity of the TCR and the self-peptide dependence of the T-cell 
alloreactivity.
Figure 3. Allo-HLA crossreactivity by viral specific memory T-cells. 
Viral specific memory T-cells target virus infected autologous cells presenting viral peptides in a self-
HLA restricted fashion. Alternatively, the same viral specific TCR may crossreact against an allogeneic 




3.2 MECHANISMS OF TCR CROSSREACTIVITY
A very high level of crossreactivity is an essential feature of the T-cell receptor (31). While the 
human immune system does generate a vast number of clonotypically unique T-cell recep-
tors, it is not possible to generate a unique TCR for every immunogenic peptide. Crossreactiv-
ity of the TCR ensures that the number of T-cells that can recognize an individual pathogenic 
peptide presented on a HLA molecule is sufficiently large to elicit a rapid response, and that 
no pathogenic peptides go unrecognized. 
Crossreactivity by pathogen specific memory T-cells may help protect against subsequent 
unrelated infections, however, in the transplantation setting such crossreactivity may give rise 
to harmful alloresponses.
Induced Fit
Structural adjustments in the TCR binding site can allow a single receptor to recognize differ-
ent peptide/MHC ligands. Usually such flexibility is observed in the CDR loops of the TCR. 
For example the TCR BM3.3 is able to recognize three distinct peptides bound to H-2Kb 
through changes in the conformation of the flexible complementarity-determining region 
loops, especially the CDR3 loop (32). 
Differential TCR docking
Disparate docking orientations can allow the same TCR to engage different peptide-MHC 
ligands. The 2C TCR utilizes a different binding strategy to recognize its allogeneic ligand H-
2Ld-QL9 and the self-ligand H-2Kb-dEV8 by which it was positively selected (33). 
Structural Degeneracy
TCR cross-reactivity can also occur when there is a paucity of peptide-MHC interactions. The 
TCR 3A6 recognizes a self-peptide from myelin basic protein presented on HLA-DR2a, but 
is also able to recognize many other peptides presented on HLA-DR2a because of absence of 
hydrogen bonds between the TCR and the peptides (34).
Molecular Mimicry
Molecular mimicry, whereby the TCR engages the allogeneic ligands and viral ligands with 
the same overall docking topology, has long been proposed to explain TCR crossreactivity. 
This can occur despite disparate sequences of the allo and viral peptides (9). It is also sug-
gested that molecular mimicry operates in other alloreactions (35-39).
Antigen-Dependent Tuning of Peptide-MHC Flexibility
Conformational flexibility of peptide-MHC can also allow recognition of different ligands by 
the same TCR. Recognition of Tax-HLA-A2 antigen (from HTLV-1 virus) by TCR A6 pro-
ceeds without substantial adjustments in the ligand, whereas the same TCR recognizes the 
Tel1p-HLA-A2 antigen (from S. Cerivisae) only following large conformational changes in 
both the peptide and MHC (40).
Chapter 1
22
4. AIM OF THIS THESIS
The aim of this thesis is to determine if the presence of alloreactive T-cells in non-sensitized 
individuals can be explained by allo-HLA crossreactivity by viral specific memory T-cells. If 
true, a further aim is to determine the frequency of allo-HLA crossreactivity by viral specific 
memory T-cells. The ability of viral specific T-cells to exert HLA alloreactivity could have 
especially serious consequences as memory T-cells lack the requirement for costimulation 
and therefore could be efficiently triggered by nonprofessional antigen-presenting cells after 
HLA-mismatched stem cell transplantation or solid organ transplantation. In order to detect 
allo-HLA crossreactivity from viral specific memory T-cells, viral specific T-cell clones were 
generated using single cell sorting based on viral peptide/HLA tetrameric complex staining. 
The viral specific T-cell clones were then tested for alloreactivity by stimulating with various 
tissue cells expressing allogeneic HLA molecules. 
Chapter 2 of this thesis describes a new tool to detect allo-HLA crossreactivity from viral 
specific memory T-cell clones using K562 cells transfected with single HLA molecules. The 
appendix to chapter 2 extensively describes the methodology used in chapter 2. Chapter 3 
uses multiple different viral specific T-cell clones to address the frequency of allo-HLA cross-
reactivity from viral specific memory T-cells. An example of how self-peptide presentation 
can alter the tissue specificity of allo-HLA crossreactivity from viral specific T-cell clones is 
described in chapter 4. In chapter 5 it is shown that anti-viral vaccination, not just viral infec-
tion, can also induce alloreactive T-cells. The current evidence for alloreactivity by human vi-
ral specific memory T-cells is reviewed in chapter 6. In chapter 7 it is confirmed that allo-HLA 
stimulation of non-sensitized blood cells can conversely elicit a viral specific cytolytic T-cell 
response, and the possible clinical implications are discussed. Chapter 8 provides a general 
conclusion and discussion to summarize all findings and put them into clinical perspective. 
Included in the general discussion are unpublished results describing how proteosomal diges-
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Accumulating evidence suggests that alloreactive memory T-cells may be generated as a re-
sult of viral infection. So far a suitable tool to define the individual HLA cross-reactivity of 
virus-specific memory T-cells is not available. We therefore aimed to develop a novel sys-
tem for the detection of cross-reactive alloresponses using single HLA antigen expressing cell 
lines (SALs) as stimulator. Herein we generated EBV EBNA-3A specific CD8 memory T-cell 
clones (HLA-B*08:01/FLRGRAYGL peptide restricted) and assayed for alloreactivity against 
a panel of SALs, using IFNγ Elispot as readout. Generation of the T-cell clones was performed 
by single cell sorting, based on staining with viral peptide/MHC complex specific tetramer. 
Monoclonality of the T-cell clones was confirmed by TCR PCR analysis. Firstly, we confirmed 
the previously described alloreactivity of the EBV EBNA3A specific T-cell clones against SAL 
expressing HLA B*44:02. Further screening against the entire panel of SALs also revealed 
additional cross-reactivity against SAL expressing HLA B*55:01. Functionality of the cross-
reactive T cell clones was confirmed by chromium release assay using PHA blasts as targets. 
SALs are an effective tool to detect cross-reactivity of viral specific CD8 memory T-cell clones, 
against individual class I HLA molecules. This technique may have important implications for 
donor selection and monitoring of transplant recipients.




Previous immunological exposures and resultant T cell memory can influence the course 
of future immune responses to unrelated pathogens (1,2). Less is known about the effect of 
an individuals immune history on the response to an allogeneic tissue transplant. However 
the presence of memory alloreactive T cells in humans who have never been exposed to al-
loantigens has been attributed to past viral infections (3-5). It is hypothesized that these viral 
specific memory T-cells are able to recognize cross-reactive allogeneic MHC with lower affin-
ity because of lower activation thresholds (4). However, a reproducible in-vitro system for the 
detection of cross-reactive alloresponses from viral specific T-cells is currently not available.
Burrows et al have shown that the cytotoxic T-lymphocyte (CTL) response against the hu-
man HLA-B*44:02 alloantigen may actually be due to cross-reactivity against a previously 
primed viral antigen (3). Limiting dilution analysis of the alloresponse to HLA-B*44:02 in 
eight healthy individuals revealed that HLA-B*08:01, EBV seropositive donors had signifi-
cantly higher CTL precursor frequencies for alloantigen HLA-B*44:02 than HLA-B8 positive, 
EBV seronegative control donors (3). The cytotoxic T-cell response against the immunodomi-
nant EBV peptide FLRGRAYGL presented on the HLA-B*0801 molecule also recognized the 
HLA-B*44:02 molecule (presumably presenting a self-peptide) to which the T-cells had never 
been exposed.
This study of Burrows demonstrates that the allospecific T-cell repertoire overlaps with the 
repertoire which recognizes a single viral epitope in the context of self-MHC. This theory is 
also supported by other groups that have reported similar cross-reactivity between environ-
mental pathogens and allogeneic MHC molecules (6-9). Although the frequency of naïve 
T-cells available to respond to any given pathogen is relatively small (approx. 1:200,000), the 
proportion of memory T cells that can directly recognize foreign MHC represents a substan-
tial fraction of the total T-cell repertoire (10,11). Analysis of cloned T-cell populations has 
demonstrated that between 20-60% of antigen specific, MHC restricted T-cell clones crossre-
act with alloantigens (12-13). It has also been shown that approximately half of a “primary” 
alloresponse is contributed by previously primed MHC-restricted T-cells (14-15).
Therefore accumulating evidence suggests that the CD8 T-cell alloresponse could, at least in 
part, result from molecular mimicry by an environmental antigen which induces an alloreac-
tive memory T-cell response (3-5,8,16). It is therefore not surprising that increased alloreac-
tivity is found following viral infection in experimental models (2, 17-19). These cross-reac-
tive memory T-cell responses not only affect allograft survival but also prevent the induction 
of transplantation tolerance (4,20).
Human memory CD8 T-cells can be defined based on phenotypic and functional character-
istics (21). Memory CD8 T-cells express CD8, CD45Ro, CD27, CD28, CD11a, CD49d, CD95 
and can secrete IL-2, IL-4, IFNγ and TNFα. This memory subset contains virus-specific cyto-
toxic T lymphocyte (CTL) precursors that can have cytotoxic function including expression 
of perforin and granzyme B. Memory CD8 T-cells have less stringent requirements for activa-
tion, with a reduced requirement for co-stimulation, and have the potential to secrete a more 
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extensive array of cytokines (22-24). As primed (cross-reactive) memory T-cells may have 
lower activation thresholds than their naive counterparts, their presence before transplanta-
tion may increase the risk of a poor outcome of an allograft.
In our laboratory, cell lines have been established expressing a single MHC class I antigen 
on the cell surface. These cells, named single HLA antigen lines (SAL’s), have originally been 
developed for humoral tests (25,26), as their expression of a single HLA antigen, instead of the 
3-6 of usual peripheral blood lymphocytes, facilitates the definition of HLA antibody specifi-
cities in patients sera. Similarly the use of a SAL as target will allow the determination of the 
exact HLA specificity of the alloreactive T-cells.
The purpose of this study was to develop a reproducible in-vitro system for the detection of 
CD8 T-cell cross-reactive alloresponses by viral specific CD8 T-cell clones. We used EBNA3A 
specific CD8 memory T-cell clones to confirm the previously described cross-reactive allore-
sponse against HLA-B*44:02 and check whether additional crossreactivities can be observed 
using a panel of different SALs as stimulators. SALs proved to be the basis of an effective 
screening system for heterologous alloreactivity that lead to the definition of additional cross-
reactive HLA-alloantigens.
METHODS
Generation of viral specific CD8 memory T-cell clones
EBNA3A-FLR/B8 CD8 T-cell clones were derived from healthy donor (x.x0116x) with HLA 
typing HLA-A*01:01,02:01; B*08:01,-; DRβ1*03:01,-. HLA-B8/FLR tetramer positive CD8 T-
cells accounted for 1.7% of the peripheral blood CD8 T-cells (Figure 1a). The EBV-specific 
T cells were isolated from the peripheral blood as previously described (27). Briefly, PBMCs 
were harvested and labeled with HLA-B8/FLR tetrameric complexes for 30 minutes at 4 0C in 
RPMI without phenol, supplemented with 2% FCS, washed three times and single cell sorted 
at 4 0C using the FACS vantageTM (Becton Dickinson). Tetramer+ CD8 T-cells were non-
specifically stimulated every 2 weeks with feeder cell mixture containing irradiated allogeneic 
PBMCs (3500 Rad), irradiated EBV transformed B-cells (5000 Rad), 800ng/ml phytohaemag-
glutinin (PHA), 100 IU/ml IL-2 in IMDM medium supplemented with glutamine, human 
serum (5%) and fetal calf serum (5%). Multiple clones for testing were generated from the 
same healthy donor.
Confirmation of T-cell clonality
TCRα and TCRβ rearrangements were analyzed on 4 separate EBNA-3A T-cell clones. 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). Oligo dT 
primed first-strand cDNA was synthesized from 1 µg RNA template using AMV reverse tran-
scriptase (Promega, Madison, WI, USA). First RT-PCR was performed to determine the TCR 
AV and BV usage, using primers that cover the complete TCR repertoire. Sequencing tem-
plates were obtained performing high fidelity PCR using Pfx50 DNA Polymerase (Invitrogen 
Corporation, Carlsbad, CA, USA). Each reaction contained forward primers targeting the 
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Va4S1 or Vb6S2 variable region and reverse primers specific for the alpha and beta chain 
constant region. Amplicons spanning the variable, CDR3 and joining regions were purified 
using illustra S-400 HR microspin columns (GE Healthcare, Buckinghamshire, UK) accord-
ing to manufacturers’ protocol. Thermo sequenase primer cycle sequencing (GE healthcare) 
reactions were performed using a CY5 labeled m13 sequencing primer (Sigma-Aldrich, St. 
Louis, MO, USA) according to manufacturers’ protocol.  Sequencing reactions were run on 
an ALFexpress DNA sequencer (GE healthcare), and analyzed with sequence analyser 2.10 
software (GE healthcare).
Generation of single HLA antigen expressing cell lines (SALs)
Plasmid constructs (pLNCX, ampicillin and neomycin resistant) containing various MHC 
class I heavy chain genes were obtained from the 13th International Histocompatability 
Working Group and were transfected in K562 cells, obtained from the American Type Cul-
ture Collection (Manassas, VA, order number CLL-243) (28) by electroporation using the 
Genepulser (Biorad, Hercules, CA) with instrument settings of 230V and 960μF. Electropo-
ration was performed with 107 cells and 10μg of plasmid DNA. On day 2 after transfection, 
selection was started with G418 (neomycin derivative, final concentration: 200μg/ml; Inv-
itrogen, Groningen, the Netherlands). The antibiotic-resistant transfectants were expanded 
for at least two weeks. Major histocompatability complex class I positive cells were enriched 
by cell sorting using w6/32 coated antimouse immunoglobulin (Ig) magnetic beads (Dynal, 
Oslo, Norway). Sorted cells were expanded using G418, tested for class I expression with HLA 
specific monoclonal antibodies (25,26) and cryopreserved in multiple aliquots. The full list of 
available transfected SAL cells is available in reference 25.
Elispot
Ninety six well ELISPOT plates (NUNC) were coated with capture antibody for IFNγ (Mab 
1-D1K – Mabtech) in PBS overnight at 4 0C. The plates were then washed with PBS three 
times. 10000 responder EBNA-3A T-cell clone were added to each well in 100μL of IMDM 
supplemented with 10% FCS (without IL-2), together with 1.105 stimulator SALs (non-ir-
radiated). Control wells contained responder EBNA-3A specific T-cell clone with medium, 
non-transfected K562 cells or FLRGRAYGL peptide (10μg/ml positive control). The plates 
were washed after 24 hours and biotinylated detection antibody (Mab 7-B6-biotin – Mabtech) 
was added to the wells for 2 hours at room temperature, followed by further washing step. 
Extravidin Alkaline Phosphatase conjugate (E2636 - Sigma) was then added for 1 hour at 
room temperature and plates were washed again. The spots were developed using 5-bromo-
4-chloro-3-indolyl phosphate (BCIP/NBT plus B-5655 – Mabtech) and counted using a com-
puter assisted ELISPOT image analyzer Immunospot.
Chromium release assay and generation of PHA blasts
EBNA-3A specific CD8 T-cell clones were evaluated for cytotoxicity by incubating 5000 PHA 
blast target cells with serial dilutions of the T-cell clone for 4 hours in a chromium release as-
say. PHA blasts were generated by stimulating PBMC with PHA (800ng/ml) and IL-2 (150IU/
ml) for 7 days (Growth medium 15% human serum/RPMI), and were incubated with chro-
mium for 60 minutes. Supernatants were harvested for gamma counting: percent specific ly-
sis= (experimental release-spontaneous release)/(Max release-spontaneous release) x 100%. An 
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inhibition assay was also performed with and without the presence of HLA-B8/FLR tetramer 
or control HLA-B35/IPS tetramer (1μg/ml). Results are expressed as the mean of triplicate 
samples.
Statistics
Values for Elispot and specific lysis are presented as the mean of triplicate wells, with standard 
deviation. Comparative analyses are non-parametric (unpaired) t-tests, p<0.05 is considered 
to be significant. Statistics are derived using Graph Pad Prism 4 for Windows (Version 4.02, 
2004).
RESULTS
Confirmation of monoclonality and TCR repertoire analyses of the EBNA3A-FLR/B8 specific 
CD8 T-cell clones
EBNA3A-FLR/B8 CD8 T-cell clones were all confirmed to bind viral peptide/HLA-B8 te-
tramer complexes (Figure 1b). Burrows et al have reported that persistent EBV infection in 
a HLA B*08:01 positive, B*44 negative individual gives rise to a public AV4S1, BV6S2 TCR 
(29). We therefore performed RT-PCR and sequencing to determine the TCR usage of the 
EBNA3A specific CD8 T-cell clones we have isolated. As shown in table 1, all clones analyzed 
Figure 1. EBNA-3A CD8 memory T-cell clone. 
Generation of the T-cell clone was performed by single cell sorting based on HLA-B*0801/FLRGRAYGL 
specific tetramer staining. (a): HLA-B8/FLR specific T-cells amounted to 1.7% of peripheral CD8 T-cells 
in the healthy donor from whom the EBNA3A-FLR/B8 T-cell clone was sorted. (b): T-cell clone is >99% 
HLA-B8/FLR tetramer binding and clonality was confirmed with TCR PCR (table 1). T-cell clone is of 
memory immunophenotype (CD45Ra-ve) and did not stain with markers specific for CD4 T-cells, B-
cells, NK cells nor monocytes.
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expressed the AV4S1 and the BV6S2 TCR. Three clones (#1,#8,#19) were identical, however 
differed from the clones described by Burrows et al at one amino acid located in the CDR3 re-
gion of the AV4S1 chain (29). Clone #2 was identical to the LC13 clone described by Burrows 
(29) (Table 1). Monoclonality of the T-cell clones was confirmed using TCR PCR analysis. The 
DNA and amino acid sequences of the TCR gene segments is given in table1, with compari-
son to clones reported by Burrows (29).
SAL cell lines are a suitable tool to detect “cross-reactive”alloresponses of viral specific memory 
CD8 T-cells
To confirm that SALs are an effective tool to detect cross-reactive alloresponses we tested the 
EBNA3A-FLR/B8 specific clones against SAL expressing HLA B*44:02. Strong IFNγ produc-
tion was elicited, as measured by detection of the number of IFNγ producing cells (p<0.0001) 
(Figure 2). FLR peptide (positive control), medium, K562 cell and HLA matched SALs all 
gave appropriate control results. In addition to cross-reactivity against SAL expressing HLA-
B*44:02, screening against the entire panel of SAL cells identified that our EBNA3A spe-
cific T-cell clones also cross-reacted with SAL expressing HLA B*55:01 (p=0.0019, Figure 
2). Cross-reactivity was also confirmed with PHA blasts expressing HLA B*44:02 and HLA-
B*55:01, in the same Elispot assay (data not shown).
Figure 2. SALs are an effective tool to detect cross-reactive alloresponse(s) from a viral specific CD8 
memory T-cell clone. EBNA3A-FLR/B8 T-cell clone recognized K562 cell transfected with either HLA-
B*44:02 or HLA-B*55:01 (***p<0.0001 and **p=0.0019 respectively) (comparison to non-transfected 
K562). Remaining panel of SALs were not recognized, including SAL B14 and SAL B35. All available 
HLA-A and HLA-B SALs were tested, while HLA-C SALs were not tested (The full list of available 
transfected SALs is available in reference 25). HLA typing of donor from whom T-cell clone was sorted 
is HLA-A1:2; B*08:01,-; DR17,-.
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EBNA-3A viral specific CD8 T-cell clones exert cytolytic activity against HLA B*44:02 and 
HLA-B*55:01 expressing PHA blasts
To confirm that the EBNA3A specific CD8 T-cell clones were cytolytic against allogeneic PB-
MCs expressing the cross-reactive HLA molecules, we performed a chromium release assay 
using PHA blasts as target cells. The EBNA-3A specific clones specifically lysed PHA blasts 
expressing either HLA B*44:02 or HLA-B*55:01 in proportion to the E/T ratio (p<0.0001 and 
p=0.0054 respectively), whereas HLA-B*44:03 expressing PHA blasts were not lysed (Figure 
3).
Figure 3. Cytolytic effector function of EBNA-3A clone against allogeneic target cells. 
Chromium release cytotoxicity assay using effector EBNA-3A T-cell clone demonstrates functional ac-
tivity against PHA blasts expressing either HLA B*44:02 or HLA-B*55:01 (***p<0.0001 and **p=0.0054 
respectively) (comparison to PHA Blast 3 ratio 10:1). Autologous PHA blasts are from the same donor 
used to sort the EBNA3A-FLR/B8 T-cell clone.
Autologous: HLA-A1:2, B*08:01, DR17.
PHA Blast 2: A2,32; B7,B*44:02; DR9,11.
PHA Blast 3: A23,31; B39,B*44:03; DR4,7.
PHA Blast 4: A24,30; B41,B*55:01; DR7,13.
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Cytotoxicity against the  cross-reactive HLA molecules is specifically inhibited by the presence 
HLA-B8/FLR tetramer
To confirm that the crossreactive potential of the EBNA-3A specific T-cell clones was medi-
ated by the same T-cell, a cytotoxicity assay was performed in the presence of HLA-B8/FLR 
tetramer or control tetramer. The results demonstrated that cytotoxicity against both HLA-
B*44:02 and HLA-B*55:01 allogeneic molecules was specifically inhibited by the presence of 
HLA-B8/FLR tetrameric complexes, but not irrelevant tetrameric complexes (p<0.0001 and 
p=0.0026 respectively) (Figure 4). Thus confirming that a single viral specific memory T-cell 
can indeed simultaneously recognize autologous HLA molecules loaded with viral peptide, as 
well as allogeneic HLA molecule(s) to which it has never been primed.
Figure 4. Alloreactivity and viral specificity are mediated by the same T-cell receptor.
Cytotoxicity of the EBNA3A-FLR/B8 CD8 T-cell clone against HLA-B*44:02 and HLA-B*55:01 ex-
pressing PHA blasts is specifically inhibited by the presence of HLA-B8/FLR tetramer. An irrelevant 
tetramer does not suppress the cross-reactivity. Responder:target ratio 10:1, targets 5000. ***p<0.0001, 
**p=0.0026, *p<0.05. Note: Cytotoxicity against autologous PHA blast loaded with FLR peptide can be 
significantly inhibited with higher amounts of HLA-B8/FLR tetramer (data not shown).
Autologous: HLA-A1:2, B*08:01, DR17.
PHA Blast 2: A2,32; B7,B*44:02; DR9,11.
PHA Blast 3: A23,31; B39,B*44:03; DR4,7.


























































































































































































































































We have shown for the first time that T-cell alloresponses from viral specific CD8 memory 
T-cell clones are reliably detectable in-vitro using transfected K562 cells expressing a single 
HLA molecule. Using this technique we have confirmed that EBNA3A-FLR/B8 CD8 memory 
T-cell clones exhibited an alloresponse against HLA-B*44:02, as reported by Burrows (3). In 
addition, our viral specific clones also exhibited an alloresponse against HLA B*55:01, dem-
onstrating the power of our technique as a screening tool.
The EBNA-3A specific CD8 T-cell clones recognized SAL cells transfected with HLA-B*44:02 
but not B*44:03. These two HLA molecules differ only by a single amino acid at position 
156, a position critical for interaction with the TCR (30). However, HLA B*55:01 does not 
share this same amino acid and in fact has the same amino acid (L) at this position as does 
HLA B*44:03. Furthermore sequence alignment of these HLA molecules reveals there is no 
common amino acid between HLA B*08:01, B*44:02 and B*55:01 that is not present on HLA 
B*44:03 (31). Key amino acids within the MHC α2 helix may be critical for these cross-reac-
tive alloresponses (32), however our work suggests that additional factors must also be neces-
sary. In fact, alloreactivity between disparate cognate and allogeneic pMHC class I complexes 
is likely the result of highly focused, peptide dependent structural mimicry (33).
Our EBNA3A specific T-cell clones recognize HLA-B*55:01, in addition to the previously 
described HLA B*44:02. The EBV antigen FLRGRAYGL presented on HLA-B8 selects for a 
public TCR (29), a fact confirmed by sequencing of our own EBNA3A specific T-cell clones 
(Table 1). It is possible that the single amino acid difference within the CDR3 region of the 
TCR of our clones (EBNA3A #1,#8 and #19), as compared to the clones reported by others, 
retains alloreactivity against HLA B*44:02 but in addition enables alloreactivity against HLA 
B*55:01. Complex structural studies are required to determine if this is indeed the case.
However since clone #2 also exhibited alloreactivity against HLA-B*55:01 and this T-cell 
clone expressed an identical TCR compared to the EBNA3A specific T-cell clones of Burrows, 
the most likely explanation is that the EBNA3A specific clones reported by Burrows also ex-
hibit alloreactivity against HLA-B*55:01, but this may not have been detectable without the 
use of single HLA expressing cell types. This demonstrates the sensitivity of our technique. 
EBV EBNA3A specific T-cell clones have never been reported not to recognize HLA-B*55:01.
Contrary to a previous report the EBNA3A specific T-cell clones described in this study did 
not cross-react with HLA-B14 nor HLA-B35 alloantigens (34). The HLA-B14 or HLA-B35 
crossreactive T-cell clones however did not express an AV4S1, BV6S2 TCR, and did not rec-
ognize HLA-B*44:02 (34). Therefore we would indeed predict that our clones should not 
recognize HLA-B14 nor HLA-B35, thus demonstrating that our detection technique is not 
only sensitive but also specific. We propose that subtle amino acid differences of the α and/or 
β chains within the CDR3 accounts for the various patterns of cross-reactivity, even if these 
T-cell clones were all restricted by the same viral peptide presented on HLA-B8.
The possibility that the T-cell clones cross-reacted against a HLA class II molecule in this 
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assay (instead of the transfected HLA class I molecule) can be excluded. The single HLA mol-
ecule expression of the SALs has been confirmed against a panel of 84 human HLA-specific 
monoclonal antibodies (25,26), there is no surface expression of HLA class II. Furthermore, 
K562 cells lack IFNγ mediated induction of the class II transactivator (35).
The importance of our findings are reinforced by functional studies showing that our EB-
NA3A specific T-cell clones are able to specifically lyse both HLA-B*44:02 and HLA-B*55:01 
expressing PHA blasts, as determined by chromium release assay. Furthermore this dual al-
loreactivity was specifically inhibited by the HLA-B8/FLR tetramer complex, confirming that 
a single viral specific memory T-cell can indeed simultaneously recognize autologous HLA 
molecules presenting viral peptide, as well as allogeneic HLA molecule(s) to which it has 
never been primed.
The lower percentage of specific lysis of the HLA-B*44:02 and HLA-B*55:01 expressing PHA 
blasts, versus the positive control (autologous PHA blast loaded with exogenous FLRGRAYGL 
peptide) is not unexpected. The HLA-B8 expressing PHA blast was exogenously loaded with 
excess amount of viral peptide, while the cross-reactive alloresponses are dependent on pres-
entation of endogenous self-peptide. Furthermore, it has been suggested by others that cross-
reactive alloresponses may be of lower affinity to the original viral specificity against which 
the T-cell was selected (2). Nevertheless, this cross-reactivity is clearly detectable using our 
novel technique.
The clinical relevance of our findings are re-enforced by the fact that a HLA-B*44:02 mis-
match has been identified as higher risk amongst HLA-B*08:01 renal transplant recipients 
(36). A HLA-B*55:01 mismatch has not been identified as high risk within EBV positive, 
HLA-B*08:01 recipients, however further database studies may be warranted in light of our 
findings.
Results presented here support evidence that virally activated memory T-cells could play a 
major role in human alloresponses. EBNA3A specific T-cells amounted to 1.7% of peripheral 
CD8 T-cells in the healthy donor from whom the EBNA3A specific T-cell clone was derived. 
The frequency of memory CD8 T-cells is highest for the chronically persistent viruses such 
as human herpes viruses EBV and CMV, infections that are common and persistent in the 
general population. To our knowledge, this is the first report of a viral specific T-cell clone that 
can simultaneously cross-react with more than one allogeneic HLA class I molecule. This tool 
is not only useful for this particular clone but also for detecting cross-reactive alloresponses 
from other different viral specific clones (manuscript in preparation). The allo-MHC/self-
peptide target antigen is presumably sufficiently similar to the MHC/viral-peptide complex 
involved in activating the T-cell, in three dimensions, to allow crossreactivity.
These findings may have important future implications for donor selection and monitoring. 
The immune response against the EBNA3A-FLR peptide presented on HLA-B8 selects for a 
public TCR, with alloreactivity against HLA-B*44:02. The ability to detect the viral specific 
memory T-cells giving rise to cross-reactive alloresponses may lead to better transplantation 
matching and/or monitoring. Assay of alloantigen specific T-cells in-vitro for renal trans-
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plantation monitoring is not new (37-40), but does not have adequate sensitivity or specificity 
to enter routine clinical practice. However, the concept of producing tailor-made cells for 
analysis of cellular reactivity against individual HLA molecules is novel and may have ad-
vantages over these previous assays. If in vitro tools can more specifically predict which renal 
transplant patients are at risk for rejection and which patients are predisposed to tolerance, 
the immunosuppressive regimen could be adjusted accordingly (37). In theory, using our 
technique (un)acceptable mismatches might be partially determined based, not only on HLA 
typing, but also on immunological history.
If our technique can define pathogen driven clonal expansions of T-cells that are involved 
in initiating allograft rejection then it is possible that immunomodulating techniques could 
be used to inhibit these harmful T-cell clonotypes, as suggested by Burrows (41). We also 
hypothesize that anti-viral therapy or viral eradication may decrease the proportion of these 
cross-reactive alloresponsive T-cells. For example, it has already been shown that CMV 
prophylaxis post-transplantation is associated with less acute rejection episodes and better 
one year graft survival (42).
The significance and characteristics of memory CD8 T-cells in viral infections have been ex-
tensively studied. In many studies of T-cell memory and transplantation tolerance many ex-
perimental immunologists go to great lengths to ensure their animal colonies are pathogen 
free. Although these studies can be enlightening, humans are not immunologically naive. We 
have shown here that a single EBV specific memory T-cell can indeed cross react with two 
alloantigens, thereby possibly influencing the success of tissue transplantation. The presence 
of Tm correlates with both acute and chronic rejection and may be responsible for the failure 
to induce tolerance in human clinical settings (4-5). Our results support the conclusion that 
transplantation/tolerance studies using pathogen free models could be flawed, as has also 
been suggested by others (4-5,16).
In conclusion, we have shown that SAL cell lines are an effective tool to detect functional 
immune responses from CD8 T-cell clones, specifically; SALs are an effective tool to screen 
for cross-reactive alloresponses from viral specific memory T-cells. This technique to define 
cross-reactive T-cells may also lead to important future improvements in donor selection and 
monitoring. Cross-reactive alloresponses should be further defined (in-vitro) using CD8 T-
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SUMMARY
The ability to directly measure viral specific lymphocytes using fluorochrome labeled tetra-
meric complexes has proven a great advancement for the transplantation field. Viral peptide/
HLA tetrameric complexes allow the rapid generation of viral specific clones using single 
cell sorting apparatus, permitting the determination of alloreactivity from a single TCR with 
known specificity. When combined with new target “detector” cells called single HLA anti-
gen transfected K562 cells (SALs) the human alloresponse can for the first time be examined 
specifically and reliably. Here we describe a method for detection of “heterologous immunity” 
from viral specific memory T-cells using single HLA expressing cell lines as allogeneic targets.




The mechanisms by which alloreactive memory T-cells are generated in non-sensitized indi-
viduals have begun to be elucidated. It is generally accepted that a very high level of crossreac-
tivity is an essential feature of the T-cell receptor, for example, memory T-cells that have been 
generated as a result of a previous viral infection can subsequently respond to a second unre-
lated infection. However, it has only recently been shown that alloreactivity from viral specific 
memory T-cells is far more common than predicted, 45% of viral specific T-cell clones were 
found to be allo-HLA crossreactive (1). 
Detection of alloreactivity from viral specific memory T-cells should first be performed by 
screening against a panel of cells expressing most common HLA molecules, such as a panel 
of EBV LCLs as described elsewhere (1). However crossreactivity should be confirmed using 
a single HLA transfected cell type. This will not only confirm the individual HLA molecule 
recognized but also exclude the possibility of the clone recognizing viral peptides presented 
on allo-HLA.
Single HLA transfected K562 cells (SALs) are a new sensitive and specific tool to detect allore-
sponses from viral specific T-cells (2). SALs express only the transfected HLA class I molecule 
(3), unlike C1R cells that may have low expression of other HLA molecules. For example, the 
previously described alloreactivity of the EBV EBNA3A specific T-cell against HLA-B*4402 
has been confirmed using SALs (2). Furthermore, the same T-cell clone was also found to 
recognize HLA-B*5501 expressing SALs (2). Suggesting that SALs may be a more sensitive 
target than other cells expressing multiple HLA molecules.
 
Therefore detection of HLA-specific alloresponses from viral specific T-cells in-vitro is now 
feasible in the routine laboratory.
This technique to define cross-reactive T-cells may lead to important future improvements 
in donor selection and monitoring. The ability to define public TCR responses that give spe-
cific allo-HLA crossreactivity may assist in the definition of (un)acceptable mismatches. If in 
vitro tools can more specifically predict which transplant recipients are at risk for rejection 
and which patients are predisposed to tolerance, the immunosuppressive regimen could be 
adjusted accordingly. We also hypothesize that anti-viral therapy may decrease the proportion 
and activation status of these alloreactive T-cells.
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2. MATERIALS
2.1 Viral specific T-cell cloning using single cell sorting
1. Viral peptide/HLA tetrameric complex of interest
2. PBMCs from donor known to have viral peptide/HLA complex binding T-cells in the pe-
ripheral blood (or at least known to be serologically positive for virus of interest)
3. Iscoves Modified Dulbecco Medium (IMDM) with L-glutamine
4. Fetal Calf Serum (FCS)
5. Human Serum (HS)
6. Phytohaemagglutinin (PHA) 800ng/mL
7. Interleukin-2 (IL-2)
8. FACS sorting apparatus e.g. FACSAriaII
2.2 Generation of single HLA transfected K562 cells lines (SALs)
1. K562 cell line
2. plasmid (pLNCX, pCDNA3.0, resistant for neomycin (G418), pEAK10 resistant for puro-
mycin, with HLA-cDNA construct (10 μg per transfection)
3. IMDM supplemented with L-glutamine
4. Fetal Calf Serum (FCS)
5. G418 (200 μg/ml)
6. Pen/strep
7. Gene pulser (Biorad)
8. Dynabeads Sheep anti Mouse Ig
9. w6/32 (anti MHC class I antibody), w6/32-PE, w6/32-FITC
10. Goat anti Mouse FITC
11. Puromycin (0.5 μg/ml)
12. Hygromycin (50 μg/ml)
13. Sterile Gen pulser 0.4 cm cuvettes (Biorad)
14. FACS calibur flow cytometer
15. FACS tubes
16. Solution of 0.1% BSA in PBS
17. HLA-specific Human Monoclonal Antibodies 
18. Rabbit anti Human IgG FITC




23. 15 ml tubes
24. Dynal magnet
2.3 IFNgELISA
1. Viral specific T-cell clone
2. SALs transfected with the HLA molecule of interest
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3. Non transfected K562 cells
4. Viral peptide for which the clone is specific (positive control), and a control viral peptide





10. Sterile 96 well round bottom plates
11. Human IFN-γ Elisa kit.
2.4 Cytotoxicity assay
1. Viral specific T-cell clone
2. SALs transfected with the HLA molecule of interest
3. Non transfected K562 cells 
4. Viral peptide for which the clone is specific (positive control), and a control viral peptide
5. IMDM supplemented with L-glutamine
6. FCS
7. HS
8. Phytohaemagglutinin (PHA) 800ng/mL
9. Interleukin-2 (IL-2)
10. Sodium Chromate (1 mCi/ml (370mBq))
11. 1% Triton X-100
12. 96-well round bottom plates  
3. METHODS
3.1 Viral Specific T-cell Cloning using single cell sorting
1. Perform all steps at 4 degrees
2. Ensure person for single cell sorting is serologically positive for virus and has a population 
of the relevant tetramer binding T-cells
3. Wash PBMCs twice in medium containing 1% FCS
4. Add tetramer-PE at high concentration e.g. 1:100
5. Add negative markers CD45Ra/CD4/CD14-FITC
6. Incubate 30 minutes
7. Wash PBMCs twice in medium containing 1% FCS
8. Place 5 million cells for sorting in 1mL 10% FCS/IMDM without phenol red
9. Prepare T-cell Medium - 5% FCS/5% Human serum in IMDM medium with 1% Penicillin/
Streptamycin, 3mg L-Glutamine and IL-2 100 IU/mL
10. Prepare T-cell feeder mix – To the T-cell medium add 0.5 million irradiated feeder cells, 
0.05 million EBV LCLs and 2mL PHA per mL of required feeder mix.
11. Prepare 96 well round bottom plate(s) with 100mL feeder mix per well.
12. Perform single cell sorting based on tetramer positive gate using single cell sorting ap-
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paratus
13. Add further 100mL T-cell medium per well on day 7
14. At day 14 select expanding wells and restimulate in 24 well plate with 1mL feeder mix.
15. After day 6 confirm tetramer positivity of T-cell clones
16. Determine Vb TCR usage using Vb kit or TCR PCR.
17. Freeze interesting clones after expansion.
18. 1 million defrosted T-cell clone can be restimulated in T-cell medium with 5 million feed-
er cells, 0.5 million EBV LCLs and 2uL/mL PHA
3.2 Generation of single HLA transfected K562 cells lines (SALs)
1. Culture K562 until you have 10*106 cells per transfection in IMDM supplemented with 
10% FCS and pen/strep
2. Spin down the cells and wash two times in IMDM/10%FCS
3. Count the cells and resuspend the cells in IMDM/10%FCS at a concentration of 10*106 
cells per ml
4. Mix 1 ml of the cells with 10μg of the plasmid DNA
5. Put 1 ml of the cell/DNA mixture in a 0.4 cm cuvette and store on ice for a minimum of 5 
minutes
6. Mix and pulse (960 μF, 230 V)
7. Store on ice for 15 minutes
8. Add a few drops of medium to the cuvette and transfer the cells to a culture flask containing 
9 ml medium (IMDM/10%FCS/pen/strep)
9. Culture the cells for two days
10. Add selection antibiotic at the correct final concentration
11. Culture for another week
12. Perform a flow cytometry test to see whether there are HLA-positive cells (incubate 105 
cells with w6/32-PE for 30 minutes on ice, wash twice, take up in 100 μl PBS/1% paraformal-
dehyde, read in FACS calibur and analyze)
13. If positive cells are present, separate positive cells from negative cells
14. Take 20-25 ml of your cultured cells (leave some in the flask and continue culturing them)
15. Spin down, remove supernatant and resuspend the cell pellet
16. Add 0.5 ml un-labeled-w6/32 and mix
17. Incubate on ice for 30 minutes
18. Wash 3 times with ice cold medium (IMDM/10%FCS) in a 15 ml tube
19. Resuspend the cells and add 30 μl Sheep anti Mouse dynabeads 
20. Incubate on a rollerbench in 4°C room for 30 minutes
21. Put the tube in the magnet, add 10 ml icecold medium
22. Wait for 5 minutes
23. Remove the medium with the non bound cells
24. Repeat from step 21 twice
25. Add 10 ml ice cold medium and resuspend the cells bound to the beads, put them in a 
small culture flask
26. Wait for the cells to grow
27. When the cells expanded well, remove the beads as follows
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28. Put the cells in a 15 ml tube in the magnet
29. Wait for five minutes
30. Collect the medium with the cells in a culture flask, leave the beads in the tube
31. Add 10 ml fresh medium
32. Repeat twice from step 28
33. After a few days growing test the class I expression of the cells (step 12)
34. If there still are cells with no expression at all, repeat the bead sorting
35. If the cells all have a good expression, freeze several samples
36. Test the cells with a flow cytometry test against a panel of Human monoclonal antibodies 
to confirm the HLA-type of the cell
3.3 IFNg ELISA using responder viral specific T-cell clones and SAL stimulator cells
1. Harvest the T-cell clone
2. Make a T-cell clone solution of 0.1*106/ml in T-cell medium
3. Dilute the SAL’s and the K562 line in T-cell medium to a concentration of 0,25.106/ml.
4. Add 50µl /well of the T-cel clone in a sterile 96 well plate
5. Add 100µl /well of the different SAL’s in duplicate or triplicate to the clone 
6. Use a SAL transfected with the restricting HLA molecule loaded with the viral peptide that 
is recognized by the clone as a positive control
7. Use a SAL transfected with the restricting HLA molecule loaded with the control peptide 
that is not recognized by the clone as a negative control
8. Use non transfected K562 as a negative control
9. As background control also add only T-cell medium to some of the wells without SALs
10. Incubate 24 hours at 37°C, 5% CO2
11. Transfer 120µl supernatant to a new 96 well plate and store the samples at -20°C till use 
in IFNg ELISA
12. Thaw the supernatants and use in an IFN-γ ELISA according to the manufacturer’s pro-
tocol. 
3.4 Cytotoxicity assay using effector viral specific T-cell clones and SAL target cells 
1. Harvest the SALs and the K562 line and spin down the cells 
2. Use a SAL transfected with the restricting HLA molecule loaded with the viral peptide that 
is recognized by the clone as a positive control
3. Use a SAL transfected with the restricting HLA molecule loaded with the control peptide 
that is not recognized by the clone as a negative control
4. Use non transfected K562 as a negative control
5. Add the appropriate amount of sodium chromate to the cell pellets 
6. Incubate the cells in a 37°C water bath for one hour
7. Meanwhile harvest the T-cell clone and make the necessary dilutions of the clone. Add 
100µl/well in a 96 well plate.
8. Wash the chromium labeled cells 3 times with 4ml IMDM+1%FCS
9. Add the labeled target cells to the T-cell clone in a concentration of 5000cells/100µl per 
well.
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10. Make a control plate for spontaneous and maximum release. For each target make 3 wells 
with 100 µl TCM and 3 wells 100 µl 1% Triton X-100. Add 100ul target suspension per well.
11. Spin the plates 1 minute 2000 rpm
12. Incubate the plates 4 hrs at 37°C, 5%CO2
13. Spin the plates 1 minute 2000 rpm
14. Harvest the supernatants
15. Measure the chromium release and calculate the specific lysis.
 
4. NOTES
4.1 Viral Specific T-cell cloning using single cell sorting
1. We recommend using PE-labelled tetrameric complexes
2. Prior to attempting sorting we recommend screening first for the presence of viral peptide/
HLA tetramer complex binding T-cells within the peripheral blood of the donor. Ensuring 
the donor has a high proportion of the viral specific T-cells of interest in the peripheral blood 
increases the probability of successful sorting and cloning. Viral seropositivity does not guar-
antee the donor blood will contain T-cells with the viral specificity of interest.
3. Do not forgot control tubes for set up of single cell sorting apparatus
4. Viral specific T-cell clones are used to confirm that the alloreactivity and viral specificity 
are mediated by the same TCR. Viral specific T-cell lines can also be generated by sorting 
multiple tetramer complex binding T-cells per well (e.g. 25 cells/well). T-cell lines are useful 
for screening purposes and may contain T-cells with the same viral specificity but different 
TVR Vb usage to that of the single cell sorted clones.
5. Freshly defrosted PBMCs are suitable for single cell sorting.
6. Only freshly collected PBMCs are suitable as feeder cells. Previously frozen cells are not 
suitable.
7. EBV LCLs can be used to provide additional non-specific stimulation to the sorted T-cells 
however are not definitely required for successful stimulation.
8. We recommend using fresh T-cell medium for every T-cell sorting or stimulation (Maxi-
mum two weeks old).
9. Perform all steps prior to sorting at 4 degrees. When tetramers are used at room tempera-
ture they are capable of activating the viral specific T-cells for sorting.
10. For single cell sorted wells expect growth at day 12-14.
11. The TCR will often be absent from the cell surface for the first 5 days after sorting/stimula-
tion.
4.2 Generation of single HLA transfected K562 cells lines (SALs)
1. Leaving SALs at 26°C for two nights increases HLA expression
2. Culturing SALs with HLA-leader peptides increases the HLA expression of HLA-A and 
HLA-C SALs
3. Flow cytometry tests for HLA should always be performed on ice to avoid capping
4. When you have a low number of HLA-positive cells (before sorting) use PE-labeled w6/32, 
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it is more sensitive than FITC-labeled w6/32 
5. IFNg stimulation probably does increase HLA expression. 
6. K562 cells do not have functional CIITA gene product (4).
4.3 IFNg production from viral specific T-cell clones using SAL stimulator cells
1. Viral specific T-cell clones should be used in IFNg ELISA assays at day 9-10 after stimula-
tion. Earlier use of the T-cell clone may be associated with ongoing IFNg production from the 
T-cells.
2. For easy transfer of your supernatants, make the layout of your culture plate the same as the 
layout of the ELISA plate and leave wells open for your standard dilutions and blank. 
3. When the supernatants have to be stored for a longer period (> 1 month) it is better to store 
them in small siliconized vials.
4.4 Cytotoxicity assay using SAL target cells
1. Cytotoxicity assays are best performed at day 7-8 after stimulation.
2. The effector target ratio’s used are commonly 30:1, 10:1, 1:1 and 0.1:1.
3. The half life off sodium chromate is short, be sure to use the right amount.
4. The cells survive better if the wash medium contains protein (e.g. 1% FCS). Instead of 
IMDM you can also use other media for washing e.g. RPMI
5. % specific lysis= ((test release - spontaneous release) /(maximum release - spontaneous 
release))x100%.
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Graft-versus-host disease and graft rejection are major complications of allogeneic HLA-mis-
matched stem cell transplantation or organ transplantation that are caused by alloreactive T 
cells. Because a range of acute viral infections have been linked to initiating these complica-
tions, we hypothesized that the cross-reactive potential of virus-specific memory T cells to 
allogeneic (allo) HLA molecules may be able to mediate these complications. To analyze the 
allo-HLA reactivity, T cells specific for Epstein-Barr virus, cytomegalovirus, varicella zoster 
virus, and influenza virus were tested against a panel of HLA-typed target cells, and target cells 
transduced with single HLA molecules. Eighty percent of T-cell lines and 45% of virus-specif-
ic T-cell clones were shown to cross-react against allo-HLA molecules. The cross-reactivity of 
the CD8 and CD4 T-cell clones was directed primarily against HLA class I and II, respectively. 
However, a restricted number of CD8 T cells exhibited cross-reactivity to HLA class II. T-cell 
receptor (TCR) gene transfer confirmed that allo-HLA reactivity and virus specificity were 
mediated via the same TCR. These results demonstrate that a substantial proportion of virus-
specific T cells exert allo-HLA reactivity, which may have important clinical implications in 
transplantation settings as well as adoptive transfer of third-party virus-specific T cells.




HLA disparity between donor and recipient increases the risk and the severity of graft-versus-
host disease (GVHD) after stem cell transplantation (SCT). The risk of graft rejection is also 
significantly increased in HLA-mismatched compared with HLA-matched SCTs and solid 
organ transplantations. The negative effect of HLA disparity on the clinical outcome of trans-
plantations is the result of high frequencies of alloreactive T cells. In HLA-mismatched mixed 
lymphocyte reactions, the frequency of reactive T cells was demonstrated to be a 1000-fold 
higher than the frequency of T cells reactive in HLA-identical mixed lymphocyte reactions 
(1,2). By testing alloreactive T cells against panels of third-party target cells expressing dif-
ferent HLA molecules (1,3–5) and against target cells blocked with different HLA antibod-
ies (6–8), it was determined that the recognition exhibited by alloreactive T cells is directed 
against non–self-HLA (allo-HLA) molecules, and that the frequency of allo-HLA–reactive T 
cells ranged from 1% to 10%.
During thymic development, T cells undergo an instruction process of positive and negative 
selection that results in the composition of a mature T-cell repertoire that is selected on the 
basis of tolerance for self-HLA molecules presenting self-peptides (9,10). However, during 
thymic development, T cells never encounter allo-HLA molecules, and therefore no selec-
tion based on tolerance for allo-HLA molecules occurs. We therefore hypothesize that every 
antigen-specific self-HLA–restricted T-cell could potentially cross-react with non–self-HLA 
molecules and exert allo-HLA reactivity. 
Although it was shown that alloreactivity is equally presented in the naive and memory T-cell 
populations (11), the ability of T cells to exhibit allo-HLA reactivity could have especially 
serious consequences when exerted by memory T cells. Memory T cells lack the require-
ment for costimulation (12,13), and therefore allo-HLA reactivity of memory T cells can be 
efficiently triggered by nonprofessional antigen-presenting cells after HLA-mismatched SCT 
or solid organ transplantation. Based on the restricted T-cell receptor (TCR) repertoire of 
virus-specific memory T cells (14–17), the number of different virus-specific T cells will be 
limited, but the total number of virus-specific T cells with an identical TCR will be much 
higher in the memory pool compared with the naive compartment. T cells directed against 
latent viruses, such as Epstein-Barr virus (EBV) and cytomegalovirus (CMV), are present at 
high frequencies in blood of healthy persons and patients (18–21). Therefore, if certain virus-
specific T cells with cross-reactive potential against the mismatched allo-HLA molecule are 
triggered by viral activation and expanded in the memory pool, these T cells will react against 
the mismatched HLA molecule, and may induce severe GVHD or graft rejection.
Studies by Burrows et al first illustrated that virus-specific T cells exert allo-HLA reactivity by 
demonstrating that EBV-EBNA3A–specific HLA-B8–restricted T cells cross-react with HLA-
B44 (22,23). T cells specific for HSV-VP13/14 presented in HLA-A2 were also found to cross-
react with HLA-B44 (24) and CD4 T cells specific for tetanus toxoid presented in HLA-DR3 
were found to be cross-reactive against HLA-DR4 (25). In addition, the association between 
reactivation of viral infections during organ transplantation and increased graft rejection (26) 
supports the hypothesis that virus-specific T cells exhibit allo-HLA–reactive potential. 
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In this study, we investigate the ability of a large panel of virus-specific T cells to exert allo-
HLA reactivity. We determined the cross-reactive potential of virus-specific T cells to allo-
HLA molecules by screening single viral antigen-specific T-cell lines and clones against a 
panel of EBV-transformed B cells (EBV-LCLs), together covering almost all prevalent HLA 
class I and II molecules, as well as single HLA-transduced target cells. The tested CD8 and 
CD4 virus-specific memory T cells were specific for Epstein-Barr virus (EBV), cytomegalo-
virus (CMV), varicella zoster virus (VZV), and influenza virus (Flu). Most virus-specific T-
cell lines and 45% of the virus-specific T-cell clones were demonstrated to be cross-reactive 
against allo-HLA molecules. TCR gene transfer demonstrated that the virus specificity and 
the cross-reactivity to allo-HLA molecules were mediated by the same TCR. These results 
demonstrate that T cells specific for different viruses exert cross-reactivity to allo-HLA mol-
ecules, and illustrate the high frequency of T cells able to exert allo-HLA reactivity. 
METHODS
Cell collection and preparation
After informed consent was given in accordance with the Declaration of Helsinki, peripheral 
blood (PB) was obtained from different persons. All experiments were approved by the Leiden 
University Medical Center ethics committee. Mononuclear cells (MNCs) were isolated by Fi-
coll-Isopaque separation and cryopreserved. Stable EBV-LCLs were generated using standard 
procedures. EBV-LCLs and K562 cells were cultured in Iscove modified Dulbecco medium 
(IMDM; Lonza) and 10% fetal bovine serum (FBS; Lonza). Phytohemagglutinin (PHA) blasts 
were generated by stimulation of PB-MNCs with PHA (0.8 µg/mL; Murex Biotec Limited) in 
IMDM, 5% FBS, 5% human serum, and interleukin-2 (IL-2; 120 IU/mL). K562 and EBV-LCLs 
expressing single allo-HLA molecules were generated by transduction with retroviral vectors 
encoding for the allo-HLA molecules or by transfection of allo-HLA molecules (27,28). For 
the isolation of T cells, B cells, and monocytes, peripheral blood mononuclear cells of healthy 
donors were stained with either anti-CD3, anti-CD19, or anti-CD14 magnetic-activated cell 
sorting beads (Miltenyi Biotec), respectively, and isolated according to the manufacturer’s 
instructions. CD40 ligand (CD40L)–activated B cells were generated by culturing the CD19+ 
fraction for 3 days on CD40L-transduced murine fibroblasts (29) in medium containing CpG 
(10 µg/mL) and IL-4 (500 IU/mL; Schering-Plough). Monocyte-derived DCs were generated 
by culturing the CD14+ fraction in medium containing activating cytokines as described 
previously (30). Fibroblasts were cultured from skin biopsies in Dulbecco modified Eagle 
medium (Lonza) with 1 g/L glucose (BioWhittaker) and 10% FBS.
 
Generation of virus-specific T-cell lines and clones
PB-MNCs from healthy persons were stained with tetramer and anti-CD8 monoclonal an-
tibody (mAb) for 1 hour at 4°C and washed once. The tetramers used were constructed as 
described previously (31) and are shown in Table 1. Tetramer-positive, CD8+ T cells were 
sorted at 50 cells per well for the generation of lines or a single cell per well for the generation 
of clones into U-bottom microtiter plates containing 100 µL of feeder mixture. Sorting was 
performed at 4°C using the FACSVantage (BD). The feeder mixture consisted of IMDM, 5% 
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FBS, 5% human serum, IL-2 (120 IU/mL), PHA, and 30 Gy irradiated allogeneic third-party 
PB-MNCs (0.5 x 106/mL). Proliferating T-cell clones were selected and further expanded by 
nonspecific stimulation every 14 days using the previously mentioned feeder mixture. The 
viral specificity of the expanded lines and clones was confirmed by tetramer staining, cytotox-
icity, and cytokine production assays. Polyclonality or monoclonality of the T-cell lines and 
clones was analyzed by TCR Vβ analysis using the TCR Vβ kit (Beckman Coulter).
Table 1. Tetramers used for the generation of virus specific T-cell lines and clones
Allo-HLA reactivity of the virus-specific T-cell lines and clones
In the interferon-g  (IFNg) production assays, 5000 T cells were cocultured with 20 000 stimu-
lator cells in a final volume of 150 µL IMDM culture medium supplemented with 100 IU/mL 
IL-2. After 18 hours of incubation, supernatants were harvested and IFNg production was 
measured by standard enzyme-linked immunosorbent assay (ELISA; CLB). In the cytotoxic-
ity assays, the virus-specific T-cell clones were tested in a standard 6-hour 51Cr-release assay 
(32) against EBV-LCLs at an effector to target ratio of 10:1. 





The TCRAV and TCRBV gene usage of the BRLF1/HLA-A3 clone 19 and the VZV-IE62/
HLA-A2–specific T-cell clone 7 was determined using reverse transcriptase–polymerase 
chain reaction and sequencing (27). Retroviral vectors were constructed that encoded the 
TCRa  chain in combination with green fluorescent protein and the TCRβ chain in combi-
nation with the marker gene NGF-R (27). CMV-IE1/HLA-A1–specific T cells derived from 
an HLA-A*0301–negative healthy person were transduced with the TCRa and TCRβ of the 
BRLF1/HLA-A3 clone 19. CMV-pp50/HLA-A1–specific T cells derived from peripheral 
blood of a healthy person negative for HLA-A*0201 and HLA-A*0205 were transduced with 
the retroviral vectors encoding for the TCRa and TCRβ chain of the VZV-specific T-cell 
clone (27). The TCR-transduced T cells were sorted on basis of double positivity for green 
fluorescent protein and NGF-R, and after expansion the T cells were tested for viral specificity 
and allo-HLA reactivity in stimulation assays. 
RESULTS
Alloreactivity of virus-specific T-cell lines
To investigate the ability of virus-specific T cells to exert alloreactivity, virus-specific T-cell 
lines were tested against a panel of EBV-LCLs, together covering almost all frequently oc-
curring HLA class I and II molecules. The HLA-typing of the EBV-LCLs used in the panel is 
listed in Table 2. The virus-specific T-cell lines were generated by isolation of tetramer-posi-
tive CD8+ T cells by fluorescence-activated cell sorting and subsequent expansion. Tetramer 
and CD8 staining confirmed the purity of the virus-specific lines and showed that all T-cell 
lines were more than 98% tetramer positive (Figure 1A-G). In total, 11 virus-specific lines 
were tested, derived from 9 different donors, specific for 7 different antigens of CMV, EBV, 
and VZV and restricted to 3 different HLA molecules. In the figures in which EBV-specific 
T-cell lines were tested, the EBV-LCLs expressing the HLA molecules to which the T-cell 
lines were restricted were not shown, to present only the alloreactivity of the T cells and not 
the virus specificity. All LCLs were tested for IFNg production in the absence of T cells and 
did not show production of IFNg (data not shown). In Figure 1A through G, 7 representative 
lines are shown. Of the 11 tested virus-specific T-cell lines, 9 were shown to be alloreactive, 
because these lines produced IFNg upon stimulation with at least 1 of the EBV-LCLs of the 
panel. Of the 11 tested lines, 2 exerted no alloreactivity against the EBV-LCLs tested in our 
panel (including Figure 1C). The recognition pattern of the virus-specific lines that demon-
strated alloreactivity ranged from recognition of almost all EBV-LCLs, as shown in Figure 1A 
and B by the CMV-pp50/HLA-A1–specific lines of patients MBX and UKL, to recognition 
of a limited number of EBV-LCLs, as shown by the IE1/HLA-B8–, BMLF1/HLA-A2–, VZV-
IE62/HLA-A2–, and EBNA3A/HLA-B8–specific lines (Figure 1D, E, F, and G, respectively). 
The pattern of allorecognition of some of the T-cell lines suggested that the alloreactivity was 
directed against 1 or several of the allo-HLA molecules presented by the EBV-LCL panel. The 
BMLF1/HLA-A2–specific line showed high reactivity against 6 EBV-LCLs, of which 5 EBV-
LCLs expressed HLA-A*1101. All HLA-A*1101–expressing EBV-LCLs within this panel 
were highly recognized by this T-cell line. The EBV-LCLs recognized by the EBNA3A/HLA-
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Table 2. HLA expression of the EBV-LCL panel
B8–specific line expressed either HLA-B*4402 or HLA-B*5501. TCR Vβ analysis of the lines 
demonstrated that the complexity of the TCR composition was correlated with the broadness 
of the alloreactivity. T-cell lines that did not show alloreactivity expressed maximally 2 differ-
ent TCR Vβ chains. T-cell lines with limited alloreactivity expressed 1 to 4 different TCR Vβ 
chains, and lines that recognized almost all EBV-LCLs expressed at least 8 different TCR Vβ 
chains. This relation between the clonal composition and the recognition of the lines suggests 
that the alloreactivity of the lines is the sum of the alloreactivity of the various clonal popula-
tions present within the lines. 
The results demonstrate that 80% of the tested virus-specific T-cell lines were able to exert 
alloreactivity. Some virus-specific lines showed a pattern of alloreactivity suggestive of allo-
HLA reactivity. However, for most of the virus-specific cell lines, allo-HLA reactivity could 
not be determined because the exerted alloreactivity was very broad.
The panel of EBV-transformed B cells (EBV-LCLs) was composed of HLA-typed EBV-LCLs, which to-
gether covered almost all frequently occurring HLA molecules. The HLA typing was determined mainly 
molecularly; however, some EBV-LCLs were only serologically typed. ND indicates that the HLA ex-
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Figure 1. Alloreactivity of virus-specific T-cell lines. 
Eleven virus-specific T-cell lines, of which 7 are shown in this figure, were stimulated with a panel of 
EBV-LCLs for 18 hours and IFNg production was measured by ELISA. In experiments in which EBV-
specific T-cell lines were tested, we excluded the EBV-LCLs expressing the HLA molecules to which 
the T-cell lines were restricted. The purity of the virus-specific lines was analyzed by tetramers and 
CD8 staining, and all T-cell lines proved to be more than 98% pure. As a positive control, the lines 
were tested against EBV-LCLs expressing the HLA-restricting molecule of the viral epitope, loaded with 
the viral peptide recognized by the T-cell lines (pept). (A) The CMV-pp50/HLA-A1–specific lines of 
patient MBX recognized almost all EBV-LCLs. (B) The CMV-pp50/HLA-A1–specific line of patient 
UKL showed broad alloreactivity. (C) Two of the 10 tested T-cell lines exerted no alloreactivity against 
the tested EBV-LCLs of which 1, the pp50/HLA-A1–specific line, is shown. (D) The CMV-IE1/HLA-B8 
recognized a limited number of EBV-LCLs. (E) The BMLF1/HLA-A2–specific line showed high reactiv-
ity against all HLA-A11–positive EBV-LCLs and 1 HLA-A11–negative EBV-LCL. (F) The VZV-IE62/
HLA-A2–specific line of patient PKO recognized a limited number of EBV-LCLs. (G) EBNA3A/HLA-
B8–specific line recognized EBV-LCLs expressing either HLA-B44 or HLA-B55. Experiments were per-
formed in duplicate, mean values are shown ± SD.
Allo-HLA reactivity of virus-specific T-cell clones
Because we were unable to determine allo-HLA reactivity with the oligoclonal virus-specific 
T-cell lines, further characterization of the allo-HLA reactivity of virus-specific T cells was 
performed with T-cell clones. For this purpose, tetramer-positive T cells were sorted at a 
single cell per well and expanded. The specificity of the T-cell clones was confirmed by te-
tramer staining, and the TCR Vβ usage of the clones was analyzed using the TCR Vβ kit. The 
T-cell clones as shown in Table 3 were different based on either their different origin, TCR 
Vβ usage, or recognition pattern. In total, 41 virus-specific CD8 and CD4 T-cell clones were 
tested against the EBV-LCL panel. These virus-specific T-cell clones were derived from 16 
persons, specific for 13 different CMV, EBV, VZV, and Flu antigens and restricted to 8 differ-
ent HLA molecules. The results demonstrated that 18 of the 41 virus-specific CD8 and CD4 
T-cell clones were alloreactive, as shown by recognition of at least 1 of the EBV-LCLs from 
the panel. Most alloreactive T-cell clones exhibited cross-reactivity against EBV-LCLs that 
shared an HLA molecule, suggesting allo-HLA reactivity. To confirm that the reactivity of a 
T-cell clone was directed against a specific allo-HLA molecule, the virus-specific T-cell clones 
were tested against HLA-negative K562 cell line or EBV-LCLs negative for the recognized 
allo-HLA molecules, which were transduced with the particular allo-HLA molecule. The allo-
HLA reactivity of 7 representative T-cell clones is shown in Figure 2A-G. The EBV-EBNA3A/
HLA-A3–specific CD8 T-cell clone exhibited alloreactivity against all HLA-A*3101–express-
ing EBV-LCLs within the panel. The reactivity directed against allo–HLA-A*3101 was con-
firmed by transfection of K562 with HLA-A*3101 and subsequent recognition by this T-cell 
clone (Figure 2A). The EBV-EBNA3A/HLA-A3 clone also recognized the HLA-A*3101–
negative EBV-LCL RSW, which however expressed HLA-A*3001. HLA-A*3101 and HLA-
A*3001 are very similar in sequence and therefore we hypothesized that the molecules exhibit 
strong similarity in structure and peptide presentation, explaining recognition by this T-cell 
clone. To analyze whether the EBV-EBNA3A/HLA-A3 clone recognized HLA-A*3001, the 
clone was tested against 3 HLA-A*3001+ EBV-LCLs, of which 1 is shown in Figure 2A, and 1 
HLA-A*3101+ EBV-LCL with or without blocking mAbs directed against HLA class I, HLA-
A30/A31, and HLA-A2. All HLA-A*3001+ EBV-LCLs and the HLA-A*3101+ EBV-LCLs were 
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recognized, and this recognition was blocked by anti–HLA class I and anti–HLA-A30/A31 
mAbs and not by anti–HLA-A2 mAb, indicating that the clone indeed also recognized HLA-
A*3001. The CMV-pp50/HLA-A1–specific T-cell clone exhibited alloreactivity against all 
HLA-A*1101–expressing EBV-LCLs (Figure 2B). The allo–HLA-A*1101 reactivity could be 
confirmed by specific recognition of K562 transduced with HLA-A*1101 by this T-cell clone. 
In addition to reactivity against HLA-A*1101, the T-cell clone also exhibited low IFNg pro-
duction upon stimulation with a few EBV-LCLs negative for HLA-A*1101. Because these less 
recognized EBV-LCLs did not share one HLA molecule, we did not determine whether this 
alloreactivity was also based on allo-HLA cross-reactivity. The EBV-BRLF1–specific HLA-
A3–restricted clone, shown in Figure 2C, exerted alloreactivity against all HLA-A*0201+ EBV-
LCLs. The CD8 T-cell clone did not recognize K562 transduced with HLA-A*0201, however 
it showed recognition of EBV-LCLs transduced with HLA-A*0201, suggesting that the pep-
tide recognized by the clone in the context of HLA-A*0201 is not presented by K562 cells. 
The clone also showed recognition of HLA-A*0201+ PHA-stimulated T-cell blasts (Figure 
2C right panel), excluding the possibility that the clone recognized an EBV-derived peptide 
presented in HLA-A*0201. Next to allo–HLA-A*0201 reactivity, this T-cell clone also ex-
hibited low cross-reactivity against EBV-LCLs negative for HLA-A*0201. Because these less 
recognized EBV-LCLs did not share 1 HLA molecule, we did not determine the alloreactivity 
in detail. The CMV-pp65/HLA-B7–specific CD8 T-cell clone exhibited alloreactivity against 
2 HLA-DRB1*0801– and 1 HLA-DRB1*0806–expressing EBV-LCL present in the panel. The 
cross-reactivity exerted by this CD8 T-cell clone could be blocked with antibodies directed 
against HLA class II and HLA-DR and not by HLA class I, HLA-DQ, or HLA-DP antibod-
ies, confirming that the cross-reactivity of this virus-specific CD8 T-cell clone was directed 
against HLA-DR8. The ability of CD8 T cells to cross-react against allo-HLA class II mol-
ecules was also demonstrated by the CMV-pp65–specific HLA-B35–restricted CD8 T-cell 
clone that was shown to be cross-reactive against HLA-DRB1*0401 (Table 3). As previously 
described, we observed that the EBV-EBNA3A/HLA-B8–specific T-cell clone exhibited al-
loreactivity against all EBV-LCLs expressing HLA-B*4402 (22). Furthermore, we observed 
alloreactivity against EBV-LCLs expressing HLA-B*5501 as was recently described by us (33). 
Allo-HLA reactivity against HLA-B*4402 and HLA-B*5501 was confirmed by recognition of 
K562 transfected with either HLA-B*4402 or HLA-B*5501 by this T-cell clone (Figure 2E). 
In addition to CD8+ T-cell lines and clones, we also analyzed the cross-reactive potential of 
CD4+ T-cell clones to allo-HLA molecules. The alloreactivity of a Flu-HA/HLA-DR4–specific 
T-cell clone demonstrated to be directed against HLA-DRB1*1301. As shown in Figure 2F, 
both HLA-DRB1*1301–positive EBV-LCLs present in the panel were efficiently recognized 
by this T-cell clone. Allo–HLA-DRB1*1301 reactivity of the T-cell clone could be confirmed 
because the T cells recognized EBV-LCLs transduced with HLA-DRB1*1301, whereas non-
transduced EBV-LCLs were not recognized. In addition, allo-HLA reactivity was demon-
strated for 2 other CD4+ T-cell clones of the 5 CD4+ T-cell clones tested, indicating that virus-
specific CD4+ T cells also exert allo-HLA reactivity (Table 3). 
For 5 of the 18 allo-HLA–reactive virus-specific T-cell clones, the recognized HLA molecules 
could not be determined because the recognized EBV-LCLs did not share 1 particular allo-
HLA molecule. The alloreactivity of 1 of these clones, CMV-pp65/HLA-A2–specific clone 
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HRN 3, is shown in Figure 2G. We hypothesize that this recognition is mediated by the rec-
ognition of several HLA molecules because the reactivity could be blocked by mAb specific 
for HLA class I. 
The results of the allo-HLA reactivity exerted by the virus-specific T-cell clones are summa-
rized in Table 3, and demonstrate that approximately 45% of the virus-specific memory CD4 
and CD8 T-cell clones exhibit cross-reactivity to allo-HLA molecules. The cross-reactivity of 
the CD8 and CD4 T-cell clones was directed primarily against HLA class I and II, respectively. 
However, cross-reactivity of CD8 T cells directed against HLA class II was also observed. 
Figure 2. Allo-HLA reactivity of virus-specific T-cell clones. 
Forty-one virus-specific T-cell clones, of which 7 are shown in this figure, were stimulated with a panel 
of EBV-LCLs for 18 hours, and IFNg production was measured by ELISA. (A) The EBV-EBNA3A/
HLA-A3–specific T-cell clone 1 exhibited alloreactivity against all EBV-LCLs expressing HLA-A*3101 
and 1 EBV-LCL expressing HLA-A*3001. To confirm allo–HLA-A*3101 reactivity, clone 1 was tested 
against K562 cells (K562), K562 cells transduced with HLA-A*0201 (K562+A2), K562 cells transfected 
with HLA-A*3101 (K562+A31), and HLA-A*3101–negative (A31neg LCL) and HLA-A*3101–positive 
(A31+LCL) EBV-LCLs. To confirm the reactivity against HLA-A*3001, the clone was tested against 3 
HLA-A*3001+ EBV-LCLs, of which 1 is shown, and 1 HLA-A*3101+ EBV-LCLs with or without blocking 
mAbs directed against HLA class I, HLA-A30/A31, and HLA-A2. (B) The CMV-pp50/HLA-A1–spe-
cific T-cell clone 24 exhibited alloreactivity against all HLA-A*1101–expressing EBV-LCLs. To confirm 
allo–HLA-A*1101 reactivity, clone 24 was tested against K562 cells (K562), K562 cells transduced with 
HLA-A*0201 (K562+A2), K562 cells transduced with HLA-A*1101 (K562+A11), and HLA-A*1101–
positive EBV-LCLs (A11+LCL). (C) The EBV-BRLF1/HLA-A3–specific clone 19 exerted alloreactivity 
against all HLA-A0201+ EBV-LCLs. This T-cell clone did not recognize K562 transduced with HLA-
A*0201 (K562+A2). To confirm allo–HLA-A*0201 reactivity, clone 19 was tested against untransduced 
HLA-A*0201–negative EBV-LCLs (HLA-A2neg LCL) or transduced with HLA-A*0201 (A2 trans), and 
HLA-A*0201–positive EBV-LCLs (A2+LCL). To investigate whether this clone recognized an EBV-
derived peptide in the context of HLA-A*0201, the clone was tested against HLA-A*0201+ PHA blasts 
and HLA-A*0201–positive and –negative EBV-LCLs as controls. (D) The CMV-pp65/HLA-B7–specific 
T-cell clone 11 exhibited reactivity against all 3 HLA-DRB1*0801+ EBV-LCLs. To confirm allo–HLA-
DRB1*0801 reactivity, clone 11 was tested against the 3 HLA-DRB1*0801+ EBV-LCLs, of which 1 is 
shown, in the presence of either no blocking mAbs (no block) or anti–HLA class I (class I), anti–HLA 
class II (class II), anti–HLA-DR (DR), anti–HLA-DR (DQ), and anti–HLA-DR (DP) blocking mAbs. 
(E) The EBV-EBNA3A/HLA-B8–specific T-cell clone 9 exhibited alloreactivity against all EBV-LCLs 
expressing either HLA-B*4402 or HLA-B*5501. To confirm HLA-B*4402 and HLA-B*5501 cross-
reactivity, clone 9 was tested against K562 cells (K562), or K562 cells transfected with HLA-B*4402 
(K562+B4402) or HLA-B*5501 (K562+B5501). As controls, clone 9 was tested against HLA-B*4402– 
and HLA-B*5501–negative EBV-LCLs (neg LCL), HLA-B*4402+ EBV-LCLs (B4402+LCL), HLA-
B*5501+ EBV-LCLs (B5501+LCL), or HLA-B*0801+ K562 loaded with viral peptide (K562+B8+pept). 
(F) The Flu-HA/HLA-DR4–specific clone 5 recognized all HLA-DRB1*1301+ EBV-LCLs. To confirm 
allo–HLA-DRB1*1301 reactivity, clone 5 was tested against HLA-DRB1*1301+ EBV-LCLs (FAQ DR13+ 
and IZA DR13+) as well as HLA-DR13–negative EBV-LCLs nontransduced (DR13 neg) or transduced 
with HLA-DRB1*1301 (DR13 trans). (G) The CMV-pp65/HLA-A2–specific clone HRN 3 recognized 
EBV-LCLs that did not share 1 particular allo-HLA molecule. To investigate whether this reactivity was 
based on allo-HLA recognition, the clone was tested against 4 of the recognized EBV-LCLs with and 
without blocking mAb directed against HLA class I. Experiments were performed in duplicate, mean 
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Table 3. Allo-HLA reactivity of virus-specific T-cell clones
TCR indicates T-cell receptor; and UD, undetermined allo-HLA reactivity, which could not be charac-
terized because the recognized EBV-LCLs did not share one particular allo-HLA molecule.
* The TCR Vβ of the clone could not be determined with the TCR Vβ kit.
Different allo-HLA recognition by T-cell clones with the same specificity but different TCR usage
Burrows et al showed that EBV-EBNA3A–specific HLA-B8–restricted T-cell clones, derived 
from different HLA-B44–negative persons, were all alloreactive against HLA-B44 (22,23). It 
could therefore be suggested that allo-HLA reactivity of virus-specific T cells can be pre-
dicted. However, the EBV-EBNA3A response in HLA-B8+, HLA-B44– persons is a very homo-
geneous response in which all T cells express an almost identical public TCR (34). This is in 
contrast to most virus responses, which are usually oligoclonal and different among persons 
(16,35) (Table 3). To assess whether virus-specific T cells sharing the same antigen specificity 
but expressing different TCRs exert the same allo-HLA reactivity, we tested the alloreactivity 
of 3 T-cell clones derived from the same person, all specific for a peptide of the IE62 protein of 
VZV presented in HLA-A*0201 but with different TCR usage. As demonstrated in Figure 3A-
C, all 3 VZV-specific T-cell clones recognized different allo-HLA molecules. Clone 5 showed 
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Figure 3. Variable allo-HLA recognition by T-cell clones with the same specificity but different TCR 
Vβ usage. To investigate whether virus-specific T cells sharing the same antigen specificity but express-
ing different TCRs exert the same allo-HLA reactivity, 3 VZV-IE62/HLA-A2–specific T-cell clones ex-
pressing different TCRs were stimulated for 18 hours with a panel of EBV-LCLs and IFNg production 
was measured by ELISA. (A) VZV clone 5 showed alloreactivity against all HLA-B*5501+ EBV-LCLs. 
To confirm allo–HLA-B*5501 reactivity, the clone was tested against K562 cells (K562), K562 cells 
transduced with HLA-A*0201 (K562+A2), K562 cells transduced with HLA-B*5501 (K562+B55), and 
HLA-B55+ EBV-LCLs (B55+LCL). (B) VZV clone 6 was alloreactive against the HLA-B*5701+ EBV-
LCLs. Clone 6 did not show reactivity against K562 cells transduced with HLA-B*5701 (K562+B57). 
To confirm allo–HLA-B*5701 reactivity, clone 6 was tested against HLA-B*5701–negative EBV-LCLs 
(HLA-B57neg LCL) or transduced with HLA-B*5701 (B57 trans), HLA-B*5701+ EBV-LCLs (B57+LCL), 
and HLA-B*5701+ PHA blasts (B57+PHA). (C) VZV clone 7 exhibited cross-reactivity against all HLA-
A*0205+ and HLA-A*0207+ EBV-LCLs. Allo–HLA-A*0205 reactivity was confirmed by testing the 
clone against K562 cells (K562), K562 transduced with HLA-HLA-A*0205 (K562+HLA-A0205), HLA-
A*0205–negative EBV-LCLs (HLA-A0205neg LCL), or these EBV-LCLs transduced with HLA-A*0205 
(A0205 trans), HLA-A*0205+ EBV-LCLs (A0205+LCL), and HLA-A*0205+ PHA blasts (A0205+PHA). 
The results demonstrate that virus-specific T cells with the same antigen specificity, but with different 
TCR usage, exert alloreactivity against different HLA molecules. Experiments were performed in dupli-
cate, mean values are shown ± SD.
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alloreactivity against HLA-B*5501, clone 6 was alloreactive against HLA-B*5701, and clone 7 
exhibited allo–HLA-A*0205 and allo–HLA-A*0207 reactivity. The recognition of the 3 clones 
together was comparable with the recognition exerted by the VZV-IE62–specific line derived 
from the same person. This confirms that alloreactivity exerted by the virus-specific lines 
shown in Figure 1 is the sum of the alloreactivity of the various clonal populations present 
within the lines. The allo-HLA reactivities of the T-cell clones were confirmed by transduc-
tion of the allo-HLA molecules in K562 or in nonrecognized EBV-LCLs. Clones 5 and 7 
recognized K562 transduced with HLA-B*5501 and HLA-*0205, respectively. Clone 6 was 
unable to recognize K562 transduced with HLA-B*5701, whereas EBV-LCLs transduced with 
HLA-B*5701 were recognized. Because this clone also recognized HLA-B*5701–expressing 
PHA-stimulated T-cell blasts, specificity against EBV-derived peptide in the context of allo–
HLA-B*5701 is excluded. These results demonstrate that virus-specific T cells with the same 
antigen specificity, but with different TCR complexes, can exert alloreactivity against different 
HLA molecules. Because T-cell responses against viruses are usually oligoclonal and different 
among people, these results indicate that allo-HLA reactivity cannot be predicted. 
The cytotoxic potential and affinity of the alloreactivity exerted by virus-specific T cells
Because cytotoxicity may be a relevant measure to predict the potency of the virus-specific T 
cells to induce GVHD or graft rejection in vivo, we investigated the allo-HLA–reactive cyto-
toxic capacity of the virus-specific T cells. Six virus-specific T-cell clones were tested against 
a panel of EBV-LCLs positive and negative for the recognized allo-HLA molecules. As shown 
in Figure 4A, all 6 T-cell clones tested showed cytotoxicity against the allo-HLA–expressing 
EBV-LCLs. 
To investigate whether the affinity of the allo-HLA–reactive response was comparable with 
the affinity of the virus-specific response, the kinetics of recognition and antigen threshold 
were tested for both specificities. For this purpose, the allo–HLA-A*3101/A*3001 reactive 
EBV-EBNA3A/HLA-A3–specific clone 19 was tested against HLA-A*0301+ EBV-LCL AST 
transduced with a retrovirus encoding for EBNA3A and against 2 HLA-A*3101+ EBV-LCLs, 
GGT and DSP at different effector-stimulator ratios. As shown in Figure 4B, the T-cell clone 
produced comparable amounts of IFNg against the virus antigen–expressing EBV-LCLs as 
against the allo-HLA expressing–EBV-LCLs in the different effector-stimulator ratios, indi-
cating that the kinetics of recognition and antigen threshold of the alloreactive response and 
the virus-specific T-cell response are comparable.
Normal cell subsets are recognized by virus-specific T cells
To extrapolate the results obtained with the EBV-LCLs and K562 cells to the recognition of 
normal cell subsets in vivo, we tested virus-specific T-cell clones against allo-HLA–express-
ing B cells, CD40L-activated B cells, T cells, PHA blasts, monocytes, monocyte-derived DCs, 
and fibroblasts with and without IFNg pretreatment. The results shown in Figure 4C demon-
strate the reactivity of 3 virus-specific T-cell clones directed against the different cell subsets. 
pp65/HLA-B*0702–specific clone 11 showed high recognition of HLA-DRB1*0801–positive 
CD40L-activated B cells and low recognition of B cells and PHA blasts. VZV-IE62/HLA-
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A*0201–specific clone 5 showed high recognition of HLA-B*5501–positive CD40L-activated 
B cells, DCs, and PHA blasts and low recognition of monocytes and T cells. This clone could 
unfortunately not be tested against fibroblasts because HLA-B*5501–positive fibroblasts were 
not available. VZV-IE62/HLA-A*0201–specific clone 6 highly recognized HLA-B*5701–pos-
itive DCs and showed low reactivity against CD40L-activated B cells, T cells, PHA blasts, and 
IFNg-stimulated fibroblasts. These results indicate that virus-specific T cells can also be reac-
tive against in vivo relevant normal cell subsets. 
Figure 4.
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One TCR complex mediates both virus specificity and allo-HLA reactivity
Because alloreactivity mediated by T cells may be explained by T cells expressing 2 TCR com-
plexes at the cell surface (36,37) we wanted to exclude that the allo-HLA reactivity was medi-
ated via another TCR than the virus-specific TCR. For this purpose, we determined the TCR 
usage of 2 representative allo-HLA–reactive virus-specific clones, the allo–HLA-A*0201–re-
active BRLF1/HLA-A*0301–specific clone 19 (Figure 2C) and the allo–HLA-A*0205–reac-
tive VZV-IE62/HLA-A*0201–specific clone 7 (Figure 3C). By reverse transcriptase–polymer-
ase chain reaction, we established that the BRLF1/HLA-A*0301–specific clone 19 expressed 
1 TCRβ gene transcript, BV7S2, and 2 TCRa transcripts, AV12S1 and AV18S1. However, 1 
of the TCRa chains, AV12S1, contained a stop codon in the CDR3 region, indicating that 
this TCR  was not expressed. Flow cytometric analysis confirmed that 100% of the T cells 
expressed TCR BV7S2 at the cell surface (data not shown). No antibodies were available for 
analysis of the specific TCRa chain expression at the cell surface. To investigate whether the 
BV7S2 and the AV18S1 mediated the dual recognition, IE1/HLA-A1–specific T cells were 
transduced with retroviral vectors encoding for these TCRa and TCRβ chains. The results 
shown in Figure 5A demonstrate that the BRLF1-TCR–transduced T cells exerted reactivity 
against HLA-A*0201–expressing target cells as well as against EBV-BRFL1 peptide–loaded 
HLA-A*0301+ target cells. No reactivity directed against peptide-loaded or HLA-A*0201–ex-
pressing target cells was observed with mock-transduced T cells. 
The VZV-IE62/HLA-A*0201 clone 7 expressed 1 TCRa transcript, AV6S1, and 1 TCRβ tran-
script, BV21S3. pp50/A1-specific T cells were transduced with retroviral vectors encoding for 
the VZV TCR chains. The results shown in Figure 5B demonstrate that the VZV-TCR–trans-
duced T cells exerted reactivity against HLA-A*0205–expressing target cells as well as against 
VZV-IE62 peptide–loaded HLA-A*0201+ target cells. No reactivity directed against peptide-
loaded or HLA-A*0205–expressing target cells was observed with mock-transduced T cells. 
These results demonstrate that the virus specificity and the allo-HLA reactivity exerted by 
these virus-specific T cells were mediated via 1 TCR complex.
Figure 4. The potency of the alloreactivity exerted by virus-specific T cells. 
(A) To investigate the allo-HLA–reactive cytotoxic capacity of virus-specific T cells, 6 virus-specific cell 
clones were tested in cytotoxicity assays against 2 EBV-LCLs expressing the recognized allo-HLA mol-
ecules and 2 EBV-LCLs negative for the allo-HLA molecules. EBV-LCLs expressing the virus-specific 
restriction molecule were loaded with the viral peptide and used as positive control for cytotoxicity. (B) 
To compare the affinities of the allo-HLA–reactive response and the virus-specific response, the allo–
HLA-A30/A31–reactive EBV-EBNA3A/HLA-A3–specific clone 19 was tested against the HLA-A*0301+ 
EBV-LCL AST transduced with a retrovirus encoding for EBNA3A and against 2 HLA-A*3101+ EBV-
LCLs GGT and DSP. To compare the kinetics of the 2 responses, the clone was tested against the EBV-
LCLs in different effector-stimulator ratios. (C) To extrapolate the results obtained with the EBV-LCLs 
and K562 cells to the recognition of normal cell subsets in vivo, we tested virus-specific T-cell clones 
against allo-HLA–expressing B cells, CD40 ligand–activated B cells (B APC), T cells, PHA blasts, mono-
cytes, monocyte-derived DCs, and fibroblasts with and without IFNg pretreatment. Experiments were 
performed in duplicate, mean values are shown ± SD.
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Figure 5. One TCR complex mediates both virus specificity and allo-HLA reactivity. 
To exclude that allo-HLA reactivity was mediated via another TCR than the virus-specific TCR, the 
TCR of 2 representative clones was transferred to T cells with a different specificity. (A) IE1/A1-spe-
cific T cells transduced with viral vectors encoding for the TCR of BRLF1/A3-specific clone 19 (IE1/
A1+BRLF1 TCR) and IE1/A1-specific T cells transduced with a mock viral vector (IE1/A1+mock) were 
tested for allo–HLA-A*0201 reactivity against HLA-A*0201–positive EBV-LCLs (A*0201 pos LCLs), 
HLA-A*0201–negative EBV-LCLs (A*0201 neg LCLs), and HLA-A*0201–negative EBV-LCLs trans-
duced with HLA-A*0201 (A*0201 td LCLs) and for BRLF1 specificity against BRLF1 peptide–loaded 
HLA-A*0301–positive EBV-LCLs (BRLF1pept /HLA-A3). (B) Pp50/A1-specific T cells transduced 
with viral vectors encoding for the TCR of VZV clone 7 (pp50/A1+VZV TCR) and pp50-specific T 
cells transduced with a mock viral vector (pp50/A1+mock) were tested for allo–HLA-A*0205 reactivity 
against HLA-A*0205–positive EBV-LCLs (A*0205 pos LCLs), K562 cells (K562), and K562 cells trans-
duced with HLA-A*0205 (K562+A*0205) and for VZV specificity against VZV-IE62 peptide–loaded 
HLA-A*0201–positive EBV-LCLs (VZVpept/HLA-A2). The results demonstrate that virus specificity 
and allo-HLA reactivity exerted by virus-specific T cells were mediated by 1 TCR complex. Experiments 
are shown in duplicate, mean values are shown ± SD.
DISCUSSION
In this study, we demonstrated that a high percentage of virus-specific memory T cells ex-
hibits cross-reactivity against allogeneic HLA molecules. CD8 as well as CD4 virus-specific 
memory T cells were demonstrated to have allo-HLA–reactive potential. In addition, we de-
termined that the alloreactivity exerted by CD8 T cells was directed against either HLA class 
I or HLA class II molecules, and that the alloreactivity of the T cells was mediated by cyto-
toxicity and cytokine production. Furthermore, we demonstrate that virus-specific T cells 
can exert allo-HLA reactivity against normal cell subsets, indicating the potential clinical 
relevance of the response. By TCR transfer, we confirmed that the allo-HLA reactivity and 
virus specificity were mediated via the same TCR. 
Most virus-specific T-cell lines and 45% of virus-specific T-cell clones directed against EBV, 
CMV, VZV, and Flu exerted alloreactivity when tested against a panel of EBV-LCLs cover-
ing almost all common HLA molecules. The cross-reactivity exerted by the virus-specific T 
cells was confirmed to be based on allo-HLA recognition by testing the T-cell clones against 
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K562 cells and EBV-LCLs transduced with single HLA molecules. Some of the alloreactive 
virus-specific T-cell clones did not recognize K562 cells transduced with the specific allo-
HLA molecules, but showed reactivity against EBV-LCLs transduced with the allo-HLA mol-
ecules. These data support the previous findings that allo-HLA reactivity is dependent on 
endogenous peptide (38). Allo-HLA cross-reactivity was directed not only against EBV-LCLs 
but also against PHA-stimulated T cells (Figure 3B), indicating that the peptides responsible 
for allo-HLA reactivity were not EBV derived. Differential recognition of HLA-transduced 
K562 cells and EBV-LCLs may indicate recognition of tissue-specific peptides in allo-HLA 
molecules. Therefore, it may be possible that we even underestimated the allo-HLA–reactive 
repertoire of T cells by initially screening only against an EBV-LCL panel. 
Burrows et al showed that EBV-EBNA3A–specific HLA-B8–restricted T cells derived from 
different HLA-B44–negative persons all exert cross-reactivity against allo–HLA-B44 (22,23). 
Based on these findings, it could be suggested that the allo-HLA reactivity of virus-specific T 
cells can be predicted. The EBV-EBNA3A–specific T cells, however, express an almost identi-
cal public TCR in all HLA-B8+ HLA-B44– persons (34), whereas most other virus responses 
are oligoclonal and the TCR usage of T cells directed against the same viral epitope is variable 
between persons (16,35) (Table 3). We have demonstrated that virus-specific T cells with 
the same antigen specificity, but expressing different TCRs, exhibit cross-reactivity against 
different HLA molecules (Figure 3). In addition, we have shown that 3 specific T-cell lines 
with the same specificity for CMV-pp50, but derived from different persons, exerted a very 
variable pattern of allo-HLA reactivity, ranging from no allo-HLA reactivity to very broad 
alloreactivity (Figure 1). These results together illustrate that the cross-reactive potential of 
antigen-specific T cells against allo-HLA molecules is difficult to predict. 
The alloreactivity exerted by the virus-specific memory CD8 and CD4 T cells was directed 
primarily against allo-HLA class I and II molecules, respectively, suggesting that the corecep-
tors expressed by the T cells contributed to the affinity of the allo-HLA reactivity. However, 
we also demonstrated allo-HLA class II recognition by a small proportion of antigen-specific 
CD8 T cells, as was also shown recently by Rist et al (39). HLA class II allorecognition by 
CD8+ T cells could indicate an HLA class II–TCR interaction that is independent of CD8 
coreceptor binding. It is, however, also possible that CD8 coreceptors bind to HLA class I 
molecules expressed on the target cell and thereby strengthen the TCR–HLA class II interac-
tion, as was previously shown (27). Although we did not observe HLA class I cross-reactive 
CD4 T cells, only a limited number of CD4 T-cell clones were tested, and therefore we cannot 
exclude that CD4 T cells may also cross-react with HLA class I complexes. 
The results of our study illustrate that approximately 45% of all T cells exert allo-HLA cross-
reactivity. However, because T cells were analyzed only for allo-HLA cross-reactivity against 
an EBV-LCL panel expressing most common HLA molecules, missing all infrequent HLA 
molecules as well as all tissue-specific peptides presented in allo-HLA molecules, we specu-
late that virtually all T cells may be allo-HLA reactive. Based on this assumption, and the fact 
that the TCR repertoire of humans is highly diverse, after HLA-mismatched transplantations 
sufficient allo-mismatched HLA cross-reactive T cells are likely to be present to induce acute 
GVHD or graft rejection. However, HLA-mismatched stem cell transplantation or solid organ 
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transplantations do not always lead to acute GVHD or graft rejection, indicating that other 
factors must be involved in these transplantation-related complications. A range of acute viral 
infections have been linked to initiating GVHD and graft rejection after transplantation (26), 
suggesting that virus-specific T cells may be mediators of GVHD and graft rejection. Because 
virus-specific T-cell responses usually have a restricted TCR usage, high numbers of T cells 
expressing an identical TCR can be found. In addition, herpes virus–specific T-cell popula-
tions can remain present at high percentages for long periods of time in healthy persons as 
well as in patients (18–21), and viral infections, leading to expansion of virus-specific T cells, 
are very common after HLA-mismatched SCT or solid organ transplantation (40–43). There-
fore, given the high proportion of virus-specific T cells and the less stringent requirements for 
activation of memory T cells (12,13), it is tempting to speculate that if the HLA type of patient 
or the transplanted organ matches the cross-reactivity of the virus-specific T cells, these allo-
HLA–reactive virus-specific memory T cells may easily induce GVHD or graft rejection. 
The ability of virus-specific T cells to exert allo-HLA reactivity may also have implications for 
the clinical applicability of virus-specific T-cell lines. Because immune deficiency for viruses 
is a common complication after SCT, broad administration of virus-specific T cells lines over 
HLA barriers to SCT patients has been proposed (44,45). The results of this study demon-
strate that administration of virus-specific T cells over HLA barriers may increase risk of 
GVHD, and indicate that virus-specific lines should be tested for alloreactivity against the 
patient before administration. 
Based on our results, we postulate that virtually all antigen-specific T cells will be cross-re-
active against allo-HLA class I or II molecules. The high alloreactive potential of particularly 
virus-specific memory T cells may have important clinical implications in transplantation 
settings.
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Background: The cross-reactivity of Epstein-Barr virus (EBV EBNA3A) specific CD8 T-cells 
against allogeneic HLA-B*44:02 has been shown to be dependent on presentation of self-
peptide EEYLQAFTY by the target antigen. Here we report that allogeneic HLA-B*44:02+ 
proximal tubular epithelial cells (PTECs) and human umbilical vein endothelial cells (HU-
VECs) are poor targets for EBV EBNA3A specific T cells. 
Methods: The EEY peptide was exogenously loaded onto HLA-B*44:02 and HLA-B*44:03 ex-
pressing PTECs and HUVECs. EEY peptide loaded, and unloaded, PTECs and HUVECs 
were then incubated with serial dilutions of our EBNA3A T-cell clone, in a cytotoxicity assay. 
Results: While HLA-B*44:02 expressing PTECs were specifically lysed in proportion to the 
effector/target ratio by the EBNA3A T-cell clone, without peptide loading, lysis was greatly 
increased by exogenous EEY peptide loading (15% vs. 75%; p<0.0001). HLA-B*44:02 ex-
pressing HUVECs were only lysed when loaded with exogenous EEY peptide (0% vs. 64%; 
p<0.0001). Lack of HLA expression and lack of ABCD3 gene expression were excluded as a 
cause for these results. PTECs and HUVECs were specifically targeted by another alloreac-
tive T-cell clone without exogenous peptide loading, suggesting that the lack of recognition 
of HLA-B*44:02+ epithelial and endothelial cells by the EBV EBNA3A T-cell clone was due to 
lack of EEYLQAFTY peptide presentation. 
Conclusions: Tissue specific (peptide dependent) alloreactivity may have important implica-





Viral infection is associated with solid organ transplant rejection and is a potent barrier to 
transplantation tolerance (1-10). It has recently been shown that allo-HLA crossreactivity 
from viral specific memory T-cells is far more common than predicted; using EBV trans-
formed B-cells (EBV LCLs) and HLA-transfected target cells (11). This allo-HLA crossre-
activity from viral specific memory T-cells has been shown to be dependent on endogenous 
self-peptide presentation by the donor cell (11-13), and therefore alloreactivity could be tissue 
cell type specific if the recognized peptide is differentially expressed by target tissues.
Early work suggested that the explanation for the presence of alloreactive memory T-cells in 
non-sensitized individuals could be crossreactivity from viral specific memory T-cells against 
allo-HLA molecules (14-15). Burrows and colleagues demonstrated the dual specificity of 
EBV EBNA3A specific T-cell clones for the immunodominant EBV peptide FLRGRAYGL 
presented on HLA-B*08:01 and the alloantigen HLA-B*44:02, to which the individual had 
never been exposed (15). The clinical relevance of this finding is reinforced by the fact that 
EBV EBNA3A specific CD8 T-cells are capable of specifically lysing HLA-B*44:02+ target cells 
in cytotoxicity assays (15-16), and that HLA-B44 is an immunogenic mismatch in HLA-B8 
kidney recipients (17).
This EBV EBNA3A T-cell allo-HLA-B*44:02 crossreactivity is dependent on presentation of 
the EEYLQAFTY self-peptide derived from the ABCD3 gene, via molecular mimicry (12). 
Despite extensive polymorphism between HLA-B*08:01 and HLA-B*44:02, and the dispa-
rate sequences of their bound viral and self-peptides respectively, the HLA-B8/FLR restricted 
TCR engages these different peptide/HLA complexes identically.
In our laboratory, various cell lines have been generated for in-vitro testing in kidney trans-
plantation research. Proximal tubular epithelial cells (PTECs) are derived from proximal tu-
bule cells taken from kidney transplant biopsy specimens (18-20), and are a useful model 
to examine alloreactivity from graft infiltrating lymphocytes (21-22). Human umbilical vein 
endothelial cells (HUVECs) are derived from healthy human post-partum umbilical tissue 
(23-25), but are also useful as a model of kidney vascular endothelial cell transplantation 
(26). Here we investigate tissue specificity of the crossreactive alloresponse by EBV EBNA3A 
specific memory T-cells, using PTECs and HUVECs as a model system for human kidney 
transplantation.
We report that in contrast to other allogeneic HLA-B*44:02+ cell lines, allogeneic HLA-
B*44:02+ PTECs are poor targets for EBV EBNA3A specific CD8 T-cells, and HLA-B*44:02 
HUVECs are not targeted at all. We hypothesized that this differential lysis of HLA-B*44:02 
expressing PTEC and HUVEC cell lines could be explained by differential tissue presentation 
of the EEYLQAFTY self-peptide. Our work with the EBV EBNA3A T-cell clone, presented 
here, confirms that (peptide-dependent) tissue specificity of allo-HLA responses from viral 
specific memory T-cells may indeed be relevant in the kidney transplantation setting. Essen-




HLA-B*44:02 expressing epithelial and endothelial cell lines are poor targets for EBV EBNA3A 
specific CD8 memory T-cells
We and others have previously shown that EBV EBNA3A specific T-cell clones exert cytolytic 
activity against allogeneic HLA-B*44:02+ EBV LCLs, PHA Blasts and HLA-B*44:02 trans-
fected K562 cells (SALs) (11, 15-16). We therefore performed cytolytic assays using HLA-
B*44:02+ PTEC and HUVEC targets to determine if allo-HLA crossreactivity from viral spe-
cific memory T-cells, as determined by hematological target cells types, corresponds with 
solid organ alloreactivity (Figure 1). In contrast to other allogeneic HLA-B*44:02+ cell lines, 
allogeneic HLA-B*44:02+ PTECs are poor targets for EBV EBNA3A specific CD8 T cells (spe-
cific lysis 12%). HLA-B*44:02+ expressing HUVECs are not targeted by an EBV EBNA3A 
specific T-cell clone (specific lysis 0%).
Figure 1. HLA-B*44:02 expressing PTECs and HUVECs are poor targets for EBV EBNA3A specific 
T-cells. In contrast to allogeneic HLA-B*44:02+ PHA Blasts, allogeneic HLA-B*44:02+ PTECs are poor 
targets for EBV EBNA3A specific CD8 T cells in a four hour cytotoxicity assay (specific lysis 12%). 
HLA-B*44:02+ expressing HUVECs are not targeted by an EBV EBNA3A T-cell clone (specific lysis 0%). 




The lack of recognition of epithelial and endothelial cell lines is not due to lack of HLA-B*44:02 
expression
To exclude lack of HLA expression as the cause for these results we performed cytotoxicity 
assays before and after IFNg stimulation of the PTEC and HUVEC targets. PTECs demon-
strated higher baseline HLA-B*44:02 expression as compared to HUVECs (data not shown). 
IFNg pre-stimulation was associated with increased HLA-B*44:02 surface expression in both 
PTECs and HUVECs (data not shown). Regardless, the increased HLA-B*44:02 expression 
following IFNg stimulation did not result in increased lysis of the PTEC or HUVEC target 
cells (data not shown).
The lack of recognition of HLA-B*44:02 epithelial and endothelial cells is not due to lack of 
ABCD3 gene expression
Alloreactivity of the EBV EBNA3A T-cell clone against HLA-B*44:02+ cell lines is dependent 
on presentation of the EEYLQAFTY peptide derived from the ABCD3 gene (12). To exclude 
lack of ABCD3 gene expression in the epithelial and endothelial target cells we performed 
qPCR for ABCD3 gene specific mRNA. ABCD3 mRNA was detectable in both PTEC and 
HUVEC target cell types (Figure 2). Furthermore, an anti-ABCD3 monoclonal antibody 
demonstrated cytoplasmic presence of the protein product (data not shown).
Figure 2. ABCD3 mRNA expression in PTEC and HUVEC cell lines. 
ABCD3 mRNA expression, relative to household gene expression, was measured in HLA-transfected 
and non-transfected K562 cells, EBV LCLs, PTECs and HUVECs. ABCD3 mRNA expression in PTECs 
and HUVECs was comparable to EBV LCLs. Indicating that the lack of allorecognition of PTECs and 
HUVECs by the EBV EBNA3A T-cell clone was not due to absence of expression of the ABCD3 pro-
tein, from which the EEYLQAFTY self-peptide is derived. SAL= Single HLA transfected K562 cell, 
EBV=Epstein-Barr virus transformed B-cell.
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The lack of recognition of HLA-B*44:02 expressing epithelial and endothelial cells is likely due to 
quantitative lack of EEYLQAFTY peptide presentation on the cell surface
To confirm that the lack of allorecognition of the HLA-B*44:02+ epithelial and endothelial 
cell lines was due to lack of peptide presentation we performed cytolytic assays using EEY-
LQAFTY peptide loaded and unloaded PTEC and HUVEC targets. HLA-B*44:02 express-
ing PTECs were poorly targeted by an EBV EBNA3A T-cell clone without peptide loading 
(specific lysis 15%; P=0.004 vs. HLA-B*44:03 PTEC), and then only at high effector/target 
ratio (Figure 3a). The specific lysis of HLA-B*44:02 expressing PTECs was greatly increased 
by exogenous EEY peptide loading (15% vs. 75%; P<0.0001) (Figure 3a). HLA-B*44:02 ex-
pressing HUVECs were only targeted by an EBV EBNA3A specific clone when loaded with 
exogenous EEY peptide (0% vs. 64%; P<0.0001) (Figure 3b). Furthermore, stimulation of 
the EBV EBNA3A specific T-cell clone with HLA-B*44:02+ HUVECs did not elicit cytokine 
production in a 24 hour luminex assay (data not shown). The EBV EBNA3A specific T-cell 
clone was able to target EEY peptide loaded HLA-B*44:02 PTECs and HUVECs even without 
IFNg pre-stimulation, suggesting that the baseline HLA-B*44:02 expression in these cell lines 
is sufficient for CTL targeting if sufficient allopeptide is presented. HLA-B*44:03 PTECs and 
HUVECs were not targeted irrespective of peptide loading, as predicted (12). Thus organ 
(kidney) specificity of the allo-HLA crossreactivity from the EBV EBNA3A specific T-cell is 
dependent on endogenous self-peptide (EEY) processing and presentation.
Figure 3. The lack of recognition of HLA-B*44:02+ PTECs and HUVECs is likely due to lack of 
EEYLQAFTY peptide presentation on the cell surface. (a) HLA-B*44:02+ PTECs were poorly targeted 
by the EBV EBNA3A specific T-cell clone (specific lysis 15%; **P=0.004 vs. HLA-B*44:03 PTEC). The 
specific lysis of HLA-B*44:02+ PTECs was greatly increased by exogenous EEY peptide loading (specific 
lysis 15% vs. 75%; ***P<0.0001). (b) HLA-B*44:02+ HUVECs were only targeted by an EBV EBNA3A 
specific T-cell clone when loaded with exogenous EEY peptide (specific lysis 0% vs. 64%; ***P<0.0001). 
The EBV EBNA3A T-cell clone did not recognize HLA-B*44:03+ PTECs or HUVECs irrespective of 
peptide loading. Experiments shown here were performed without IFNg pre-stimulation further dem-
onstrating that the baseline HLA-B*44:02 expression is sufficient to elicit cytotoxicity if the EEY peptide 




Cognate antigen recognition and allorecognition increase in proportion to the concentration of 
exogenously added viral or allo-peptide
To determine the concentration of specific peptide required to elicit cytolytic effector function 
by the EBV EBNA3A specific T-cells, FLR or EEY peptide were loaded onto HLA-B*08:01+ 
or HLA-B*44:02+ target cells respectively, in a peptide dose-response experiment (Figure 4). 
Cognate viral antigen recognition and allorecognition increase in proportion to the concen-
tration of exogenously added cognate or allo-peptide (Figure 4). Equivalent concentrations of 
the FLR cognate peptide on HLA-B*08:01+ target cells and EEY allopeptide on HLA-B*44:02+ 
target cells was required to elicit cytolytic effector function by the EBV EBNA3A specific 
T-cells. For both cognate and allo-peptides 50% of the maximum specific lysis occurred be-
tween 10mg/ml and 50mg/ml of exogenously added peptide. 
Figure 4. Cognate antigen recognition and allorecognition increase in proportion to the concentra-
tion of exogenously added viral or allo-peptide. To determine the concentration of specific peptide 
required to elicit cytolytic effector function by the EBV EBNA3A specific T-cells, FLR or EEY peptide 
was loaded onto HLA-B*08:01+ or HLA-B*44:02+ target cells respectively, in a peptide dose-response 
experiment. Cytolytic effector function of the EBV EBNA3A specific T-cells increases in proportion 
to exogenously added peptide concentration for both the cognate viral peptide and the allopeptide. 
Equivalent concentrations of the FLR cognate peptide on HLA-B*08:01+ target cells and EEY allopep-
tide on HLA-B*44:02+ target cells is required to elicit cytolytic effector function by the EBV EBNA3A 
specific T-cells. Assays performed with a HLA-B*08:01+ and two different HLA-B*44:02+ PTEC and 




Epithelial and endothelial cells are not resistant to lysis by CTL clones
Finally, to exclude the possibility that the EEYLQAFTY peptide is presented on the target 
HLA molecule but the cells are not targeted due to lytic resistance or CTL suppression we 
performed cytolytic assays using the EBV EBNA3A clone and a HLA-A2 alloreactive T-cell 
clone (JS132) in parallel. The JS132 clone specifically lysed HLA-A2+ B*44:02+ heterozygote 
PTECs and HUVECs, without any exogenous peptide addition (Figure 5). The EBV EBNA3A 
CD8 T-cell clone was unable to efficiently target the identical epithelial or endothelial cell 
lines without exogenous addition of EEYLQAFTY peptide (Figure 5). Thus, the epithelial and 





Figure 5. PTECs and HUVECs are suitable targets for CTL mediated killing without exogenous 
peptide addition. The JS132 HLA-A2 alloreactive T-cell clone specifically lysed HLA-A*02+ B*44:02+ 
heterozygous PTECs and HUVECs irrespective of exogenous peptide loading (specific lysis >85%). The 
EBV EBNA3A CD8 T-cell clone was unable to efficiently target the identical epithelial or endothelial cell 
lines without exogenous addition of EEYLQAFTY peptide. Furthermore, the EBV EBNA3A clone lysed 
both HLA-B*08:01+ and HLA-B*44:02+ epithelial and endothelial cell lines when loaded with FLR pep-
tide or EEY peptide respectively, but not RAK (HLA-B*08:01 control) nor EEK (HLA-B*44:02 control) 
peptides; confirming that the viral specificity and alloreactivity are peptide dependent and mediated 
by the same T-cell. Thus, it is highly likely that the lack of recognition of HLA-B*44:02+ epithelial and 
endothelial cells is due to a quantitative lack of EEY peptide presentation. Experiments performed in 
triplicate, mean values shown with SD. Effector:target ratio 30:1, targets=5000.
DISCUSSION
In this report we demonstrate that allo-HLA crossreactivity by viral specific memory T-cells 
can be tissue cell-type specific because of differential tissue specific self-peptide presentation. 
We have confirmed that not only is the HLA-B*44:02 alloreactivity from the EBV EBNA3A 
specific T-cell clone self-peptide dependent but that normal allogeneic kidney cells may not 
be targeted unless sufficient EEY self-peptide is processed and presented. Alloreactivity is 
mediated by cytotoxicity, when the peptide is presented, indicating the potential clinical rel-
evance of cross-reactive alloresponses against cell types present in kidney transplant tissue.
Our results do not suggest that allo-HLA crossreactivity from the EBV EBNA3A T-cell is 
irrelevant to kidney transplantation. The EBV EBNA3A specific T-cell does have cytolytic 
activity against HLA-B*44:02+ kidney epithelial cells in a 4 hour assay. Memory T-cells persist 
and therefore could perform effector functions over a prolonged period, or at times when 
immunosuppression is tapered (2). Furthermore T-cells mediate effector functions through 
a variety of mechanisms, including cytokine production, not just cytotoxicity (27). The EBV 
EBNA3A specific immune response is a public TCR response present in all HLA-B8+ B44- in-
dividuals (28) and HLA-B44 mismatching has been identified as high risk in HLA-B8 kidney 
recipients (17).
However results presented here suggest it is unlikely that EBV EBNA3A specific T-cells ex-
hibit effector functions against HLA-B*44:02+ endothelial cells present in solid organ tissue. 
Conversely, a viral specific T-cell that targets a kidney cell specific peptide presented on an 
allogeneic HLA molecule may not recognize PBMCs or spleen cells from the same allogeneic 
donor.
In light of our findings it is worth considering some of the possible mechanisms by which 
organ specific alloreactivity could occur. Quantitative differences in HLA expression could 
explain organ specific alloreactivity, but has been excluded in the present study. Differences in 
co-stimulation and accessory molecule expression are also feasible but there is little evidence 
for this as memory CD8 T-cells have reduced requirements for co-stimulation and do not 
require CD4 T-cell help (29-30). Furthermore, the EBV EBNA3A clone used here is clearly 
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capable of targeting HLA-B*44:02 transfected K562 cells which have absent co-stimulatory 
molecules (16).
Tissue specific expression of a protein that is the source of the self-peptide recognized on the 
allo-HLA molecule would be extremely likely to result in organ specific alloreactivity. For ex-
ample, a peptide derived from a renal specific ion transporter will only be presented on renal 
tubular cells. Furthermore, alloreactivity might only be induced when the gene expression is 
up regulated.
Results presented here are of particular interest because we have demonstrated expression of 
the ABCD3 protein product in the target epithelial and endothelial cells. The HLA-B*44:02+ 
PTECs were targeted albeit to a lower level of lysis (15%), therefore there must be naturally 
some EEY peptide presented on the cell surface but not enough to trigger a high percentage 
of specific lysis. The HLA-B*44:02+ HUVECs are not targeted and therefore it is likely that 
insufficient EEY peptide is presented on the surface.
Differences in antigen processing and presentation could account for tissue specific allore-
activity, even if similar levels of the ABCD3 gene product are expressed within the epithelial 
and endothelial cells. For example, EBV LCLs, PHA Blasts and K562 cells constitutively ex-
press the immunoproteosome which may generate novel antigenic peptides. Furthermore, 
the study of Macdonald defines the EEYLQAFTY peptide as an antigenic target of the EBV 
EBNA3A T-cell presented via allogeneic HLA-B*44:02 (12), however this study does not ex-
clude the possibility that several different peptides presented on HLA-B*44:02 are capable of 
activating the EBV EBNA3A specific T-cell. Theoretically, these additional peptides may not 
be presented by epithelial or endothelial cell types.
Alternatively, differences in expression of a protein that contains a peptide capable of compet-
ing with an antigenic peptide for the peptide-binding groove of the allogeneic molecule could 
also cause organ specific alloreactivity, as also suggested by others (31). A tissue specific com-
peting peptide may reduce the amount of the target self-peptide/allo-HLA complex available 
for recognition by the alloreactive CTL.
HLA-B*44:02 is a highly tapasin-dependent HLA molecule (32-33) and therefore limited 
tapasin expression in PTECs and/or HUVECs could decrease EEY peptide presentation in 
these cell lines. However tapasin mRNA is strongly induced in endothelial cells following 
IFNg treatment (34), and IFNg treatment did not increase the targeting of HUVECs in our 
assays despite inducing elevated HLA-B44 expression. The HLA-B*44:05 molecule is also a 
target of the EBV EBNA3A T-cell (12) and can load peptides independently of tapasin, unfor-
tunately no HLA-B*44:05 expressing PTECs or HUVECs are available.
Our assays using the JS132 clone exclude the possibility that the EEY peptide is presented 
but that epithelial and/or endothelial cells are resistant to lysis or are tolerogenic. The HLA-
A2 alloreactive JS132 clone was generated by stimulating PBMCs with HLA-A2 mismatched 
irradiated EBV LCLs in-vitro. The JS132 allo-A2 reactivity is likely peptide dependent and 




stitutively presented by the epithelial and endothelial cell lines.
The ultimate proof that our results are attributable to lower/absent EEYLQAFTY peptide 
presentation could be provided by peptide elution studies. However elution of peptides from 
HLA-B*44:02+ PTECs and HUVECs is not feasible due to the large number of cells required 
for peptide elution and mass spectrometry analysis. Nonetheless, we favour the conclusion 
that the differential allorecognition of HLA-B*44:02+ PTECs and HUVECs by the EBV EB-
NA3A specific T-cell clone is the result of differential quantitative presentation of the EEY-
LQAFTY self-peptide by the target cells.
The finding of organ specific allorecognition is extensively described in mice (31, 35-38). For 
example, priming of mice with normal allogeneic spleen cells generated peptide-dependent 
Kb-specific alloreactive CTL clones that exhibited cell-type specific allorecognition (31). Hu-
man tissue specific alloreactivity has been suggested by studies using graft-infiltrating lym-
phocytes obtained from renal allografts undergoing rejection (21, 39-43). Graft infiltrating 
lymphocytes were shown to exhibit T cell functional activity against PTEC grown from the 
corresponding biopsy, but not donor derived splenocytes nor PTEC from biopsies obtained 
from other patients. For example, van der Woude and colleagues found that thirteen out of 
forty (33%) of graft infiltrating cell lines reacted in a donor-specific fashion to PTEC but not 
to donor splenocytes (41).
Results presented here may have important clinical implications for renal transplantation 
monitoring, rejection and tolerance. Monitoring of alloreactive T-cells may allow individu-
alization of immunosuppression (44), but such assays routinely use donor PBMCS or spleen 
cells as stimulator. Allo-HLA crossreactivity by viral specific memory T-cells as defined 
against hematological target cell types will not correspond with solid organ alloreactivity un-
less the targeted self-peptide is ubiquitously and equally presented. If alloreactive CTL rec-
ognize allo-HLA presenting a specific peptide then it is possible that competitive peptides 
could be designed to inhibit allorecognition, as has also been suggested by others (31, 45). We 
have confirmed that the absence of a single tissue specific self-peptide is enough to abrogate 
alloreactivity. Also, long term immunosuppressive free graft survival is the ultimate aim of 
much transplantation research, but our work suggests induction of tolerance by using pre-
transplant blood transfusion may not delete organ specific CTLs.
Finally, we acknowledge that this study uses umbilical vein endothelial cells as a model for 
kidney vascular endothelial cell transplantation, however, gene expression and/or functional 
differences have not been reported between kidney and umbilical endothelial cells. Others 
have also found that donor-derived gonadal vein endothelial cells can be specifically targeted 
by graft infiltrating alloreactive T-cells (39).
In conclusion, we show that the EBV EBNA3A T-cell exhibits tissue cell type specific alloreac-
tivity because of quantitative differences in presentation of the recognized self-peptide. Tissue 
specific allorecognition may have important clinical consequences, especially for monitoring, 
rejection and tolerance induction of solid organ grafts. Future work should determine if tissue 
specific allorecognition is a common characteristic of human alloreactive CTL.
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 MATERIALS AND METHODS
Generation of EBV EBNA3A viral specific CD8 memory T-cell clone
The generation and allo-HLA-B*44:02 crossreactivity of the EBV EBNA3A CD8 memory T-
cell clone used here has been previously described (16). Briefly, EBV EBNA3A specific CD8 
T-cell clones (HLA-B8/FLRGRAYGL restricted) were derived from a healthy donor with 
HLA typing HLA-A*01:01,02:01; B*08:01,-; DRB1*03:01,-; using single cell sorting based on 
viral peptide/tetramer complex staining. Clonality of the T-cell clone was confirmed using 
RT-PCR to determine TCR AV and BV usage (16).
Generation of JS132 clone
The generation and the allo-HLA-A2 alloreactivity of the JS132 CD8 T-cell clone have been 
previously described (46-47). Briefly, PBMCs from healthy donor JS (HLA-A3,3; B7,7; DR2,2; 
DQ1,1) were stimulated with irradiated EBV transformed B-cell line JY (HLA-A2,2; B7,7; 
DR4,6). Following several rounds of stimulation and enrichment the HLA-A2 alloreactive 
population was cloned by limiting dilution at 0.5 cell/well.
Generation and culture of PTECs and HUVECs
Generation of PTECs (18-19) and HUVECs (23-24) has been previously described. PTECs 
were cultured from cortical tissue of human kidneys not suitable for transplantation because 
of anatomical reasons or from pretransplant biopsies, and HUVECs from umbilical vein of 
human umbilical cord. Morphologic appearance and immunofluorescence staining con-
firmed specific outgrowth of PTECs and HUVECs.
HLA typing and FACS staining for HLA expression of epithelial and endothelial cells
Molecular typing for class I and class II was performed in the tissue typing laboratory Lei-
den University Medical Centre, the Netherlands. The relative amount of HLA surface ex-
pression was determined using human monoclonal antibodies specific for the HLA molecule 
expressed. Epithelial and endothelial cell lines were treated with trypsin, harvested and then 
washed two times. Cells were incubated with the human HLA specific monoclonal antibody 
for 30 minutes and then washed twice. Cells were then labeled with a rabbit-anti-human-
FITC secondary detection antibody for a further 30 minutes and then washed three times. 
HLA expression was determined before and after IFNg treatment, 500 units/ml for 24 hours.
ABCD3 gene expression in PTEC and HUVEC cell lines
For detection of ABCD3 mRNA expression cells were harvested and preserved in RNAlater 
solution (Qiagen, Chatsworth, CA, USA). RNA was extracted using the RNeasy mini kit (Qia-
gen) following the manufacturers instructions. RNA was treated with DNase (Qiagen) on the 
spin columns. RNA quantity was assessed with a spectrophotometer (Nanodrop technolo-
gies, Wilmington, DE, USA) and all samples showed A260/A280 ratios between 1.9 and 2.1. 




sequences used in the quantitative PCR for ABCD3 mRNA were CCTGGTGCTGGAGA-
AATCAT and CCCCAGATCGAACTTCAAAA respectively, giving an amplicon of 118 bp. 
The PCR was performed using an iCycler MyiQ (Bio-Rad). The PCR program was finalized 
with a melting curve analysis. The signal of the stably expressed household genes b-actin and 
GAPDH served as normalization factors.
Cytotoxicity Assays
The EBV EBNA-3A specific T-cell clone and/or the JS132 CD8 T-cell clone were evaluated 
for cytotoxicity by incubating 5000 PTEC or HUVEC target cells with serial dilutions of the 
T-cell clone(s) for 4 hours in 51Cr release assays. HLA-B*44:02+ target cells were loaded with 
either the EEYLQAFTY allopeptide or EEKLIVVLF control peptide, or no peptide. HLA-
B*08:01+ target cells were loaded with either FLRGRAYGL cognate peptide or RAKFKQLL 
control peptide, or no peptide. In the peptide dose-response assays HLA-B*08:01+ target 
cells or HLA-B*44:02+ target cells were incubated with different concentrations of the FL-
RGRAYGL cognate peptide or the EEYLQAFTY allopeptide respectively, for one hour and 
then washed twice. The peptide-dose response assays were performed with an effector:target 
ratio of 20:1 only. Target cells were incubated with chromium for 60 minutes. Supernatants 
were harvested for gamma counting: percent specific lysis= (experimental release-spontaneous 
release)/(Max release-spontaneous release) x 100%. Results are expressed as the mean of tripli-
cate samples, with standard deviation.
Statistics
Values for specific lysis are presented as the mean of triplicate wells, with standard deviation. 
Comparative analyses are non-parametric (unpaired) t-tests, p<0.05 is considered to be sig-
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Background: Allo-HLA reactivity by naturally acquired viral specific memory T-cells is com-
mon. However, the effect of successful vaccination on the alloreactive memory T-cell reper-
toire is unclear. We hypothesized that vaccination could specifically induce allo-HLA reactive 
memory T-cells.
Methods: A varicella zoster virus (VZV) IE62 specific CD8 memory T-cell clone was single 
cell sorted from a VZV seronegative renal transplant candidate, following response to live 
attenuated varicella vaccination. To analyze the allo-HLA reactivity, the VZV IE62 specific 
T-cell clone was tested against HLA typed target cells and target cells transfected with HLA 
molecules, in both cytokine production and cytotoxicity assays.
Results: The varicella vaccine induced VZV IE62 specific T-cell clone specifically produced 
IFNg when stimulated with HLA-B*55:01 expressing Epstein-Barr virus (EBV) transformed 
B-cells and HLA-B*55:01 transfected K562 cells (SALs) only. The clone also demonstrated 
specific cytolytic effector function against HLA-B*55:01 SALs and PHA Blasts. Cytotoxicity 
assays using proximal tubular epithelial cell (PTEC) and human umbilical cord endothelial 
cell (HUVEC) targets confirmed the kidney tissue specificity of the allo-HLA-B*55:01 reac-
tivity, and the relevance of the crossreactivity to clinical kidney transplantation. The results 
also suggest that molecular mimicry, and not bystander proliferation, is the mechanism un-
derlying vaccine induced alloreactivity.
Conclusions: Varicella vaccination generated a de novo alloreactive kidney cell specific cytol-
ytic effector memory T-cell in a patient awaiting renal transplantation. Vaccination induced 






Allo-HLA reactivity by naturally acquired viral specific memory T-cells is far more com-
mon than anticipated, and the allo-HLA reactivity and virus specificity are mediated via the 
same T-cell receptor (TCR) (1). 45% of virus specific CD4 and CD8 memory T-cell clones 
have been shown to be cross-reactive against allo-HLA molecules. Allo-HLA crossreactivity 
has been shown for Epstein-Barr virus (EBV), Cytomegalovirus (CMV), Influenza virus and 
Varicella-Zoster Virus (VZV) specific T-cells (1). Alloreactive memory T-cells are a major 
barrier to successful transplantation because they resist immunosuppression and can rapidly 
engage effector functions (2-10).
Vaccine preventable infections remain a major source of morbidity and mortality in trans-
plant recipients (11-12). Guidelines for recommended vaccinations to be given before and 
after transplantation are provided by many centres (11) and whenever possible the full com-
plement of vaccines should be administered prior to transplantation (12). Adaptive immunity 
and the development of pathogen specific memory T-cells underlie successful vaccination. 
However the effect of vaccination on the allo-HLA reactive T-cell pool is largely unknown. 
Danziger-Isakov and colleagues recently demonstrated that influenza vaccination can have a 
significant impact on the potency of the alloreactive T-cell repertoire, as determined by IFNg 
production in a mixed lymphocyte culture (13). However this study did not determine the 
origin of the alloreactive memory T-cells or if the alloreactivity was elicited by non-specific 
reactivation, bystander proliferation or molecular mimicry.
VZV seronegative transplant recipients who contract varicella may suffer lethal consequences 
(14). Therefore, guidelines for vaccination of solid organ transplant candidates recommend 
that live attenuated varicella-zoster virus (VZV) vaccination be administered prior to trans-
plantation, amongst others (11). Consequently at the Erasmus Medical Centre all kidney 
transplantation candidates with negative varicella serology are given the recommended live 
attenuated varicella vaccine (15). We hypothesized that this varicella vaccination could spe-
cifically induce allo-HLA reactive memory T-cells in patients awaiting renal transplantation.
We therefore sorted a VZV specific T-cell clone from a seronegative renal transplant candi-
date with a demonstrable VZV specific T-cell response following varicella vaccination, using 
VZV specific peptide/tetramer complex staining. Successful vaccination generated de novo 




Confirmation of monoclonality and TCR repertoire analyses of the vaccine induced VZV IE62 
specific CD8 T-cell clone
Post-vaccine VZV seroconversion was confirmed (Figure 1a). VZV IE62 specific T-cells were 
not detectable in the blood prior to vaccination. HLA-A2/ALW tetramer positive CD8 T-cells 
were detectable in the blood only following live attenuated varicella vaccination (Figure 1b), 
and were single cell sorted based on tetramer staining. VZV IE62 specific memory T-cell 
clones were confirmed to bind viral peptide/HLA-A2 tetramer complexes (Figure 1c). RT-
PCR and sequencing were performed to confirm monoclonality and determine the TCR us-
age of the sorted VZV IE62 specific CD8 memory T-cell clones. All clones isolated expressed 
an identical Va2s1 Vb14s1 TCR, and therefore only a single clone for testing was generated. 





Allo-HLA crossreactivity of the vaccine induced VZV IE62 specific T-cell clone
To screen for the ability of the varicella vaccine induced T-cell clone to exert alloreactivity, the 
clone was tested against a panel of EBV-LCLs selected to cover almost all frequently occurring 
HLA class I and II molecules. The T-cell clone produced IFNg when stimulated with EBV-
LCLs 5 and 19 only (Figure 2). These two EBV LCLs shared expression of the HLA-B*55:01 
molecule, which was not expressed on any other tested EBV LCL. The T-cell clone recognized 
HLA-A*02:01 expressing EBV LCLs only when exogenously loaded with the ALW peptide 
(positive control), and did not produce IFNg when cultured in IL-2 containing medium alone 
(negative control). Therefore the screening results were highly suggestive that varicella vac-
cination had induced a de novo HLA-B*55:01 alloreactive memory T-cell.
Figure 1b. Figure 1c.
Figure 1. Varicella vaccine induced VZV IE62 specific CD8 memory T-cells. 
Generation of the T-cell clone was performed by single cell sorting based on HLA-A*0201/ALWAL-
PHAA specific tetramer staining. (a) A VZV seronegative renal transplantation candidate was given 
varicella vaccination, with seroconversion confirmed after 6 weeks. A booster vaccination was then 
given. Vaccine was administered immediately after collection of serum samples. Following vaccination 
VZV IE62 specific T-cells became detectable in the peripheral blood, and were then single cell sorted 
based on HLA-A2/ALW tetramer staining. VZV IE62 specific T-cells were not detectable in the blood 
prior to vaccination. AU=Arbitrary Units. Seropositivity cut-off value=0.9AU (b): HLA-A2/ALW spe-
cific T-cells were sorted 5 months following varicella vaccination of a VZV seronegative transplantation 
candidate. P4=Sort gate. Total events=200000. Sorted events=16. (c) T-cell clone is >99% HLA-A2/ALW 
tetramer binding and clonality was confirmed with TCR PCR. All sorted clones possessed an identical 
Va2s1 Vb14s1 TCR. HLA typing of renal transplantation candidate from whom VZV IE62 specific clone 
was sorted - HLA-A*02:01,-; B*13,40; Cw3,Cw6; DRB1*07,-.
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TCR sequences were analysed using IMGT/V-QUEST version 3.2.16 (Brochet et al. Nucl. Acids Res. 
(2008) 36 (suppl 2): w503-508). The junction analysis of the TCRα -and TCRβ chains are shown left to 
right. The one-letter amino acid code is shown above the first nucleotide of the codon. Variable gene 
segments are depicted according to Arden nomenclature (Arden et al. Immunogenet 1995).
Figure 2. Allo-HLA-B*55:01 crossreactivity by the varicella vaccine induced VZV IE62 specific T-
cell clone. The VZV IE62 specific T-cell clone was stimulated with a panel of EBV LCLs, selected to 
cover all common HLA class I and II molecules, in a 24 hour IFNg ELISA. The T-cell clone produced 
IFNg when stimulated with EBV-LCLs 5 and 19 only. These two EBV LCLs shared expression of the 
HLA-B*55:01 molecule, which was not expressed on any other tested EBV LCL. The T-cell clone recog-
nized a HLA-A*02:01 EBV LCL only when loaded with the ALW peptide (Positive control– A2/ALW). 
Responder=10000 cells, Stimulator=50000 cells. Experiments performed in duplicate, mean values 
shown with SD. The screening results strongly suggest that varicella vaccination had induced a de novo 
HLA-B*55:01 alloreactive memory T-cell.




Confirmation of allo-HLA-B*55:01 crossreactivity by the vaccine induced VZV IE62 specific 
T-cell clone
To confirm the allo-HLA crossreactivity of the VZV IE62 specific T-cell clone against the al-
logeneic HLA-B*55:01 molecule, the T-cell clone was tested for IFNg production using HLA 
transfected K562 cells (SALs) as stimulators. Strong IFNg production was only elicited by 
the HLA-B*55:01 transfected SAL (Figure 3) (***p<0.0001). IFNg production was also elic-
ited by HLA-A*02:01 SAL loaded with ALW peptide (positive control). No IFNg production 
was elicited by culture with medium alone, non transfected K562 cells or HLA-A*0201 SALs 
(negative controls).
Figure 3. Confirmation of allo-HLA-B*55:01 reactivity by the varicella vaccine induced VZV IE62 
specific T-cell clone. The VZV IE62 specific T-cell clone recognized only K562 cells transfected with 
allogeneic HLA-B*55:01, in a 24 hour IFNg ELISA (***p<0.0001; comparison to K562 cell). SAL A2 was 
recognized only when exogenously loaded with ALW peptide (Positive control – A2/ALW). Non-trans-
fected K562 cells, SAL A*02:01 (HLA restriction of clone), HLA matched and allo-HLA transfected 
SALs (other than HLA-B*55:01) were not recognized. Responder=10000 cells, Stimulator=50000 cells. 
Experiments performed in duplicate, mean values shown with SD.
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Cytotoxicity of the vaccine induced VZV IE62 specific T-cell clone
To confirm that the VZV IE62 specific CD8 T-cell clone was also cytolytic against allogeneic 
cells expressing the HLA-B*55:01 molecule, we performed a cytotoxicity assay using SALs 
and PHA blasts as target cells (Figures 4a and 4b). The VZV IE62 specific T-cell clone spe-
cifically lysed HLA-B*55:01 expressing SALs and PHA blasts in proportion to the E/T ratio 
(Figure 4a and 4b) (**p=0.0007 and **p=0.0002 respectively), whereas HLA-A*02:01 express-
ing PHA blasts and SALs were not lysed unless exogenously loaded with the ALW peptide. 
Cytotoxicity was low, as compared to the HLA-A2+ viral peptide loaded positive controls after 
4 hours, but increased after overnight cytotoxicity assay (Figure 4b) (***p<0.0001).
Tissue Specificity of the vaccine induced VZV IE62 specific T-cell clone
To investigate tissue (kidney) specificity of the crossreactive alloresponse by the VZV IE62 
specific memory T-cells, we used PTECs and HUVECs as a model system for human kidney 
transplantation. The VZV IE62 specific T-cell clone demonstrated specific cytolytic effector 
function against a HLA-B*55:01 expressing PTEC, in a 4 hour cytotoxicity assay (Figure 5a). 
This confirms that the vaccine induced memory T-cells in this kidney transplantation candi-
date can recognize normal kidney tissue cell types present in a transplanted kidney. However 
a HLA-B*55:01 expressing HUVEC was not targeted by the VZV IE62 specific T-cell clone, in 
a 4 hour cytotoxicity assay, even with IFNg pre-stimulation to increase the amount of HLA-
B*55:01 expression (Figure 5b). 
Figure 4. Varicella vaccine induced VZV IE62 specific memory T-cell clone is cytolytic against al-
logeneic HLA-B*55:01 expressing target cells. (A) Cytotoxicity assay using effector T-cell clone dem-
onstrates cytotoxic effector function against HLA-B*55:01 SAL (**p=0.0007; comparison to K562 cell 
ratio 30:1), in proportion to effector:target ratio. Targets=5000 cells. Experiment performed in triplicate, 
mean values shown with SD. (B) VZV IE62 allogeneic cell cytotoxicity capacity increases with time. 
Cytotoxicity assay using effector T-cell clone demonstrates cytotoxic effector function against HLA-
B*55:01 expressing PHA blasts (** p=0.0002; comparison to HLA-A2 PHA blast at 4 hours), in a 4 hour 
cytotoxicity assay. Cytotoxicity capacity of the VZV IE62 specific T-cell clone against HLA-B*55:01 
PHA blast increased with longer co-culture time (***p<0.0001; comparison between HLA-B*55:01 PHA 
blast target cell at 4 and 16 hours). E:T ratio=30:1, Targets=5000 cells. Experiment performed in tripli-




Transplant candidates are at increased risk of infectious complications and every effort should 
be made to assure that they complete the full complement of recommended vaccinations 
prior to transplantation. We addressed whether successful vaccination may also induce al-
loreactive memory T-cells. In this study we show that live attenuated varicella vaccine can in-
duce de novo human cytolytic allo-HLA reactive memory T-cells, in a kidney transplantation 
candidate. It also suggests that successful vaccination induces alloimmunity against specific 
allo-HLA molecules via peptide dependent molecular mimicry.
The VZV IE62 specific memory T-cells specifically recognized the allogeneic HLA-B*55:01 
molecule. This allorecognition resulted in both cytokine production and cytotoxicity. We also 
demonstrated that this VZV specific T-cell from a kidney transplantation candidate can exert 
allo-HLA reactivity against normal kidney cell types present in transplantation tissue, thus 
demonstrating the clinical relevance of the vaccine induced response to kidney transplanta-
tion.
Lower cytotoxicity against allo-HLA-B*55:01 expressing PHA blasts and SALs in a four hour 
cytotoxicity assay, as compared to the positive controls (ALW peptide loaded HLA-A2+ target 
Figure 5. Tissue specificity of the allo-HLA reactivity by the VZV IE62 specific T-cell clone. 
(A) The VZV IE62 specific T-cell clone demonstrates specific cytolytic effector function against a HLA-
B*55:01 expressing PTEC, in a 4 hour cytotoxicity assay. Thus confirming that the vaccine induced mem-
ory T-cells can recognize normal renal tissue cell types present in a transplanted kidney. Targets=5000 
cells. Experiment performed in triplicate, mean values shown with SD. Assay with HLA-B*55:01 PTEC 
target performed in single due to low target cell numbers. (B) A HLA-B*55:01 expressing HUVEC was 
not targeted by the VZV IE62 specific T-cell clone, in a 4 hour cytotoxicity assay, even following IFNg 
pre-stimulation to increase the HLA-B*55:01 expression. Targets=5000 cells. Experiment performed in 
triplicate, mean values shown with SD.
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cells), is not unexpected. The HLA-A2 expressing PHA blasts and SALs were exogenously 
loaded with excess amount of viral peptide, while the cross-reactive alloresponses are de-
pendent on presentation of endogenous self-peptide. Furthermore the lower percentage of 
specific lysis against PHA blasts, increased to levels comparable to the positive controls after 
an overnight cytotoxicity assay. Alloreactive memory T-cells are able to persist and may be 
capable of causing long-term damage, especially at times when immunosuppression is ta-
pered (3).
The lack of recognition of HLA-B*55:01+ HUVECs supports the conclusion that alloreactivity 
is tissue specific, and that the vaccine induced alloreactivity is HLA and endogenous peptide 
dependent. These results support molecular mimicry, and not bystander proliferation, as the 
mechanism for the vaccine induced alloreactivity. Similarly a HLA-DR3 restricted human 
tetanus toxoid-specific T-cell clone was previously found to give HLA-DR4 specific alloreac-
tivity (16).
The presently described VZV IE62 specific T-cell expresses a Vb14 TCR and recognizes the 
allogeneic HLA-B*55:01 molecule. Another T-cell clone with the same specificity and the 
same Vb usage sorted from an individual with naturally acquired VZV infection was previ-
ously also reported to give allogeneic HLA-B*55:01 crossreactivity (1). VZV IE62 specific 
T-cell clones have also been reported to give allogeneic HLA-A*02:05 and HLA-B*57:01 reac-
tivity, however these T-cell clones did not express Vb14 TCRs (1).
The crossreactive potential of antigen specific T-cells is difficult to predict. However data pre-
sented here supports the notion that memory T-cells with the same antigen specificity and the 
same Vb usage will exert alloreactivity against the same allo-HLA molecule.
VZV infects about 95% of the population (15,17-18). The immediate early (IE62) protein is 
required for the initiation of VZV replication, and VZV IE62 specific T-cells are correlated 
with immunity after VZV infection (19-20). VZV IE62 specific T-cells were found in 12/19 
(63%) of stem cell transplantation patients with VZV reactivation, and 3/18 (17%) serologi-
cally positive healthy donors, indicating that this HLA-A2 restricted epitope is commonly 
used in HLA-A2 positive individuals (21). Here we show that live attenuated varicella vac-
cination also induces memory T-cells with identical specificity. Therefore HLA-B*55:01 mis-
matching may be an unacceptable mismatch in HLA-A2+ transplantation recipients, but fur-
ther database studies are warranted.
Live attenuated vaccines are very potent at eliciting protective T-cell immunity because they 
possess many antigenic targets, provide natural co-stimulation and can usually replicate to a 
limited extent. Recently activated effector memory T-cells may have differential or even no 
requirements for co-stimulatory signals, as compared to resting peripheral blood memory T-
cells (22-23), and the CD8 memory T-cell state of readiness is antigen dependent and actively 
maintained but reversible (24-25). Therefore live attenuated vaccination may enable quanti-
tatively and qualitatively stronger allo-HLA reactivity from the newly generated crossreactive 
memory T-cells. Similarly alloreactive memory T-cells in an already seropositive transplant 




effector function in the absence of co-stimulation.
Alloreactive memory T-cells are central mediators of the immune-mediated injury to the al-
lograft and therefore results presented here may have important clinical implications. We 
suggest vaccination could be given at least three months prior to expected transplantation to 
avoid the peak of specific cellular alloreactivity, as also suggested by others (13). Closer moni-
toring could be applicable to transplanted patients following recent vaccination. Live attenu-
ated vaccination may be particularly potent at activating alloreactive memory T-cells. Further 
clinical studies on the effects of vaccination on the alloreactive T-cell repertoire are required.
Finally, Danziger-Isakov and colleagues demonstrated an effect of Influenza vaccination on 
cellular alloreactivity in humans (13), and favoured the conclusion that the observed increase 
in T-cell alloreactivity may be due to non-specific reactivation of a variety of T-cells clones. 
However their work lacked mechanistic studies to help understand the immunological pro-
cess behind the reported observations. Furthermore they did not study HLA specificities of 
the cellular alloreactivity. Nonetheless, the absence of self responses in those transplant re-
cipients who also showed evidence of anti-influenza reactivity suggests that specific allo-HLA 
reactivity is likely. Our previous work (1,26) combined with results presented here strongly 
suggests that molecular mimicry underlies the effect of vaccination on cellular alloreactivity.
Transplant candidates are at increased risk of infectious complications mandating a full com-
plement of recommended vaccinations prior to transplantation. We provide evidence that 
live attenuated vaccination is associated with the generation of de novo HLA specific allore-
active memory T-cells, likely via molecular mimicry. Vaccination induced alloreactivity may 
have important clinical implications, especially for vaccine timing and recipient monitoring. 
Future work should determine if induction of HLA specific alloreactivity is a common char-





HLA-A*02:01+, varicella seronegative renal transplantation candidates were considered for 
participation in this study. The patient from whom the VZV specific T-cell clone was sorted 
is a 52 year old male with end stage renal disease due to diabetes mellitus type 2, receiving 
haemodialysis therapy, with HLA typing HLA-A*02:01,-; B*13,40; Cw3,Cw6; DRB1*07,-. The 
candidate had never previously received an organ transplant. History taking confirmed no 
previous varicella infection or vaccination. Two separate serum samples taken before varicella 
vaccination were both VZV seronegative (Figure 1a). A commercially available ELISA kit was 
used (Vidas Varicella Zoster IgG, BioMerieux, Marcy l’Etoile, France). The patient was vac-
cinated with a live attenuated varicella vaccine (Varilix, GlaxoSmithKline) on two occasions, 
separated by six weeks.
Generation of VZV IE62 specific CD8 memory T-cell clone
We used the newly validated ALWALPHAA/HLA-A*02:01 restricted epitope from the imme-
diate early 62 (IE62) protein of varicella zoster virus to detect de-novo virus specific memory 
T-cells generated following varicella vaccination (21). VZV IE62 specific T cells were isolated 
from the peripheral blood as previously described (1,26). Briefly, PBMCs were harvested and 
labeled with HLA-A2/ALW tetrameric complexes for 30 minutes at 4 0C in RPMI without 
phenol red, supplemented with 2% FCS, washed three times and single cell sorted at 4 0C 
using the FACS vantageTM (Becton Dickinson). Tetramer positive CD8 T-cells were non-
specifically stimulated every 2 weeks with feeder cell mixture containing irradiated allogeneic 
PBMCs (3500 Rad), 800ng/ml phytohaemagglutinin (PHA), 100 IU/ml IL-2 in IMDM me-
dium supplemented with glutamine, human serum (5%) and fetal calf serum (5%). 
Confirmation of T-cell clonality
TCRa and TCRb rearrangements were analyzed on the VZV IE62 specific T-cell clone. 
Total RNA was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). Oligo dT 
primed first-strand cDNA was synthesized from 1 µg RNA template using Superscript III 
reverse transcriptase (Invitrogen corporation, Carlsbad, CA, USA). First RT-PCR was per-
formed to determine the TCR AV and BV usage, using primers that cover the complete TCR 
repertoire. Sequencing templates were obtained performing high fidelity PCR using Pfx50 
DNA Polymerase (Invitrogen Corporation, Carlsbad, CA, USA). Each reaction contained 
forward primers targeting the Va2S1 or Vb14S1 variable region and reverse primers specific 
for the alpha and beta chain constant region. Amplicons spanning the variable, CDR3 and 
joining regions were purified using ExoSAP-IT (GE Healthcare, Buckinghamshire, UK) ac-
cording to manufacturer’s protocol. Thermo sequenase primer cycle sequencing (GE health-
care) reactions were performed using a CY5 labeled M13 sequencing primer (Sigma-Aldrich, 
St. Louis, MO, USA) according to manufacturer’s protocol.  Sequencing reactions were run on 






Screening for allo-HLA crossreactivity of the VZV IE62 specific T-cell clone was done using 
a panel of EBV transformed B-cells (EBV LCLs) selected to cover almost all frequently occur-
ring HLA class I and II molecules, using IFNg production as readout. IFNg production was 
also used to confirm the allo-HLA crossreactivity by the VZV IE62 specific T-cell clone, using 
single HLA transfected K562 cells (SALs) as stimulator (27). 10000 T-cells were co-cultured 
with 50000 irradiated stimulator cells in a final volume of 150mL IMDM culture medium sup-
plemented with 10% fetal calf serum and 100IU/mL IL-2. After 18 hours of incubation, su-
pernatants were harvested and IFNg production was measured using standard enzyme-linked 
immunosorbent assay (ELISA, U-Cytech, Netherlands).
Cytotoxicity assays
The VZV IE62 specific T-cell clone was evaluated for cytotoxicity by incubating 5000 target 
cells with serial dilutions of the T-cell clone for 4 hours in a standard 51Cr-release cytotox-
icity assay. Target cells used in the standard cytotoxicity assays include PHA Blasts, single 
HLA transfected K562 cells (SALs) (26-27), proximal tubular epithelial cells (PTECs) (28-31) 
and human umbilical vein endothelial cells (HUVECs) (32-34). Cytotoxicity assays involving 
PTEC and HUVEC target cells were performed before and after IFNg treatment, 500 units/ml 
for 24 hours. PHA blasts were also incubated with the T-cell clone in an overnight cytotoxic-
ity assay (16 hours), however, SALs were not suitable targets in an overnight assay due to 51Cr 
leakage. Target cells were incubated with 51Cr for 60 minutes. Supernatants were harvested 
for gamma counting: percent specific lysis= (experimental release-spontaneous release)/(Max 
release-spontaneous release) x 100%. Results are expressed as the mean of triplicate samples.
Statistics
Values for specific lysis are presented as the mean of triplicate wells, with standard deviation 
(SD). Values for IFNg production are presented as the mean of duplicate wells, with standard 
deviation. Comparative analyses are non-parametric (unpaired) t-tests, p<0.05 is considered 
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Chapter 6
Alloreactivity from human viral specific 
memory T-cells
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The mechanisms by which alloreactive memory T-cells are generated in non-sensitized indi-
viduals have begun to be elucidated. It is generally accepted that a very high level of crossre-
activity is an essential feature of the T-cell receptor. Indeed it has recently been shown that 
alloreactivity from viral specific memory T-cells is far more common than predicted, 45% of 
viral specific T-cell clones were found to be allo-HLA crossreactive. In this overview the evi-
dence for crossreactive alloresponses from human viral specific memory T-cells is discussed 
with special emphasis on the unexpected high frequency of these crossreactive responses, 
the peptide and tissue specificity of the responses, and the mechanistic insights gleaned from 
the elucidation of the crystal structure of an allo-HLA crossreactive viral specific TCR. The 
possible implications for clinical solid organ and bone marrow transplantation and tolerance 
induction will be discussed.
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1. NON-SENSITIZED TRANSPLANTATION RECIPIENTS HAVE STRONG “MEMORY” 
RESPONSES FOR ALLO-HLA
Transplantation recipients can be sensitized against alloantigen by pregnancy, blood trans-
fusion or previous transplantation. B-cell sensitization is revealed by the presence of HLA 
specific antibodies, which are not detectable in non-sensitized individuals. However, even in 
non-sensitized individuals a substantial portion of the pre-existing memory T-cell repertoire 
is already alloreactive (1-4), which is far greater than the proportion of T-cells that respond to 
any individual pathogen. The origin of these high-frequency pre-existing alloreactive memo-
ry T-cells in non-sensitized individuals was previously unclear, but has been hypothesized to 
relate to crossreactive allo-HLA responses from viral specific memory T-cells (5-7).
In humans, acute rejection has been associated with varying viral infections, and CMV proph-
ylaxis with oral ganciclovir is associated with improved long-term renal graft survival (8). 
Mismatched donor HLA antigens have differential impact on graft survival depending on the 
HLA phenotype of the recipient (9), and one possible explanation for the occurrence of these 
harmful HLA combinations may be that patients have had previous immunological contact 
with pathogens that elicit T-cell responses which crossreact against the HLA mismatches (6-
7,9). The fact that cord blood T-cells are less able to mediate graft vs. host disease (GvHD) 
than marrow derived T-cells because of their naïve status supports this theory (10-11).
In-vivo, the presence of virally induced alloreactive T-cell memory is a potent barrier to trans-
plantation tolerance in mice (12-17). Many strategies have been used to successfully induce 
tolerance to transplanted tissue in mice, most of which primarily block the CD80/CD86/
CD28 and/or CD40/CD154 co-stimulatory pathways. For example, donor specific transfu-
sion and anti-CD154 antibody readily induce tolerance to solid organ grafts in pathogen free 
mice; however, all these protocols fail in pathogen exposed mice as viral infections induce al-
loreactivity and abrogate the induction of transplant tolerance (18-22). Furthermore, Adams 
clearly demonstrated a viral dose effect whereby mice previously exposed to multiple viral 
infections were refractory to tolerance induction and rejected their allografts, whereas naïve 
mice or single pathogen exposed mice were susceptible to tolerance induction (15). Evidence 
for virally induced alloreactive T-cell memory in mice is already extensively reviewed in the 
literature (12-15), therefore this review will focus on the evidence for allo-HLA crossreactiv-
ity by human T-cell clones.
 Once generated, viral specific memory T-cells persist in high frequency and have 
lower activation requirements with novel co-stimulatory pathways that may be constitutively 
expressed (12, 23). Upon activation, memory T-cells produce a wide variety of cytokines in-
cluding IL-2, IL-4, IFNg, TNFa and are capable of rapid up-regulation of cytolytic effector 
function without the need for CD4 T-cell help (24). Taken together these factors provide 
strong support for the ability of viral specific memory T-cells to directly elicit acute rejection, 




2. EBV SPECIFIC CLONES ARE CROSSREACTIVE AGAINST ALLO HLA-B*4402 VIA 
MOLECULAR MIMICRY
Early work suggested that the explanation for the presence of alloreactive memory T-cells in 
non-sensitized individuals could be crossreactivity from viral specific memory T-cells against 
allo-HLA molecules (5-6). Burrows and colleagues demonstrated the dual specificity of EBV 
EBNA3A specific T-cell clones for the immunodominant peptide FLRGRAYGL presented 
on HLA-B*0801 and the alloantigen HLA-B*4402, to which the individual had never been 
exposed (6). This data also showed that the T-cell alloresponse can be dominated by a cross-
reactive CTL induced by a single viral epitope.
In fact the HLA-B8/FLR restricted response in a HLA-B8+ B44- individual gives rise to a 
public BV6S2 TCR which always cross-reacts against allogeneic HLA-B*4402 (25). This find-
ing has been reproducibly found in different individuals from different genetic backgrounds 
using different techniques (2, 26-27). For example, we confirmed the alloreactivity of the EBV 
EBNA3A specific T-cell against HLA-B*4402 using single antigen expressing cell lines (sin-
gle HLA transfected K562 cells) (26). In theory, viral infections that give rise to public TCR 
responses could therefore be used to determine unacceptable mismatches based solely on im-
munological history. Indeed HLA-B44 mismatching has been identified as higher risk among 
HLA-B8+ renal transplant recipients (28).
The EBV EBNA3A T-cell allo-HLA-B*4402 crossreactivity is dependent on presentation of 
the EEYLQAFTY self-peptide derived from the ABCD3 gene (29). Molecular mimicry, as 
revealed by crystallography studies, is the mechanism for this human T-cell alloreactivity 
from a viral specific memory T-cell (e.g. see figure 1). Despite extensive amino acid differ-
ences between HLA-B*0801 and HLA-B*4402, and the disparate sequences of their bound 
viral and self peptides respectively, the HLA-B8/FLR restricted TCR engages these peptide-
HLA complexes identically. The viral and allopeptides adopted similar conformations after 
TCR ligation, revealing that molecular mimicry is associated with TCR specificity. This paper 
highlights the exquisite specificity of the TCR and the self peptide dependence of the T-cell 
alloreactivity. 
It is also suggested that molecular mimicry operates in other alloreactions (30-33). Nonethe-
less, more definitive data on the mechanisms of T-cell allo-HLA crossreactivity from other 
clonotypes are still required.
 
3. ALLOREACTIVITY FROM VIRAL SPECIFIC MEMORY T-CELLS IS COMMON
Recently we reported that allo-HLA responses from viral specific memory T-cells are in fact 
far more common than anticipated (27). To analyze allo-HLA crossreactivity from viral spe-
cific T-cells, T-cell clones were tested against a panel of HLA typed target cells, and target 
cells transduced with single HLA molecules. These studies showed that 80% of virus specific 
T-cell lines and 45% of virus specific T-cell clones crossreact against certain allo-HLA mol-
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Figure 1. Allo-HLA crossreactivity by viral specific memory T-cells. 
Viral specific memory T-cells target virus infected autologous cells presenting viral peptides in a self-
HLA restricted fashion. The same viral specific TCR may crossreact against an allogeneic HLA molecule 
presenting a self-peptide. CTL=Cytotoxic T Lymphocyte.
ecules. Allo-HLA crossreactivity was shown from EBV, CMV, VZV and influenza specific T-
cell clones (27). Multiple viral specific CD8 T-cell clones were shown to be alloreactive against 
allogeneic class I molecules, and likewise several viral specific CD4 T-cell clones were shown 
to crossreact against allogeneic class II molecules. Surprisingly, two separate CMV specific, 
class I restricted T-cell clones recognized allogeneic class II molecules (27), as has also been 
reported by others (34).
Additionally others have demonstrated allo-HLA crossreactivity by viral specific T-cell 
clones, although the target HLA molecule was not always clearly defined. HLA-A*0201 re-
stricted HSV-2 specific T-cell clones have been shown to crossreact against the HLA-B44 
family (35), and CMV specific CD8 T-cells have been shown to crossreact against undefined 
class I alloantigens by another group (36). EBV and tetanus toxoid specific CD4 T-cell clones 
have also been shown to exhibit allo-HLA class II responses (37-38). Table 1 lists human viral 
specific memory T-cells reported to give allo-HLA crossreactivity while table 2 compares the 
methods used for detection of the allo-HLA crossreactivity.
The importance of these findings are reinforced by functional studies showing that the vari-
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ous viral specific CD8 T-cell clones can lyse multiple different target cells expressing the target 
HLA molecule, in a 4 hour 51Chromium release assay (6,26-27). The fact that the same TCR 
complex mediates both virus specificity and allo-HLA crossreactivity has been confirmed by 
TCR PCR, viral tetramer inhibition and TCR transfection assays (6,26-27).
The multiple mechanisms of T-cell receptor crossreactivity have been reviewed extensively 
by others (39-42). Despite peptide/HLA diversity and TCR plasticity, these T-cell responses 
always exhibit exquisite HLA and peptide specificity.
3.1 Peptide dependence of allo-HLA crossreactivity from viral specific T-cells
It is now generally accepted that alloreactive T-cells recognize allo-HLA molecules present-
ing self-peptides (7,27,29,43-44). Macdonald and colleagues have provided clear structural 
evidence that self-peptide dependent molecular mimicry underpins the alloreactivity of the 
EBV EBNA3A specific T-cell against allogeneic HLA-B*4402 (29).
Furthermore, the peptide dependence of the allo-HLA crossreactivity from other viral spe-
cific memory T-cells is reinforced by differing potency of the alloreactivity exerted by virus 
specific T-cells against different cell targets. For example, a VZV specific HLA-A2 restricted 
T-cell clone recognizes allogeneic HLA-B*5701 expressing EBV LCLs, PHA Blasts and mono-
cyte derived DCs, but does not recognize HLA-B*5701 expressing B-cells, T-cells, monocytes 
nor fibroblasts (27). Therefore allo-HLA expression is not solely sufficient to elicit target kill-
ing. Presumably the cell types that are not recognized do not present the relevant self-peptide.
In contrast to allogeneic HLA-B*4402+ EBV LCLs and SALs, allogeneic HLA-B*4402+ hu-
man umbilical vein endothelial cells (HUVECs) and proximal tubular epithelial cells (PTECs) 
are poor targets for EBV EBNA3A specific CD8 T cells. HLA-B*4402 expressing PTECs are 
specifically lysed by an EBNA3A T-cell clone without peptide loading albeit at high effector/
target ratio only. The specific lysis of HLA-B*4402 expressing PTECs is greatly increased by 
exogenous EEY peptide loading. HLA-B*4402 expressing HUVECs are only targeted by an 
EBV EBNA3A clone when loaded with exogenous EEY peptide. The lack of recognition of 
endothelial and epithelial cells was not due to the lack of HLA-B*4402 expression. Thus organ 
(kidney) specificity of the alloresponse from the EBNA3A specific T-cell is dependent on 
endogenous self-peptide (EEY) processing and presentation.
3.2 Viral specific T-cell responses may not give predictable allo-HLA crossreactivity
Unlike the public BV6S2 TCR response against FLR peptide presented on HLA-B8, immune 
responses against other common pathogens are not so immunodominant and memory CD8 
T-cells generated following viral infections often demonstrate a wide diversity of Vb usage 
and therefore allo-HLA crossreactivity (Table 1). For example, Burrows showed that EBV 
EBNA3A specific T-cells that do not use the Vb6S2 TCR are alloreactive against HLA-B14 
and -B35, but not HLA-B*4402 (45). Several other examples of differing alloresponses from 
T-cell clones with the same viral peptide/HLA restriction are also reported by Amir (27) and 
summarized in Table 1.
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Variable allo-HLA crossreactivity by T-cell clones sorted from the same individual with the 
same specificity, but different TCR Vb usage, was also reported. Single cell sorting of VZV 
IE62 specific T-cells from an individual with VZV infection generated three different clones 
with usage of Vb 21.3, Vb 14 and an undetermined Vb (27). These T-cell clones cross-reacted 
against allo HLA-A*0205, HLA-B*5501 and HLA-B*5701 respectively. Demonstrating how a 
single viral peptide/HLA restricted immune response can generate different clonotypes with 
differing allo-HLA crossreactivity within the same individual.
Furthermore, a single EBV EBNA3A specific memory T-cell clone was able to recognize both 
allogeneic HLA-B*4402 and B*5501, in addition to the viral peptide presented on HLA-B8 
against which it was originally selected (26).
Table 2. Cellular Targets used for Detection of Allo-HLA Crossreac-
tivity by Viral Specific Memory T-cells
* The authors have found that our EBV EBNA3A specific T-cell clone 
does not recognize HLA-B8+ EBV seropositive PBMCs or PHA Blasts 
without addition of exogenous FLR peptide
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Pan HLA recognition is inherent in germline TCR sequences (46). T-cells can presumably 
exit the thymus due to their high crossreactivity, as they are “positively” selected by self-HLA 
molecules. These alloreactive T-cells are unable to discriminate between self and non-self 
peptides presented on allo-HLA molecules (29). Only T-cells with high affinity for self-pep-
tides presented on self-HLA molecules are “negatively” selected from the pan HLA reactive 
T-cell repertoire. Indeed, in HLA-B8/B44 heterozygotes the public Vb6S2 TCR expressing 
EBV EBNA3A clonotype is deleted from the T-cell repertoire (47). CTLs from HLA-B8+B44+ 
individuals express different TCR gene combinations which maintain HLA-B8/FLR specific-
ity, but do not possess HLA-B*4402 reactivity, thereby preventing auto-immunity. Self-toler-
ance shapes the TCR repertoire available to respond to any individual viral antigen (47-48), 
thereby also altering the allo-HLA crossreactivity of the viral specific TCR pool.
Therefore, alloreactive T-cells do escape thymic deletion and are subsequently activated by vi-
ral infection. However virus specific T-cells with the same antigen specificity, but with differ-
ent TCR Vb usage, clearly exert alloreactivity against different HLA molecules. It is currently 
not known if viral specific T-cells from different individuals with the same specificity and the 
same Vb usage will always demonstrate similar allo-HLA crossreactivity. This knowledge is 
essential in order to be able to predict (un)acceptable mismatches based on donor-recipient 
HLA mismatches and immunological history of the recipient.
 
4. PREVIOUS VIRAL (PATHOGEN) INFECTION IS CRITICAL TO INDUCTION OF 
THE ALLOREACTIVE T-CELLS
Memory T-cells demonstrate critical functional differences versus their naïve counterparts, 
such as immediate cytotoxicity without the need for co-stimulation nor CD4 T-cell help. For 
example, EBV EBNA3A specific memory T-cells demonstrate immediate cytolytic effector 
function against HLA-B*4402+ PHA blasts in a 4 hour 51chromium release assay (6,26). A 
CCR7+ CD45Ra+ naive T-cell with the same TCR (e.g. from a EBV seronegative individual), 
upon first contact with antigen, will secrete only IL2, is not cytolytic and requires CD4 T-cell 
and B-cell help within the germinal centre to initiate an immune response before expanding 
into the memory T-cell pool. Naïve T-cells recognizing an alloantigen without the appropri-
ate co-stimulatory signals and T-cell help may gain regulatory function, be deleted or become 
anergic (49-50). This illustrates the critical importance of previous viral infection to the acti-
vation of alloreactive T-cells.
5. CLINICAL IMPLICATIONS OF STUDIES USING VIRAL SPECIFIC T-CELL CLONES
 
In humans, alloreactive memory T-cells are frequently generated by viral infection. This allo-
HLA crossreactivity is likely peptide dependent but not predictable based on donor-recip-
ient HLA mismatches alone. Allo-HLA crossreactivity from viral specific memory T-cells 
may have important clinical implications for the alloimmune response after transplantation 
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because memory T-cells have lower activation requirements, no need for CD4 T-cell help 
and can have immediate cytotoxic effector function as compared to their naïve counterparts. 
Therefore if truly alloreactive in-vivo, pre-existing memory T-cells may represent a common 
source of acute and/or chronic rejection and be a major obstacle to tolerance induction.
The frequency of memory T-cells are highest for the chronically persistent viruses such as 
human herpes viruses EBV and CMV. It remains to be determined if the alloreactive memory 
T-cell pool consists of many responding memory T-cells each of different specificities and 
each of low precursor frequency, or of a single (or few) viral specific memory T-cells that 
individually account for a large portion of the alloresponse. If alloreactive T-cells are driven 
by reactivation of viral infection then anti-viral therapy may decrease the proportion of these 
allo-HLA crossreactive alloresponses. Supportive evidence is provided by the finding that 
CMV prophylaxis with oral ganciclovir is associated with less acute rejection and improved 
long-term renal graft survival (8). Alternatively vaccination could induce alloreactivity, as 
suggested by others (38,51).
Given the longevity of viral specific memory T-cells, it is likely that allo-HLA crossreactive 
memory T-cells generated after infection are maintained and able to elicit acute rejection, 
particularly when immunosuppression is tapered (12). Ex-vivo staining for the presence of 
viral specific T-cells within rejecting kidney or GvHD biopsy samples may help confirm the 
clinical relevance of crossreactive allo-HLA responses.
Long term antigen specific tolerance to engrafted tissue is the ultimate goal in transplantation 
but despite numerous successful rodent models clinical human tolerance has remained an 
elusive goal. The presence of viral specific memory T-cells may be responsible for the failure 
to induce tolerance in clinical settings (12,15), although it is unclear what role primary infec-
tion vs. reactivation may play. For example, mice work reveals that viral infection abrogates 
the tolerance induced by donor specific transfusion and anti-CD154 blocking (13). Similar 
effects from memory T-cells following viral infection are also reported in many other stud-
ies (12,14-15,18). This relates to decreased dependence of memory T-cells on co-stimulatory 
pathways. Humans are not immunologically naïve and we propose that memory T-cells gen-
erated after environmental exposures may account for the difficulty in transferring tolerance 
studies from mice into the human setting. Therefore, we suggest caution when interpreting 
tolerance protocols studied in pathogen free animals.
The self-peptide dependency of alloreactivity from viral specific memory T-cells, as con-
firmed by Macdonald and colleagues (29), is of interest and may present several therapeutic 
opportunities. Allo-HLA recognition from viral specific T-cells may exhibit different tissue 
specificities depending on household gene expression and self-peptide presentation. For ex-
ample, preliminary work shows that PTEC and HUVEC cell lines are poor targets for EBV 
EBNA3A specific T-cells, likely due to decreased EEY peptide presentation. Therefore a HLA-
B*4402 mismatch in a HLA-B8+ B44- kidney recipient may not be associated with high risk of 
rejection if the EEY peptide is not presented on the donor cell surface. 
Conversely, a HLA-B8 mismatch in a HLA-B8- B*4402+ bone marrow recipient could theoret-
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ically be associated with graft vs. leukaemia (GvL) effect but low risk of GvHD. Interestingly, 
haploidentical bone marrow transplantation may be associated with increased GvL effect. Ex-
ploitation of the differential peptide and tissue specificity of alloreactivity from viral specific 
T-cells for therapeutic benefit should become a major research focus.
Peptide dependent alloreactivity also implies that immunomodulating techniques could be 
used to inhibit these harmful T-cell clonotypes, as suggested by Burrows (52). While the allo-
reactivity of the EBV EBNA3A specific T-cell has been confirmed to be dependent on peptide 
dependent molecular mimicry, and not degenerate recognition, further structural studies on 
the mechanisms of allorecognition are clearly warranted.
Given the abundant crossreactivity contained within the T-cell repertoire deletion of any in-
dividual virus specific clonotype might not be associated with viral reactivation. While the 
CD8 memory T-cell pool created after a viral infection has a distinct immunodominant hier-
archy, many clonotypes are capable of recognizing the viral peptide/HLA complex. Nonethe-
less, it can not yet be excluded that successful tolerance induction may occur at the expense 
of a T-cell clone that has an important role in controlling a chronic viral infection, possibly 
leading to viral reactivation.
Monitoring of alloreactive T-cells is also critical as this may allow individualization of im-
munosuppression (53). Currently in-vitro assay for renal transplantation monitoring does 
not have adequate sensitivity or specificity to enter routine clinical practice. However such 
assays routinely use donor PBMCS or spleen cells as stimulator, and it is unclear if these target 
cells present a comparable peptide pool to that presented by the relevant donor (kidney) cells. 
Perhaps future studies of transplantation monitoring could use a pool of tissue specific self-
peptides which are known to be presented by the donor organ. At the current point in time 
HLA matching remains the best predictor of long-term renal graft survival.
DR-matching has beneficial effects on transplantation survival. Allo-HLA class II crossre-
activity from class I restricted viral specific T-cells was previously unreported (27,34). We 
suggest that DR matching may, in part, be associated with improved graft survival due to the 
inability of viral specific T-cells to crossreact against allogeneic HLA class II. Further exami-
nation of MHC class II restricted pathogen specific CD4 T-cells is required, as it is likely that 
this T-cell population plays a dominant role in allograft rejection (2,54-55).
Ultimately not only HLA phenotype, but also immunological history, may be used to deter-
mine donor-recipient suitability. However major studies on the public nature of anti-viral 
responses in individuals of different HLA background are still required. Early work suggests 
that, unlike the HLA-B8/FLR restricted immune response, most viral specific T-cell responses 
do not give rise to a public TCR nor predictable allo-HLA crossreactivity. Nonetheless studies 
of viral peptide/HLA restricted T-cell responses, TCR Vb usage and allo-HLA crossreactivity 
are ongoing.
Even if immunological history can not be utilized to avoid alloreactivity, selective therapies 
at the time of transplantation may allow inhibition of allo-HLA crossreactivity from pre-ex-
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isting memory T-cells while still allowing de-novo naïve responses against viral antigens. For 
example, selective blockade of ICOSL and CD86 which represent two major co-stimulatory 
signals for the activation of resting peripheral blood memory T-cells (12,56) may still allow 
immune responses via the CD40/CD154 and/or CD70/CD27 co-stimulatory pathways which 
are important for naïve T-cell activation. While the effect of immunosuppressive drugs on 
allo-HLA crossreactivity from viral specific T-cells has not been studied, the calcineurin in-
hibitors are able to inhibit proliferation and cytokine production from effector CD4 memory 
T cells (54). Unfortunately leukocyte depleting therapies such as antithymocyte globulin and 
alemtuzumab are less able to diminish the memory T-cell pool (54).
Adoptive transfer of virus or fungal specific T-cells offers an effective option for the man-
agement of specific immune defects in an immune compromised host (57), particularly fol-
lowing allogeneic BMT. However given the high frequency of allo-HLA crossreactivity from 
viral specific T-cells, it is not surprising that adoptive transfer has already been associated 
with GvHD. For example, adoptive transfer of CMV specific T-cells to nine recipients after 
allogeneic BMT resulted in three cases of GvHD, including one patient who died (58). Simi-
larly, TCR gene transfer to induce anti-leukaemia reactivity is associated with a and b chain 
rearrangements and therefore the formation of mixed dimer TCRs (59), which could also be 
alloreactive. Screening of adoptively transferred antigen or leukaemia specific T-cells for allo-
HLA crossreactivity may help prevent GvHD.
Consistent with this theory cord blood T cells are less able to mediate GvHD than marrow 
derived T-cells because of their naïve status (49,60).
Finally, some groups have suggested that allo-HLA crossreactivity by viral specific T-cells 
does not play a significant role in transplantation. Nickel and colleagues found no association 
between CMV specific memory T cells and alloreactivity (61). However this study only meas-
ured CMV specific responses against viral peptides loaded on autologous cells and did not 
specifically document if these responses were crossreactive against mismatched donor HLA 
molecules. While 45% of virus specific T-cells have demonstrable allo-HLA crossreactivity 
against one HLA molecule (27), the target HLA molecule may not have been present on the 
donor cell. All kidney recipients received anti-IL2R mAb, calcineurin inhibitor, mycopheno-
late mofitil and steroids as induction therapy, possibly suppressing allo-HLA crossreactive 
responses until the immunosuppressive drugs were tapered. Furthermore, recipients received 
pre-emptive ganciclovir therapy guided by asymptomatic CMV viraemia. While we agree 
that CMV specific T-cell responses that are not allo-HLA crossreactive are likely to benefit a 
recipient, this study does not exclude the role of allo-HLA crossreactivity from viral specific 
T-cells in kidney rejection.
Therefore, crossreactivity by viral specific memory T-cells or “heterologous immunity” is 
common. While this crossreactivity by pathogen specific memory T-cells may help protect 
against subsequent unrelated infections, in the transplantation setting such crossreactivity 
may give rise to harmful alloresponses.




An essential feature of the T-cell response is the ability to recognize a diverse array of poten-
tially unlimited antigens, necessitating that the TCR be inherently crossreactive. The memory 
T-cells that are specific to previously encountered pathogens accumulate following repeated 
infectious exposure and have low activation thresholds. Mice in-vivo, and human in-vitro, 
experiments reveal that these viral specific memory T-cells are commonly crossreactive with 
allo-HLA molecules in a self-peptide specific manner. Thus, getting a certain infection in an 
individual with a certain HLA type might have significant adverse consequences in the event 
of organ or marrow transplantation. Human ex-vivo studies are clearly warranted. We suggest 
that current research objectives should focus on the human in-vivo relevance of allo-HLA 
crossreactivity from viral specific memory T-cells, and specifically how self-peptide depend-
ent allorecognition from viral specific T-cells alters tissue specificity. Allo-HLA crossreactivity 
could also have serious adverse effects in the setting of adoptive transfer and TCR transfection 
of viral specific T-cells. New understandings of the origin of alloreactivity may lead to an era 
whereby donor suitability is defined not only by HLA typing but also using immunological 
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Stimulation of human viral specific cytolytic 
effector function using allogeneic cell therapy
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Viral infection is a major cause of morbidity and mortality, and there are few therapeutic 
options available to augment a viral specific T-cell response. While allo-HLA crossreactivity 
from viral specific memory T-cells is common, it is unclear if priming with allogeneic cells 
could conversely elicit a viral peptide/self-HLA restricted T-cell response. Firstly we used 
the previously described allo-HLA-B*44:02 crossreactivity by EBV peptide/HLA-B*08:01 re-
stricted T-cells, to determine if allogeneic HLA stimulation can elicit a cytolytic immune re-
sponse against Epstein-Barr virus. HLA-B*08:01+ HLA-B*44- EBV seropositive PBMCs were 
stimulated with either HLA-B*44:02+ or HLA-B*44:03+ mismatched irradiated PBMCs in a 
7-10 day mixed lymphocyte reaction. The stimulated responder cells were then evaluated for 
cytotoxicity using EBV peptide loaded autologous target cells and unloaded HLA-B*08:01+ 
EBV LCL target cells. PBMCs from EBV seropositive donors gained EBV specific cytolytic 
effector function following specific allo-HLA stimulation. Finally, as a proof-of-principle, we 
also elicited cytolytic CMV specific responses using allogeneic cell stimulation, to confirm 
that this technique can be used to elicit viral peptide/self-HLA restricted responses against 
any virus or specificity. Allogeneic cell stimulation used as a cell therapy may be a potential 
tool to augment an anti-viral T-cell response in patients with viral infection.




Control of viral replication depends primarily on viral specific memory T-lymphocyte activ-
ity (1,2). In the normal course of viral infections, anti-viral immunity and non-infectivity 
correlates with the development of virus specific effector memory T-cells. Absence of HIV-
specific CD8 T-cells is associated with progression to AIDS in HIV infected individuals (3), 
and use of lymphocyte targeted biological therapies has recently been associated with viral 
reactivation which may not respond to anti-viral antibiotics (4). For example, while alloge-
neic marrow depleted of T-cells prevents acute and chronic forms of graft versus host disease 
(GvHD) posttransplant, the risk of infections, particularly with Epstein-Barr virus (EBV) 
and cytomegalovirus (CMV), are increased (5). Furthermore, viral infection can cause severe 
morbidity and mortality, even in individuals without defined immune deficiency.
Currently there are no in-vivo autologous therapies to increase the number or effector func-
tion of viral specific T-cells. Antiviral prophylaxis can be toxic and does not result in an in-
crease in viral-specific T-cells nor achieve long-term eradication. Adoptive transfer of 3rd 
party cell lines is associated with GvHD or failure due to allogeneic rejection (6), and is tech-
nically difficult (7). While antigen specific T-cell responses are actively maintained, they are 
reversible and short lived in the absence of antigen (8-10).
We have recently confirmed that alloreactivity from viral specific T-cells is common, and that 
the allo-HLA reactivity and virus specificity is mediated via the same T-cell receptor (TCR)
(11). 45% of virus specific CD4 and CD8 T-cell clones were shown to be cross-reactive against 
allo-HLA molecules. For example, EBV infection in a HLA-B*08:01+ individual always selects 
for a dominant “public” Vb6S2 TCR (12), which cross-reacts against allo-HLA-B*44:02(13). 
We confirmed the previously described alloreactivity of this EBV EBNA3A specific T-cell 
(HLA-B8/FLRGRAYGL restricted) against allogeneic HLA-B*44:02 (11,14). Allo-HLA cross-
reactivity was also shown for cytomegalovirus (CMV), varicella-zoster virus (VZV) and in-
fluenza virus specific T-cells (Amir) which express non-public TCRs.
A very high level of cross-reactivity against allo-HLA molecules is therefore an essential fea-
ture of the virus specific memory TCR (11-21). This allo-HLA crossreactivity by viral specific 
T-cells can be reproducibly predicted in-vitro. However, currently it is unknown if stimula-
tion with allogeneic-HLA molecules could conversely specifically augment a HLA-restricted 
viral specific T-cell response.
The purpose of this study was therefore to assess if allogeneic HLA challenge could be a useful 
tool to augment a HLA-restricted anti-viral CD8 T-cell response, as determined by cytolytic 
functional assays. We used viral specific tetramers to confirm that in-vitro allogeneic chal-
lenge of EBV and CMV seropositive individuals, resulted in proliferation of human virus 
specific CD8 T-cells. Furthermore, we confirmed that this proliferation was associated with 
increased cytolytic effector function from the allo-HLA primed cells against viral antigens. 
Our proof-of-principle results demonstrate that allo-HLA stimulation may be a potential tool 




EBV specific CD8 T-cells proliferate following allogeneic cell stimulation
To determine whether an allogeneic HLA challenge could specifically stimulate a viral spe-
cific CD8 T-cell response within whole blood, a modification of the MLC assay was used. EBV 
EBNA3A specific T-cells proliferated only in response to stimulation with HLA-B*44:02+, 
and not HLA-B*44:03+, mismatched irradiated PBMCs implying specific stimulation of 
cross-reactive viral specific T-cells by allogeneic HLA molecules (Figure 1). EBV EBNA3A 
specific T-cells did not proliferate in response to stimulation with allogeneic HLA-B*0801+ 
HLA-B*44- PBMCs, excluding the possibility that the cells could be responding to EBV pep-
tides contained within the culture medium or presented via stimulator cells (Data not shown). 
Proliferation was associated with a specific increase in the proportion of EBV EBNA3A spe-
cific T-cells within the CD8 T-cell compartment (Figure 2 and table 1), and no proliferation 
of HLA-A2/GLC or HLA-B8/RAK restricted T-cells was detected (data not shown); thereby 
excluding bystander proliferation and confirming the allo-HLA dependency of the stimula-
tion. The observed response was abrogated when heterozygote HLA-B*08:01+ HLA-B*44:02+ 
responder PBMCs were used, consistent with specific thymic editing of the T-cell repertoire 
(Data not shown). These results confirm that viral specific CTL can directly recognize and 
proliferate in response to allogeneic HLA to which they are crossreactive and have never been 
exposed.
Figure 1. EBV specific CD8 memory T-cells specifically proliferate following allogeneic cell stimula-
tion.
EBV EBNA3A specific T-cells are specifically stimulated to proliferate following 7-10 day in-vitro co-
culture with heterozygous HLA-B*44:02+, but not HLA-B*44:03+, mismatched irradiated PBMCs. By-
stander activation was excluded. FACS plots gated on total HLA-B8/FLR tetramer complex positive 
lymphocytes. Assay repeated 4 times with different responder-stimulator pairings, with similar results. 
A representative result is shown. Responder HLA-A*02,31; B*08:01,39; DRB1*03,16. HLA-B*44:02+ 
stimulator HLA-A*11,-; B*44:02,51; DRB1*12,15. HLA-B*44:03+ stimulator HLA-A*02,68; B*44:03,51; 
DRB1*08,13.
Stimulation of viral specific T-cell responses
133
7
Figure 2. The proportion of EBV specific CD8 T-cells is specifically increased following allogeneic 
cell stimulation.
EBV EBNA3A specific CD8 T-cells accounted for 20.8% of total CD8 T-cells, following 8 day co-cul-
ture with homozygote HLA-B*44:02 mismatched irradiated PBMCs. The proportion of EBV EBNA3A 
specific CD8 T-cells was unaltered by co-culture with homozygote HLA-B*44:03+ PBMCs. FACS plots 
gated on total CD8 T-cell population. The primed responder cells shown here were then harvested and 
used as effector cells in the cytolytic assays shown in Figure 5. Responder HLA-A*01,02; B*08:01,-; 
DRB1*03,-. HLA-B*44:02+ stimulator HLA-A*02,68; B*44:02,-; DRB1*07,14. HLA-B*44:03+ stimulator 
HLA-A*02,32; B*44:03,-; DRB1*01,08.
Viral specific T-cell proliferation may be greater following homozygote cell stimulation
To determine if homozygote allo-HLA is a greater stimulus for viral specific T-cells HLA-
B*08:01+ B*44- responder PBMCs were stimulated with either homozygous or heterozygous, 
HLA-B*44:02 or HLA-B*44:03, allogeneic cells. EBV EBNA3A specific T-cells accounted for 
20.8% of the total CD8 T-cell population following homozygous HLA-B*44:02 allogeneic cell 
stimulation, but only 5.04% of the total CD8 T-cell population following heterozygous HLA-
B*44:02 cell stimulation (Table 1 and Figure 2). The proportion of EBV EBNA3A specific 
CD8 T-cells was not significantly altered by homozygous or heterozygous allo-HLA-B*44:03 
stimulation in the same assay (Table 1). The percentage of EBV EBNA3A specific CD8 T-cells 
prior to stimulation was 1.5%.
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CMV specific CD8 T-cells proliferate following allogeneic cell stimulation
To determine whether allo-HLA stimulation can elicit proliferation of T-cells specific for any 
viral peptide/self-HLA restriction of interest, we screened for responder CMV specific T-
cell proliferation using pools of PBMC stimulator cells. Proliferation of CMV specific CD8 
memory T-cells was detectable using pools of 4 different PBMC stimulators together (Table 
2). The individual PBMC giving the specific stimulation was then easily determined in a sec-
ond assay. For example, CMV pp65 specific T-cells (HLA-A2/NLV restricted) from a healthy 
donor (Responder 2) proliferated in response to a PBMC pool of 4 different PBMCs (Pool 4 
- Figure 3a and table 2). The same responder was then tested individually against the stimu-
lators present in the screening pool in order to identify the specific stimulator (Figure 3b). 
Proliferation was associated with a specific increase in the proportion of CMV pp65 specific 
T-cells within the CD8 T-cell compartment (Figure 4). Screening experiments were repeated 
multiple times with different responders and for different CMV CD8 T-cell specificities. Us-
ing this technique proliferation of HLA-A2/NLV and HLA-B35/IPS restricted CD8 T-cells 
from different responders was elicited (Table 2). Furthermore this stimulation is demonstra-
ble without the need to generate viral specific T-cell clones from the responder, even when 
the viral specific T-cell of interest does not express a public TCR, thereby confirming that al-
logeneic cells stimulating viral-peptide/HLA restricted T-cells from any given responder are 
readily identifiable in the routine laboratory.
Table 1. Viral specific T-cell proliferation 
may be greater following homozygote al-
logeneic cell stimulation.
Table 2. Screening for allo-HLA crossreactivity 
using pools of allogeneic cells.
HLA-B*08:01+ responder PBMCs were 
stimulated with either homozygous or het-
erozygous, HLA-B*44:02 or HLA-B*44:03, 
allogeneic cells. The proportion of EBV EB-
NA3A specific CD8 T-cells was measured 
using viral specific tetrameric complexes 
and results are expressed as percentage of 
EBV EBNA3A specific CD8 T-cells within 
the total CD8 T-lymphocyte population. 
The percentage of EBV EBNA3A specific 
CD8 T-cells prior to stimulation was 1.5%. 
The responder PBMCs stimulated with 
HLA-B*44 homozygous allogeneic cells are 
shown in figure 2, and were harvested and 
used as the effector cells in the assays shown 
in figure 5.
Pools of 4 different allogeneic cells were first used to 
screen for allo-HLA crossreactivity of CMV specific 
CD8 T-cells within whole blood, using CFSE stain-
ing of proliferating responder cells. The specific 
allogeneic cell giving the stimulation was then eas-
ily identified in a second assay. Specific allogeneic 
stimulation was associated with not only prolifera-
tion but also increased cytolytic activity against the 
original cognate viral antigen. Specific allogeneic 
cells stimulating a viral specific T-cell response were 
identifiable for most responders and specificities. 
+ Specific proliferation detected. 
– No proliferation detected.
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Figure 3. Screening for allo-HLA crossreactivity of viral specific memory T-cells.
(a) CMV pp65 specific CD8 Memory T-cells (A2/NLV restricted) from Responder 2 (R2) proliferate 
following stimulation with a pool of 4 PBMCs (Pool 4 containing stimulators 13-16), but not other pools 
of 4 different stimulator PBMCs (Pool 2 shown). (b) Responder 2 was then tested individually against 
all four stimulators present in pool 4 (S13-16). R2 proliferated only when stimulated with S13 and not 
when stimulated with the other 3 stimulators present in pool 4 (S15 shown). Thereby confirming the 
CMV pp65 specific T-cells from responder 2 were specifically stimulated by only S13 allogeneic cells. 
HLA typing of responder 2 HLA-A*02,11; B*35,40; DRB1*11,15. Stimulator 13 HLA-A*02:01,02:05; 
B*18,50; DRB1*11,13. Stimulator 15 HLA-A*23,29; B*15,53; DRB1*11,13.
Chapter 7
136
EBV and CMV specific CD8 memory T-cells gain viral peptide/self-HLA restricted cytolytic ef-
fector function following specific allo-HLA stimulation
For viral protection it is essential that the proliferation of viral specific T-cells following al-
logeneic stimulation is associated with a gain of cytolytic effector function against the origi-
nal viral peptide/self-HLA restricted target antigen. We therefore performed a cytolytic assay 
using responder HLA-B*08:01+ EBV seropositive healthy donor PBMCs following in-vitro 
stimulation with either homozygote HLA-B*44:02 or HLA-B*44:03 mismatched irradiated 
PBMCs, and with viral peptide loaded autologous cells and unloaded EBV transformed 
B-cells (EBV LCLs) as target cells. Following 7-10 day stimulation with HLA-B*44:02 ho-
mozygote mismatched irradiated PBMCs, primed responder cells from a HLA-B*08:01+ EBV 
seropositive healthy donor showed increased cytolytic effector function against both HLA-
B*08:01+ EBV LCLs and FLR peptide loaded autologous target cells, but not HLA-B8- EBV 
LCLs nor RAK peptide loaded autologous target cells (Figure 5); as compared to the same PB-
MCs co-cultured with either HLA-B*44:03 mismatched PBMCs or culture with IL-2 contain-
ing medium alone. This increased cytolytic effector function was associated with proliferation 
Figure 4. The proportion of CMV specific CD8 T-cells is specifically increased following allogeneic 
cell stimulation.
CMV pp65 specific CD8 T-cells accounted for 2.1% of total CD8 T-cells from responder 2 (R2), follow-
ing 8 day co-culture with Stimulator 13 (S13). The proportion of CMV pp65 specific CD8 T-cells was un-
altered by co-culture with Stimulator 15 (S15) or IL-2 containing medium alone. The primed responder 
cells shown here were then harvested and used as effector cells in the cytolytic assay shown in Figure 
6. HLA typing of responder 2 HLA-A*02,11; B*35,40; DRB1*11,15. Stimulator 13 HLA-A*02:01,02:05; 
B*18,50; DRB1*11,13. Stimulator 15 HLA-A*23,29; B*15,53; DRB1*11,13.
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and an increase in the proportion of EBV EBNA3A specific CD8 T-cells (Figure 2). Likewise, 
specific stimulation of CMV specific CD8 T-cells with allo-HLA resulted in increased cyto-
lytic effector function against CMV peptide loaded autologous cells (Figure 6). Once again 
confirming that allogeneic HLA challenge can indeed increase the (in-vitro) cytolytic effector 
function of human viral specific T-cells against their original cognate viral antigen. We argue 
these proof-of-principle results may have important implications for treatment of viral infec-
tions, if confirmed in-vivo.
Figure 5a. EBV specific cytolytic effector func-
tion of allo-HLA primed cells using EBV LCL 
target cells. PBMCs from a HLA-B*08:01+ EBV 
seropositive donor gain EBV specific cytolytic 
effector function following allogeneic HLA-
B*44:02+ cell stimulation, ***P<0.0001 versus 
HLA-B*08- EBV LCL. Unstimulated HLA-
B*08:01+ PBMCs and HLA-B*44:03 stimulated 
HLA-B*08:01+ PBMCs do not demonstrate cy-
tolytic effector function against HLA-B*08*01+ 
EBV LCLs. Effector:target ratio 50:1, targets 
2000. *Positive control EBNA3A T-cell clone is 
previously described (14), and responder PB-
MCs used in this assay are also obtained from 
the same donor. HLA typing of responder PB-
MCs and EBNA3A T-cell clone HLA-A*01,02; 
B*08:01,-; DRB1*03,-. HLA-B8+ EBV LCL 
HLA-A*01,-; B*08:01,-; DRB1*03,-. HLA-B8- 
EBV LCL HLA-A*03,-; B*07,-; DRB1*15,-.
Figure 5b. EBV specific cytolytic effector 
function of allo-HLA primed cells using vi-
ral peptide loaded autologous target cells. 
PBMCs from a HLA-B*08:01+ EBV seroposi-
tive donor gain HLA-B8/FLR restricted cy-
tolytic effector function following allogeneic 
HLA-B*44:02 stimulation. ***P=0.0094 versus 
RAK peptide loaded autologous cells. Unstimu-
lated HLA-B*08:01+ PBMCs and HLA-B*44:03 
stimulated HLA-B*08:01+ PBMCs do not dem-
onstrate cytolytic effector function against FLR 
peptide loaded autologous cells. Effector:target 
ratio 50:1, targets 2000. *Positive control EB-
NA3A T-cell clone is previously described (14), 
and responder PBMCs used in this assay are 
also obtained from the same donor. HLA typ-
ing of responder PBMCs, autologous target PB-




Figure 6. CMV specific cytolytic effector function of allo-HLA primed cells. 
PBMCs from a CMV seropositive HLA-A*02:01+ donor (R2) gain HLA-A2/NLV restricted cytolytic 
effector function following heterozygote allogeneic cell stimulation with stimulator 13 cells (R2 x S13). 
***P<0.0001 versus IPS loaded autologous cells. S15 stimulated PBMCs do not demonstrate cytolytic 
effector function against NLV peptide loaded autologous cells (R2 x S15). A strong secondary response 
against S13 is demonstrated from R2 responder cells primed with S13 (Positive Control), but not S15. 
Effector:target ratio 100:1, targets 2000. Responder 2 HLA-A*02,11; B*35,40; DRB1*11,15. Stimulator 
13 HLA-A*02:01,02:05; B*18,50; DRB1*11,13. Stimulator 15 HLA-A*23,29; B*15,53; DRB1*11,13.
DISCUSSION
This study demonstrates that human viral specific memory T-cells gain cognate viral anti-
gen specific cytolytic effector function following stimulation with allogeneic HLA molecules 
against which they are crossreactive. Stimulation of peripheral blood from a non-sensitized 
HLA-B*08:01+ EBV seropositive healthy donor with HLA-B*44:02 mismatched irradiated 
PBMCs increases (in-vitro) cytolytic effector function against EBV. Furthermore, we show 
this technique can be used to elicit cytolytic effector function against any potential viral an-
tigen, as shown for CMV. These results provide proof-of-principle evidence that specific al-
logeneic cell therapy could be useful for treatment of viral infections.
The importance of our findings are reinforced by functional studies showing that the prolifer-
ation of EBV and CMV specific CD8 memory T-cells corresponded with a specific increase of 
cytolytic effector function against viral peptide loaded autologous cells, which was not detect-
able without specific allo-HLA stimulation. Cytolysis of the EBV LCLs by the HLA-B*44:02 
primed effector cells suggests that virus infected cells can spontaneously process and pre-
sent viral peptides via HLA class I molecules in the course of normal infection, and that the 
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amount of peptide present is sufficient to trigger killing from allo-HLA primed effector cells.
For the EBV specific cytotoxicity assays we used homozygote HLA-B*44:02+ PBMCs to stim-
ulate the EBV EBNA3A specific T-cell response, as this should provide a larger antigenic 
stimulus. However our CMV specific cytotoxicity assay clearly demonstrates that heterozy-
gote cell stimulation is sufficient to prime viral specific cytolytic effector functions. Nonethe-
less, further studies may be required to determine if homozygote allogeneic cell therapy truly 
provides a significantly better stimulation over heterozygote allogeneic cell therapy.
EBV infection in a HLA-B*08:01+ HLA-B*44- individual selects for a public BV6S2 TCR 
which cross-reacts against allogeneic HLA-B*44:02 (12). While not all viral specific immune 
responses give rise to a public TCR, the allo-HLA crossreactivity of virus specific T-cells from 
a given individual can be easily detected in-vitro using techniques we have described here 
and elsewhere (11,14). Indeed, successful stimulation of cytolytic effector function against 
CMV antigen reveals that this technique can be reproducibly used to elicit T-cell cytolytic 
effector function against any virus or specificity. Furthermore, identification of the allogeneic 
cells that stimulated the anti-viral cytotoxicity did not require generation of virus specific 
T-cell clones. Techniques described here should therefore be reproducible in most routine 
laboratories.
We have confirmed that these effects are mediated by leukocytes present in the blood compo-
nents and are related to the expression of HLA antigens. We used irradiated isolated PBMCs 
for stimulation of the viral specific memory T-cells thereby excluding any contributions by 
plasma, platelets and/or erythrocytes. Therefore we suggest allogeneic cell therapy should be 
investigated using only isolated leukocytes as stimulators.
Immunological memory is one of the hallmarks of the adaptive immune response. Functional 
viral specific memory T-cells are essential for proper host defense as in the periphery infected 
cells can now be targeted for immediate killing, both during the initial infection and on sub-
sequent re-infection or viral reactivation.
Results presented here suggest that specific allogeneic cell therapy could prime and/or main-
tain viral specific memory. The proportion of EBV EBNA3A specific T-cells in the CD8 
compartment increased from 1.5% to 20.8% following stimulation with homozygote HLA-
B*44:02+ allogeneic cells and the proportion of CMV pp65 specific T-cells from 0.31% to 
2.1% following heterozygote allogeneic cell stimulation. Data from preliminary clinical stud-
ies suggest that CMV specific CD8 T-cell levels greater than 1x107/L of peripheral blood may 
correlate with protection (22), therefore the total number of viral specific T-cells induced by 
proliferation following allogeneic cell stimulation may be important in isolation.
However, others have also shown that the memory T-cell state of readiness is actively main-
tained and reversible, requiring ongoing specific TCR signaling (8,10). Transfer of memory 
T-cells to naïve mice, in the presence or absence of priming antigen, reveals that maintenance 
of T-cell memory is short lived in the absence of TCR mediated signaling (8). Furthermore, 
recently activated memory T-cells can bypass the requirement for CD28/CD80/CD86 co-
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stimulation, as compared to resting memory T-cells that are still dependent on CD28 trig-
gering for their activation (23). Although at baseline in our EBV specific assays 1.5% of CD8 
T-cells in the peripheral blood of the individual were EBV EBNA3A specific T-cells, prior to 
allo-HLA-B*44:02 stimulation no cytolysis of FLR peptide loaded autologous cells could be 
detected, suggesting allogeneic cell priming was important to induce the observed cytolysis. 
Therefore, the allogeneic stimulation used in our assays may also have increased cytolytic 
effector function of the viral specific T-cells via triggering TCR signaling and/or abrogating 
co-stimulation requirements, irrespective of the changes to the total number of cells.
To evade these cytolytic CD8 T-cell responses viruses have evolved many different strategies 
for immune evasion (24-26), most of which interfere with the various steps necessary for 
MHC class I restricted antigen presentation. For example, CMV evades MHC class I antigen 
presentation by reducing the stability of class I heavy chains (27) and also by dislocating MHC 
class I heavy chains from the endoplasmic reticulum (28). The co-ordinated function of mu-
rine CMV genes can completely inhibit CTL lysis (29). Amongst others, the EBV EBNA1 pro-
tein contains an element that interferes with its proteasomal proteolysis and the HSV ICP47 
protein inhibits the TAP complex (30-31). Many other viral immune evasion strategies are 
also described (32-36).
Allogeneic cell therapy may be capable of bypassing all these viral strategies of immune eva-
sion as the viral specific memory T-cells are directly stimulated via molecular mimicry (37). 
The allo-HLA molecule against which the virus specific T-cell is crossreactive is constitutively 
expressed and occupied by the stimulating self-peptide. Theoretically allogeneic cell therapy 
could even stimulate additional virus specific responses other than the specificity of interest. 
Steffens and colleagues demonstrated that pre-emptive CMV specific CD8 T-cell immuno-
therapy, guided by viral DNA load, prevented lethal disease and reduced the risk of virus re-
currence (38). Similarly, allogeneic cell therapy may ensure a high proportion of pre-existing 
activated virus specific memory T-cells to prevent disease and accelerate the resolution of 
productive infection.
HIV specific effector memory CD8 T-cells are present in most HIV infected individuals and 
play a critical role in controlling viral replication and disease progression, however HIV is 
also highly efficient at evading immune responses (39). Recent data demonstrate that HIV 
escape mutations may impair dendritic cell function (3) and that the HIV-1 Vpu protein 
modulates MHC class II presentation (40), thereby possibly impairing later CD4 and/or CD8 
T-cell responses to the same and other epitopes. High viraemia is also associated with in-vivo 
downregulation of MHC class I in rhesus macaques infected with SIV (41). The maintenance 
of early differentiated, highly avid HIV specific CD8 T-cells by allogeneic cell therapy could 
induce a non-progressive course of the disease. Further in-vitro studies are warranted using 
responder PBMCs from HIV infected individuals.
Poorly controlled viral infections are also associated with malignancy. Post-transplant lym-
phoproliferative disease (PTLD) is a well recognized complication of both solid organ and 
allogeneic bone marrow transplantation, and is associated with a deficient cellular response 
from the host to EBV infected B-cells. Most PTLD occurring in solid organ setting arise from 
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recipient cells, therefore, allogeneic HLA-B*44:02 cell therapy may elicit an anti-tumour re-
sponse in a HLA-B*08:01+ recipient with PTLD. Results presented here strongly support this 
hypothesis.
Results presented here demonstrate the stimulation of cytolytic effector function from pre-
existing memory T-cells. It is unclear if allogeneic cell therapy could also be used to stimulate 
a de-novo viral specific response from naïve T-cells. However it is likely that stimulation of 
de-novo viral specific T-cell responses using allogeneic cells, from naïve T-cells, would re-
quire additional co-stimulatory factors than those provided by irradiated allogeneic PBMCs 
alone (42-44).
Finally, we acknowledge that further work is required before allogeneic cell therapy can be 
used in the clinical setting to treat viral infections. In these experiments we have used healthy 
blood donors as responder PBMCs, not cells from immunosuppressed patients. While infu-
sion of irradiated leukocytes should not be associated with chimerism or engraftment, this 
possibility should be considered in an extremely immunodeficient recipient. Repeated alloge-
neic cell therapy may cause sensitization of a recipient to future transplantations. Nonetheless 
results demonstrated here suggest cell therapy may have potential as an alternative to adoptive 
transfer or pharmacological therapy to treat viral infections.
The high frequency of allo-HLA crossreactivity by viral specific T-cells in the transplantation 
setting is increasingly being recognised. We provide (in-vitro) evidence that allogeneic cell 
therapy may be useful to conversely stimulate a beneficial anti-viral cytolytic effector response 
for treatment of viral infection. This proof-of-principle technique could provide important 





Preparation of responder, stimulator and target cells
Responder and stimulator cells were both obtained using blood samples from healthy donors, 
after informed consent. PBMC were isolated from heparinized blood by standard density 
gradient centrifugation, and were subsequently cryopreserved until use. Epstein-Barr virus-
transformed B-cell lines (EBV LCLs) were generated using standard procedures, and were 
cultured in Iscoves Modified Dulbeccos Medium (IMDM, Cambrex) with 10% fetal calf se-
rum (FCS). The HLA type of all cells used in our experiments was determined molecularly by 
SSO and SSP genotyping at the Leiden University Medical Centre, Dept of Immunohematol-
ogy and Blood Transfusion, the Netherlands.
Proliferation Assays for EBV EBNA3A specific T-cell responses
For the proliferation assays 1x10*6 Carboxyfluoresceinsuccinimidyl ester (CFSE)-labeled 
PBMC from a HLA-B*08:01+ HLA-B*44- EBV seropositive healthy donor, were co-cultured 
with 1x10*6 HLA-B*44:02+ or HLA-B*44:03+ mismatched irradiated PBMCs (3000 Rad) 
also from healthy donors, in a 24 well flat bottom plate. Cells were incubated for 7-10 days 
in IMDM culture medium with 15% human serum and IL-2 (25IU/ml). Then, fluorescence 
activated cell sorter analysis was performed, after staining the cells with CD8-APC (Becton-
Dickinson) and PE-labeled HLA-B8/FLR tetrameric complexes to detect cell division. In all 
experiments HLA-A2/GLC and HLA-B8/RAK tetrameric complex staining served as nega-
tive controls. The proportion of EBV EBNA3A specific T-cells within the total CD8 T-cell 
population of a single responder was also determined before and after homozygous vs. hete-
rozygous allo-HLA-B*44 cell stimulation in a separate assay without CFSE labeling. The HLA 
typing of the selected responder-stimulator examples is given below the figures.
Proliferation Assays for CMV specific T-cell responses
To determine if allo-HLA stimulation could elicit an anti-viral response against any virus or 
specificity, we had to first determine a new method whereby specific allogeneic cells stimu-
lating the proliferation of viral specific T-cells from any given individual could be identified. 
1x10*6 Carboxyfluoresceinsuccinimidyl ester (CFSE)-labeled PBMC from CMV seropositive 
healthy donors, were first co-cultured with a pool of 1x10*6 total mismatched irradiated PB-
MCs (3000 Rad) from 4 different healthy donors (0.25x10*6 cells of each individual stimu-
lator), in a 24 well flat bottom plate. Each responder was screened against 4 different pools 
of PBMCs. The 16 total different allogeneic stimulator cells were selected to cover the most 
common occurring HLA molecules. Cells were incubated for 7-10 days in RPMI culture me-
dium with 15% human serum and IL-2 (25IU/ml). Fluorescence activated cell sorter analysis 
was performed after staining the cells with PE-labeled CMV specific tetrameric complexes to 
detect cell division. If proliferation of CMV specific cells was detected following stimulation 
with a screening pool of 4 different allogeneic PBMCs, then the same responder PBMCs were 
tested individually against the 4 stimulator PBMCs to determine which allogeneic cell(s) elic-
ited proliferation of the CMV specific T-cells. The proportion of CMV specific tetramer posi-
tive T-cells within the total CD8 T-cell population were also determined before and after al-
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logeneic cell stimulation using routine FACS analyses. The CMV seropositive responder cells 
were then stimulated with the individual relevant PBMCs (or control) in a new assay (without 
CFSE labeling), following which the allo-HLA primed responder cells were harvested and 
used as effector cells in the cytotoxicity assays (see methods below). The HLA typing of the 
selected responder-stimulator examples is given below the figures.
Cytotoxicity Assays
To confirm that allogeneic cell stimulation resulted in increased viral specific cytolytic ef-
fector  function, not just proliferation, from the stimulated PBMCs we performed cytolytic 
assays using autologous cells loaded with the relevant viral peptide or unloaded EBV LCLs 
as target cells. Responder PBMCs from EBV or CMV seropositive healthy donors were first 
specifically stimulated in a 7-10 day mixed lymphocyte reaction with allo-HLA mismatched 
irradiated cells to stimulate a viral specific memory T-cell of interest (see methods above). The 
stimulated PBMCs were then evaluated for cytotoxicity by incubating serial dilutions with 
2000 viral peptide loaded autologous target cells or EBV LCL target cells, in a 4 hour 51Cr re-
lease assay. Cognate viral peptide or control viral peptide was directly added to the autologous 
target cells and incubated for 60 minutes, simultaneously with chromium incubation, and 
then washed three times. Supernatants were harvested for gamma counting: per cent-specific 
lysis= (experimental release-spontaneous release)/(Max release-spontaneous release) x 100%.
Statistical Analysis
Values for specific lysis are presented as the mean of triplicate wells with standard deviation. 
Comparative analyses are nonparametric (unpaired) t-tests, and P<0.05 is considered signifi-
cant. Statistics are derived using Graph Pad Prism 4 for Windows (version 4.02, 2004).
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SUMMARY AND GENERAL DISCUSSION
T-cell memory is a hallmark of the adaptive immune response and is critical for protective 
immunity against pathogens. However, many studies reveal that pre-existing memory T-cells 
also pose a potent barrier to transplantation tolerance, even in non-sensitized individuals (1-
12). It was previously unclear how these alloreactive memory T-cells arose in non-sensitized 
organ recipients.
A possible explanation is that alloreactive memory T-cells arise via exposure to environmen-
tal antigens (13-19). Recipients might have had immunological contact with pathogens that 
lead to crossreactive immune responses with the HLA mismatches. Limited evidence for this 
phenomenon exists in both mouse and human models, but was thought to be a rare occur-
rence. Allo-HLA crossreactivity from viral specific memory T-cells may have important clini-
cal implications for the alloimmune response after transplantation because memory T-cells 
have lower activation requirements, no need for CD4 T-cell help and can have immediate 
cytotoxic effector function as compared to their naïve counterparts (20-24). Therefore if truly 
alloreactive in-vivo, pre-existing memory T-cells may represent a common source of acute 
and/or chronic rejection and be a major obstacle to tolerance induction.
The molecular mechanisms that might underlie such crossreactivity were also unexplained.
In order to study the effect of environmental exposure on the alloreactive T-cell repertoire 
viral specific T-cell clones were single cell sorted based on viral peptide/HLA tetrameric com-
plex staining, from healthy (non-sensitized) individuals. This technique proved to be the basis 
of an effective system for detection of allo-HLA crossreactivity (heterologous immunity) by 
viral specific memory T-cells. Results presented in this thesis indicate that heterologous im-
munity is much more common than anticipated. Furthermore, it has been confirmed that the 
virus specificity and alloreactivity are mediated by the same TCR and that the allo-HLA cross-
reactivity can not be predicted based solely on immunological history and HLA mismatch 
alone. Future clinical studies are now clearly warranted.
Several novel and important discoveries for the field of transplantation have been made in this 
thesis and are summarized below:
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Alloreactivity from viral specific memory T-cells is common
This thesis confirms that allo-HLA responses from viral specific memory T-cells are in fact 
far more common than anticipated (25) (Chapter 3). 80% of virus specific T-cell lines and 
45% of virus specific T-cell clones crossreacted against individual allo-HLA molecules. Allo-
HLA crossreactivity was shown from EBV, CMV, VZV and influenza specific T-cell clones. 
Multiple viral specific CD8 T-cell clones were shown to be alloreactive against allogeneic class 
I molecules, and likewise several viral specific CD4 T-cell clones were shown to crossreact 
against allogeneic class II molecules. Surprisingly, two separate CMV specific, class I restrict-
ed T-cell clones recognized allogeneic class II molecules (25).
The fact that the same TCR complex mediates both virus specificity and allo-HLA crossreac-
tivity has been confirmed by TCR PCR, viral tetramer inhibition and TCR transfection assays 
(25-26) (Chapters 2 and 3). Vaccination with live attenuated virus can also induce alloreactive 
memory T-cells, as shown in chapter 5 of this thesis for varicella vaccination.
The importance of these findings are reinforced by functional studies showing that the vari-
ous viral specific CD8 T-cell clones can lyse multiple different target cells expressing the target 
HLA molecule, in a 4 hour cytotoxicity assay (25-26) (Chapters 2, 3 and 5). Further examina-
tion of MHC class II restricted pathogen specific CD4 T-cells is required, as it is likely that this 
T-cell population also plays a dominant role in allograft rejection (10,27-28). Ex-vivo staining 
for the presence of viral specific T-cells within rejecting kidney or GvHD biopsy samples may 
help confirm the clinical relevance of these in-vitro crossreactive allo-HLA responses.
Human viral specific memory T-cells reported to give allo-HLA crossreactivity are summa-
rized in table 1 of chapter 6 of this thesis (29). 
 
HLA alloreactivity by viral specific memory T-cells is (self) peptide dependent
It is now generally accepted that alloreactive T-cells recognize allo-HLA molecules presenting 
self-peptides (25,30-33). Macdonald and colleagues have provided clear structural evidence 
that self-peptide dependent molecular mimicry underpins the alloreactivity of the EBV EB-
NA3A specific T-cell against allogeneic HLA-B*44:02 (31). The EBV EBNA3A specific T-cell 
crossreactivity against allogeneic HLA-B*44:02 is dependent on presentation of EEYLQAFTY 
peptide (derived from the ABCD3 protein) by the target tissue.
In this thesis, the peptide dependence of the allo-HLA crossreactivity from viral specific 
memory T-cells is reinforced by differing potency of the alloreactivity exerted by virus specif-
ic T-cells against different cell targets. For example, a VZV specific HLA-A2 restricted T-cell 
clone recognizes allogeneic HLA-B*57:01 expressing EBV LCLs, PHA Blasts and monocyte 
derived DCs, but does not recognize HLA-B*57:01 expressing B-cells, T-cells, monocytes nor 
fibroblasts (25) (Chapter 3). Therefore allo-HLA expression is not solely sufficient to elicit 




In contrast to allogeneic HLA-B*44:02+ EBV LCLs and SALs, allogeneic HLA-B*44:02+ proxi-
mal tubular epithelial cells (PTECs) are poor targets for EBV EBNA3A specific CD8 T cells 
(Chapter 4). However the specific lysis of HLA-B*44:02 expressing PTECs was greatly in-
creased by exogenous EEY peptide loading. HLA-B*44:02 expressing HUVECs were only 
killed by an EBV EBNA3A clone when loaded with exogenous EEY peptide. This confirms 
that kidney specificity of the alloresponse from the EBV EBNA3A specific T-cell is dependent 
on endogenous self-peptide processing and presentation.
Peptide dependent alloreactivity suggests that immunomodulating techniques could be used 
to inhibit these harmful T-cell clonotypes, as suggested by Burrows (30). Further studies are 
required.
HLA alloreactivity by viral specific memory T-cells can be tissue specific
Tissue specific alloresponses by viral specific memory T-cells are described in chapters 3,4 
and 5. Differences in peptide antigen processing and presentation could account for this tis-
sue specific alloreactivity. For example, EBV LCLs, PHA Blasts and K562 cells constitutively 
express the immunoproteosome which may generate novel antigenic allopeptides. 
To further investigate tissue specificity by EBV EBNA3A specific T-cells, long peptides from 
the ABCD3 protein containing the EEYLQAFTY epitope were generated. Cleavage products 
from these long peptides were compared following immunoproteosome vs constitutive pro-
teosome digestion, using mass spectrometry analysis. Results of the proteosomal digestion 
are shown in tables 1a and b. 
These results are unexpected given the tissue specificity reported in chapter 4 of this thesis. 
EBV LCL and PHA blasts were efficiently targeted by EBV EBNA3A specific T-cells, whereas 
endothelial and epithelial cells were poor targets. If these differences were attributable to pro-
teosome peptide processing then theoretically the immunoproteosome (present in EBV LCLs 
and PHA Blasts) should generate relatively more EEYLQAFTY peptide, as compared to the 
constitutive proteosome. In fact the epitope is a target of proteosomal cleavage and there may 
therefore be little EEYLQAFTY peptide available for presentation on the cell surface in all 
cell lines. Alternatively the EEYLQAFTY peptide may not be the natural ligand. Nonetheless, 
these results nicely demonstrate how proteosomal digestion could alter the self-peptide (al-
lopeptide) repertoire presented on allo-HLA molecules. Further antigenic processing studies 
are clearly warranted.
Alternatively, differences in expression of a protein that contains a peptide capable of compet-
ing with an antigenic peptide for the peptide-binding groove of the allogeneic molecule could 
also cause the tissue specific alloreactivity reported in chapter 4. HLA-B*44:02 is a highly 
tapasin-dependent HLA molecule (34-35) and therefore limited tapasin expression in PTECs 
and/or HUVECs could decrease EEY peptide presentation in these cell lines. However tapa-
sin mRNA is strongly induced in endothelial cells following IFNg treatment (36), and IFNg 
treatment did not increase the targeting of HUVECs in our assays despite inducing elevated 
HLA-B44 expression.
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Viral specific T-cell responses may not give predictable allo-HLA crossreactivity
Unlike the public BV6S2 TCR response against FLR peptide presented on HLA-B8, immune 
responses against other common pathogens are not so immunodominant and memory CD8 
T-cells generated following viral infections often demonstrate a wide diversity of Vb usage 
and therefore allo-HLA crossreactivity. Several examples of differing alloresponses from T-
cell clones with the same viral peptide/HLA restriction are reported in this thesis (25) (Chap-
ters 3, 5 and 7).
Variable allo-HLA crossreactivity by T-cell clones sorted from the same individual with the 
same specificity, but different TCR Vb usage, was also reported in this thesis (25) (Chapter 3). 
Single cell sorting of VZV IE62 specific T-cells from an individual with VZV infection gener-
ated three different clones with usage of Vb 21.3, Vb 14 and an undetermined Vb. These T-cell 
clones cross-reacted against allo HLA-A*02:05, HLA-B*55:01 and HLA-B*57:01 respectively. 
Demonstrating how a single viral peptide/HLA restricted immune response can generate dif-
ferent clonotypes with differing allo-HLA crossreactivity within the same individual.
It is currently not known if viral specific T-cells from different individuals with the same 
specificity and the same Vb usage will always demonstrate similar allo-HLA crossreactivity. 
This knowledge is essential in order to be able to predict (un)acceptable mismatches based on 
donor-recipient HLA mismatches and immunological history of the recipient. At the current 
point in time functional assays, such as those described in this thesis, are required to deter-
mine if a certain HLA mismatch is a target for memory T-cells in a given individual. HLA 
matching remains the best predictor of long-term renal graft survival.
 
HLA alloreactivity likely occurs via molecular mimicry
The multiple mechanisms of T-cell receptor crossreactivity have been reviewed extensively 
by others (37-40). Despite peptide/HLA diversity and TCR plasticity, these T-cell responses 
always exhibit exquisite HLA and peptide specificity.
Work presented here strongly supports molecular mimicry, but not structural degeneracy, as 
the mechanism of TCR crossreactivity from viral specific memory T-cells. Differing potency 
of the virus specific T-cells against different cell targets, as reported in chapters 3, 4 and 5, 
is consistent with a TCR specifically crossreacting against single (or limited) self-peptide(s) 
presented on an allo-HLA molecule. If a viral specific TCR was crossreactive against an allo-
HLA molecule via structural degeneracy then the peptides presented via the allo-HLA mol-
ecule should be irrelevant and the T-cell would recognize all allo-HLA expressing tissue cells 
equally.
Previous viral (pathogen) infection is critical to induction of the alloreactive T-cells
In this thesis we show that virus specific memory T-cells can demonstrate immediate cytolytic 
effector function against allogeneic HLA molecules in cytotoxicity assays (25-26) (Chapter 2, 
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3 and 5). A CCR7+ CD45Ra+ naive T-cell with the same TCR (e.g. from a seronegative indi-
vidual), upon first contact with alloantigen, will secrete only IL-2, is not cytolytic and requires 
CD4 T-cell and B-cell help within the germinal centre to initiate an immune response. In a 
pilot study we found that stimulation of HLA-B8+ B44- cord blood T-cells with HLA-B*44:02+ 
irradiated blood cells does not result in an alloresponse by HLA-B8/FLR specific naïve T-
cells. Naïve T-cells recognizing an alloantigen without the appropriate co-stimulatory signals 
and T-cell help may gain regulatory function, be deleted or become anergic (41-42). This 
illustrates the critical importance of previous viral infection to the activation of alloreactive 
T-cells.
Consistent with this theory cord blood T cells are less able to mediate GvHD than marrow 
derived T-cells because of their naïve status (41,43).
Selective therapies to inhibit alloreactive memory T-cells are required
Renal transplantation is a life saving procedure for end stage renal disease and generally short-
term transplantation outcome is excellent. The introduction of calcineurin inhibitor therapy 
has been critical for the prevention of acute rejection and improved one-year graft survival, 
although any beneficial effect on long-term graft survival is small. “Memory” is a critical bar-
rier to long-term transplantation outcome and tolerance induction (1), therefore, the effect 
of newer immunosuppressive drugs on alloresponses by viral specific memory T-cells may be 
critical to graft survival and/or tolerance induction and should be studied further.
Selective therapies at the time of transplantation may allow inhibition of allo-HLA crossreac-
tivity from pre-existing memory T-cells while still allowing de-novo naïve responses against 
viral antigens. For example, selective blockade of ICOSL and CD86 which represent two ma-
jor co-stimulatory signals for the activation of resting peripheral blood memory T-cells (2,44) 
may still allow immune responses via the CD40/CD154 and/or CD70/CD27 co-stimulatory 
pathways which are important for naïve T-cell activation. While the effect of immunosuppres-
sive drugs on allo-HLA crossreactivity from viral specific T-cells has not been studied, the 
calcineurin inhibitors are able to inhibit proliferation and cytokine production from effector 
CD4 memory T cells (27). Unfortunately leukocyte depleting therapies such as antithymocyte 
globulin and alemtuzumab are less able to diminish the memory T-cell pool (27).
Results presented in this thesis also suggest caution is warranted when interpreting tolerance 
protocols studied in pathogen free animals.
 
Adoptive transfer of pathogen specific T-cells could be complicated by GvHD disease
Adoptive transfer of virus or fungal specific T-cells offers an effective option for the man-
agement of specific immune defects in an immune compromised host (45), particularly fol-
lowing allogeneic BMT. However given the high frequency of allo-HLA crossreactivity from 
viral specific T-cells, it is not surprising that adoptive transfer has already been associated 
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with GvHD. For example, adoptive transfer of CMV specific T-cells to nine recipients after 
allogeneic BMT resulted in three cases of GvHD, including one patient who died (46). Simi-
larly, TCR gene transfer to induce anti-leukaemia reactivity is associated with a and b chain 
rearrangements and therefore the formation of mixed dimer TCRs (47), which could also be 
alloreactive. Screening of adoptively transferred antigen or leukaemia specific T-cells for allo-
HLA crossreactivity may help prevent GvHD.
 
HLA alloreactivity could be useful to conversely stimulate a human cytolytic viral specific T-cell 
responses using allogeneic cell therapy
Finally in chapter 7 of this thesis we provide evidence that allogeneic cell therapy may be 
useful to conversely stimulate a beneficial anti-viral cytolytic effector response for treatment 
of viral infection. We demonstrated that human viral specific memory T-cells gain cognate 
viral antigen specific cytolytic effector function following stimulation with allogeneic HLA 
molecules against which they are crossreactive. This proof-of-principle technique could pro-





An essential feature of the T-cell response is the ability to recognize a diverse array of poten-
tially unlimited antigens, necessitating that the TCR be inherently crossreactive. The memory 
T-cells that are specific to previously encountered pathogens accumulate following repeated 
infectious exposure and have low activation thresholds. Experiments presented in this thesis 
reveal that these viral specific memory T-cells are commonly crossreactive with allo-HLA 
molecules in a self-peptide specific manner. Thus, getting a certain infection in an individual 
with a certain HLA type might have significant adverse consequences in the event of organ 
or marrow transplantation. Human ex-vivo studies are clearly warranted. We suggest that 
current research objectives should focus on the human in-vivo relevance of allo-HLA cross-
reactivity from viral specific memory T-cells, and specifically how self-peptide dependent 
allorecognition from viral specific T-cells alters tissue specificity. Allo-HLA crossreactivity 
could also have serious adverse effects in the setting of adoptive transfer and TCR transfection 
of viral specific T-cells. New understandings of the origin of alloreactivity may lead to an era 
whereby donor suitability is defined not only by HLA typing but also using immunological 
history, and hopefully toward successful donor (antigen) specific transplantation tolerance.
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De beste behandeling voor patiënten met eindfase nierfalen is een niertransplantatie. Het 
probleem na transplantatie is echter dat de nier door het immuunsysteem van de patiënt 
herkend wordt als lichaamsvreemd. De T-cellen (witte bloedcellen) van de patiënt herkennen 
de donorcellen als niet-eigen (allogeen) en veroorzaken afstoting van het orgaan. Om dit pro-
ces zo veel mogelijk te voorkomen dient de patiënt voor de rest van zijn leven immunosup-
pressieve medicijnen te gebruiken.
Iedereen heeft unieke eiwitten van het immuunsysteem, HLA moleculen (humaan leuko-
cyten antigenen) genaamd, op het oppervlak van zijn cellen. Afstoting kan optreden wanneer 
T-cellen vreemde HLA moleculen herkennen op de cellen van het getransplanteerd orgaan.
Het is al langer bekend dat virale infecties een nadelige invloed hebben op de uitkomst van 
niertransplantatie. Infecties die opgetreden zijn vóór de transplantatie kunnen in verband ge-
bracht worden met afstoting na transplantatie. Het mechanisme waardoor een in het verleden 
doorstane virusinfectie de afstoting van een getransplanteerde nier kan veroorzaken was nog 
onduidelijk. Eén hypothese is dat de T-cellen die geactiveerd worden door de infectie langere 
tijd kunnen overleven en op een later moment afstoting van het getransplanteerde orgaan 
kunnen veroorzaken. Echter, deze hypothese vereist dat dezelfde T-cel twee volstrekt verschil-
lende vreemde antigenen kan herkennen, namelijk zowel het virus als het vreemde HLA op 
de allogene cellen van het transplantaat. In het verleden werd aangenomen dat deze kruisre-
activiteit zelden voorkomt.
Het doel van het onderzoek beschreven in dit proefschrift was om vast te stellen of deze 
kruisreactiviteit van virusspecifieke T-cellen de verklaring is voor de aanwezigheid van do-
nor specifieke T-cellen in patiënten die niet eerder getransplanteerd zijn. Indien dit wordt 
bevestigd, is het volgende doel om de frequentie van het optreden van deze kruisreactiviteit 
vast te stellen. Voor het bepalen van virusspecifieke T-cellen, die tevens kruisreageren tegen 
getransplanteerde cellen, hebben wij een nieuwe techniek ontwikkeld. Het is mogelijk om 
een enkele T-cel, ontstaan na een normale virusinfectie, te identificeren en te isoleren. Deze 
enkele T-cel werd gestimuleerd om te delen en uit te groeien tot vele miljoenen identieke T-
cellen (T-cel kloon) die gebruikt konden worden voor experimenten. Daarna is getest of deze 
individuele T-cel kloon ook de verschillende celtypes kon herkennen die aanwezig zijn in een 
getransplanteerde nier.
Deze techniek bleek de basis te zijn voor een effectief systeem om te bevestigen dat door een 
virusinfectie geactiveerde T-cellen in staat zijn om afstoting van allogene cellen te veroor-
zaken. Tevens hebben we bevestigd dat afstoting kan worden veroorzaakt door dezelfde T-cel 




Hier volgt een overzicht van de nieuwe bevindingen op het gebied van transplantatie waartoe 
het onderzoek dat beschreven wordt in dit proefschrift heeft geleid:
Hoofdstuk 1 is een inleiding op het proefschrift. Het geeft een overzicht van wat tot nu toe 
bekend is over de normale immuunrespons tegen virussen en over de immunologische afstot-
ing van getransplanteerde cellen.
Hoofdstuk 2 beschrijft een nieuwe techniek voor het isoleren en opkweken van vele identieke 
T-cellen uit een individuele virusspecifieke T-cel om de immuunreactie tegen allogene cellen 
te kunnen bepalen. In de appendix van hoofdstuk 2 wordt uitgebreid de methode beschreven 
die is gebruikt.
In hoofdstuk 3 is nagegaan hoe vaak kruisreactiviteit van T cellen, geactiveerd door een virus-
infectie, optreedt. Hiervoor hebben we meerdere virusspecifieke T cellen van verschillende 
personen getest. Er is aangetoond dat één-en-dezelfde T-cel zowel het originele virus als be-
paalde HLA moleculen op de allogene cellen herkent.
Hoofdstuk 4 laat zien dat de kruisreactiviteit gebaseerd is op het feit dat de T-cel een lichaam-
seigen eiwit herkent dat gepresenteerd wordt op het celoppervlak van allogene cellen. 
In hoofdstuk 5 wordt aangetoond dat niet alleen virale infecties, maar ook anti-virale vaccina-
ties, T-cellen kunnen activeren die mogelijk in staat zijn afstoting van niertransplantaten te 
veroorzaken. Er is een patiënt bestudeerd die op de wachtlijst stond voor niertransplantatie, 
en die een vaccinatie had gekregen tegen het varicella-zoster (waterpokken) virus. Het bleek 
dat de T-cellen die geactiveerd werden door de vaccinatie in staat waren om cellen te vernieti-
gen die normaliter aanwezig zijn in een getransplanteerde nier.
De huidige stand van zaken wat betreft kruisreactiviteit van virusspecifieke T-cellen tegen al-
logene menselijke cellen wordt besproken in hoofdstuk 6. Dit hoofdstuk geeft een samenvat-
ting van onze eigen bevindingen, en ook van eerder onderzoek van anderen met betrekking 
tot virusspecifieke T-cellen die afstoting van niertransplantaten kunnen veroorzaken.
Hoofdstuk 7 laat zien dat, andersom, stimulatie van bloedcellen met allogene cellen bruikbaar 
kan zijn om een virusspecifieke T-cel reactie te versterken bij patiënten met een infectie. De 
mogelijke klinische toepassingen worden besproken.
In hoofdstuk 8 worden alle bevindingen samengevat en in een klinisch perspectief geplaatst. 
Verder wordt bediscussieerd hoe onze bevindingen gebruikt zouden kunnen worden om afs-
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aa   Amino acid
ABCD3   ATP-binding cassette sub-family D member 3
Ag   Antigen
APC   Antigen presenting cell and Allophycocyanin
bp   Base pair
CCR7   CC chemokine receptor 7
CFSE   Carboxyfluorescein succinimidyl ester
CMV   Cytomegalovirus
CTL   Cytotoxic T-lymphocyte
DNA    Deoxyribonucleic acid
EBV   Epstein-Barr virus
EBV LCL  EBV transformed B-cell
EBNA3A  Epstein-Barr virus nuclear antigen 3A
ELISA   Enzyme linked immunosorbent assay
ELISPOT  Enzyme linked immunosorbent spot
FACS   Fluorescence-activated cell sorting
FCS   Fetal calf serum
FITC   Fluorescein isothiocyanate
HLA   Human leukocyte antigen
HIV   Human immunodeficiency virus
HSV   Herpes simplex virus
HUVEC   Human umbilical vein endothelial cell
ICP47   Infected cell peptide 47
IE62   Immediate early protein 62
IFNg   Interferon gamma
IL   Interleukin
Abbreviations
179
IMDM   Iscove’s modified dulbecco’s media
MHC   Major histocompatibility complex
MLC    Mixed lymphocyte culture
mRNA   Messenger RNA
PE   Phycoerythrin
PerCP   Peridinin chlorophyll protein
PBMC   Peripheral blood mononuclear cell
PBS   Phosphate buffered saline
PCR   Polymerase chain reaction
PHA   Phytohaemagglutinin
PTEC    Proximal tubular epithelial cell
PTLD   Post-transplant lymphoproliferative disorder
RNA   Ribonucleic acid
RT-AMV  Reverse transcriptase-avian myeloblastosis virus
SAL   Single antigen cell line (Single HLA transfected K562 cell)
SD   Standard deviation
SIV   Simian immunodeficiency virus
TAP   Transporter associated with antigen processing
TCR   T-cell receptor
TNFa   Tumour necrosis factor alpha
UCB   Umbilical cord blood
Vpu    Viral protein U
VZV   Varicella-zoster virus



